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A Thesis on the Ontogeny and Functions of Macrophages in Pancreatic Ductal Adenocarcinoma 
by 
Yu Zhu 
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The immune system plays an essential role in protecting the host organisms against both 
foreign invaders and self-attacks arisen within the host, such as tumors. Instead of promoting the 
long-term fitness of the organism, the immune system is often suppressed or hijacked by tumor 
cells to accelerate the progression of malignancies. Among the key drivers of immune 
suppression, macrophages are one of the most abundant immune cells present in tumor tissues. 
High levels of macrophage infiltration in the malignant tissues correlate with negative patient 
outcome in many types of cancers, including pancreatic ductal adenocarcinoma (PDAC), one of 
the most lethal malignancies in human beings. Therefore, attempts have been directed towards 
targeting tumor-associated macrophages (TAMs) to improve the efficacy of cancer treatment.   
We attempted to target TAM responses in murine PDAC models through inhibiting the 
colony stimulating factor-1 receptor (CSF1R) signaling pathway. CSF1R signal blockade not 
only depleted half of the TAMs within the tumor microenvironment, but also functionally 
reprogrammed the remaining TAM compartment to support anti-tumor T cell responses. More 
	   xii	  
importantly, CSF1R signal blockade sensitized the tumors to T cell checkpoint-based 
immunotherapies, which failed to achieve clinical efficacy as monotherapies. These findings 
revealed the potential benefits of targeting TAMs to improve treatment of PDAC patients.   
However, TAM-targeting strategies have limitations. Optimal TAM-based therapeutic 
intervention requires in-depth understanding of the sources that supply macrophages to 
malignant tissues. Towards that end, we investigated the ontogeny of TAMs in murine PDAC 
models, and identified both inflammatory monocytes and tissue-resident macrophages as sources 
of TAMs. Unexpectedly, significant portions of pancreas-resident macrophages originate during 
embryonic development at the yolk sac stage. These cells undergo significant local expansion 
through in situ proliferation during tumor progression. While monocyte-derived TAMs play 
more potent roles in tumor antigen presentation, embryonically derived TAMs exhibit pro-
fibrotic transcriptional profiles and ex vivo fibrotic activities, indicative of their role in producing 
and remodeling extracellular matrix molecules. Collectively, these findings uncovered the 
heterogeneity of TAM origin and functions, and could provide insights into therapeutically 
targeting different TAM subsets based on the different pathological features of the PDAC 
microenvironment.  
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Chapter 1: Introduction 
1.1 Overview of Pancreatic Cancer 
1.1.1 Pancreas and Pancreatic Cancer 
Pancreas, named after the Greek words pan (all) and kreas (flesh), is a multi-modular 
glandular organ that lies in the retroperitoneal position of the abdomen behind the stomach. It is 
composed of exocrine glands and endocrine glands tightly organized together. Through these 
glands, pancreas functions as a critical component of both the digestive system and the endocrine 
system.  
The pancreas predominantly consists of exocrine glands that play a central role in the 
conversion of consumed foodstuff into “usable fuels” for cells in the body. These exocrine 
glands accomplish their functions through the secretion of digestive enzymes and bicarbonate 
ions into the duodenum of the gastrointestinal tract. The key components of the exocrine 
pancreas are acinar cells and duct cells. The acinus, named after the Latin term meaning “berry 
in a cluster”, are specialized in synthesizing, storing, and secreting digestive enzymes. The major 
types of pancreatic enzymes are proteolytic enzymes (involved in protein digestion), pancreatic 
amylase and chitinase (involved in carbohydarate digestion), and pancreatic lipase (involved in 
fat digestion). The three principal types of proteolytic enzymes are trypsinogen, 
chymotrypsinogen, and procarboxypeptide. These enzymes are stored in granules in inactive 
forms, known as zymogens, in the apical region of acinar cells. The apical surface of the cells 
also line up as microvilli, within which a filamentous actin network is organized to mediate the 
exocytosis of zymogen granules. Hormones and neurotransmitters that mediate the stimulation of 
enzyme secretion are mediated through receptors located in the basolateral membranes of these 
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cells. As the zymogens get secreted into the duodenum under hormonal regulation, they are 
cleaved into active forms through a cascade of proteolytic events initiated by enzymes secreted 
by cells lining the luminal border of the duodenum mucosa. Duct cells, on the other hand, are the 
main producers of bicarbonate ions. These ions are secreted to the duodenum to neutralize the 
acidity of chyme. This process creates a neutral or alkaline environment that is not only optimal 
for pancreatic enzymatic functions, but also minimizes acidic damages to duodenum mucosa.    
On the other hand, the endocrine gland of the pancreas tightly regulates the digestive 
procedures by secreting hormones to control blood sugar levels. The major components are 
clusters of endocrine cells known as the islets of Langerhans, which are dispersed throughout the 
pancreas between the exocrine cells. Beta cells are the most abundant components of the islets of 
Langerhans, whose function is to produce and secrete insulin that regulates the blood glucose 
level. In addition, alpha cells, delta cells, PP cells are also integral part of the endocrine pancreas; 
these cells produce glucagon, somastatin, and pancreatic polypeptide respectively.  
Given the importance of the pancreas in both the exocrine and the endocrine system, 
disorders in this organ can have significant impacts on the fitness of an entire organism. 
Common diseases in the pancreas include pancreatitis, type 1 diabetes mellitus, and pancreatic 
cancer. Pancreatitis is inflammation of the pancreas, which comes in acute or chronic forms. 
Type 1 diabetes mellitus results from the destruction of beta cells in the pancreas islets of 
Langerhans that leads to compromised abilities to produce insulin in response to high blood 
sugar levels. Pancreatic cancers are malignant tumors that arise within the organ. A small subset 
of pancreatic cancer arises from the pancreatic islet cells. These cancers are called pancreatic 
neuroendocrine tumors (PNETs) and account for 5% of pancreatic cancer cases. PNETs produce 
excessive amount of hormones, such as insulin, glucogan, and gastrin, which disrupt systemic 
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homeostasis. The vast majority of pancreatic cancers arise within the exocrine portion of the 
organ. These tumors are called pancreatic ductal adenocarcinoma (PDAC). 
PDAC leads to a series of disruptions to organismal homeostasis. As a consequence of 
the destruction of acinar cells, the normal release of digestive enzymes is compromised. This 
leads to incomplete digestion of consumed molecules, malabsorption, diarrhea, and increased 
intestinal infections, among other consequences. Subgroups of patients develop uneven textures 
of fatty issue under the skin, due to the release of pancreatic enzymes that digest fat. Tumors in 
exocrine pancreas can also cause destruction or dysfunction of beta cells, leading to abnormal 
insulin secretion. Patients could experience irregular changes in blood sugar levels, or diabetes in 
some cases. Among all the abnormalities, liver dysfunction is most frequently observed. This 
often results from the obstruction of the bile duct by the tumor, which frequently localizes to the 
head of the pancreas close to the bile duct. Normally, the liver secretes bilirubin as part of the 
bile liquid, and bile goes through the bile duct into the intestine. As tumors block the bile duct, 
excessive amount of bilirubin builds up in the liver, causing liver dysfunction. In addition, liver 
is the most common site of metastasis. Presence of tumor cells in the liver will alter the tissue 
function. Moreover, increasing amount of evidence in mouse models suggests that before the 
dissemination of tumor cells, pre-metastatic livers undergo tissue remodeling and inflammation, 
which may well likely disrupt their functions.    
PDAC is one the most lethal forms of solid cancers. Five-year survival rate of PDAC 
patients between 2006 and 2012 is 7.7% (https://seer.cancer.gov/). As a point of reference, the 5-
year survival rate for breast cancer, prostate cancer, colorectal cancer, and skin melanoma 
patients are 89.7%, 98.9%, 65.1%, and 91.5% respectively. The median survival of pancreatic 
cancer patients is less than 6 months. Pancreatic cancer is the 4th most common cause of cancer-
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related death, despite being the 12th most type of cancer in the United States. The dismal 
prognosis of pancreatic cancers is partially due to its late diagnosis, as the majority of pancreatic 
cancer patients have already developed metastasis at the time of diagnosis. Only 9% of patients 
demonstrate a confinement of the tumor at the primary site. An additional 29% of patients have 
cancers spread to regional lymph nodes. Even for the 9% patients with local diseases, the 5-year 
survival rate is only 29.3%, which contrasts with 98.8% in localized breast cancer patients.  
Currently established treatment protocols do not confer significant clinical benefits in 
PDAC treatment. Treatment options are very limited. Surgical resection is applicable only in 
patients with local diseases. Traditional chemotherapies and radiation therapies are not effective 
in restraining tumor progression. Importantly, development of new treatment regimens has been 
very slow and relatively ineffective in comparison to other tumors. For example, the death rate 
for colorectal cancer patients was dropping by 2.7% annually between the years of 2004 and 
2013, which is reflective of improved efficacies in targeted therapeutics; the rates for new 
colorectal cases have been dropping by 3.2% annually in the past decade as well. In comparison, 
the rates for new pancreatic cancer cases have been rising by 0.6% each year; five-year survival 
rate has been fluctuating between 3% and 7% since 1975 without significant improvement, all of 
which reflect a lack of improvement in treatment strategies. Newer treatment options, such as 
immune checkpoint-based therapies in particular, do not improve patient outcomes as 
monotherapies. In comparison, checkpoint immunotherapies demonstrated impressive response 
rates in many types of cancer, including metastatic diseases. Development of treatment strategies 
is desperately needed for PDAC patients, which requires in-depth understanding of pancreatic 
cancer biology.  
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PDAC is driven by mutations altering genetic programs that govern cellular activities. 
Oncogenic mutation in Kras is a signature of PDAC genetics, and is present in 90-95% of the 
patients. Kras is also the earliest detected mutations found in preneoplastic lesions, such as 
pancreatic intraepithelial neoplasia (PanINs). Tumor suppressor genes are also very frequently 
mutated, including p16/CDKN2A, p53, and SMAD4, whose functions are lost in approximately 
90%, 75%, and 55% of cancers, respectively. Initial genetic abnormalities include not only 
oncogenic mutations, but also shortening of chromosomal ends, i.e. telomeres. Epigenetic 
regulation is also severely disrupted. Collectively, these cell autonomous aberrations lead to the 
transformation of PDAC cell of origin, causing disease to initiate and progress.  
PDAC is believed to arise from a series of non-invasive precursor lesions. These include 
pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), 
and mucinous cyctic neoplasm (MCN). The risk of patients with these lesions to develop 
pancreatic cancer is increased by more than 20-fold (Hruban et al., 2007). PanINs are the most 
common among these lesions. They harbor many of the same genetic mutations found in PDAC, 
even within the same patients. This adds strengths to the hypothesis that PDAC arises within 
these pre-neoplastic lesions.  
The precise nature of cellular origin of PDAC is still under debate. PDAC obtained its 
name due to the ductal-like morphological features of the neoplastic cells. However, induction of 
oncogenic mutations in mature pancreatic ductal epithelial cells does not efficiently induce 
tumorigenesis. Instead, acinar cells are dramatically more prone to Kras-induced transformation 
(Kopp et al., 2012), suggesting the possibility that the cell of origin for PDAC may be acinar 
cells instead. Indeed, one of the early events during tumorigenesis in genetic mouse models is 
acinar-to-ductal metaplasia (ADM), an event where acinar cells change their identity to ductal 
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epithelial cells (Schmid, 2002). ADM is commonly observed in PanIN lesions, further 
suggesting the possibility that acinar cells may be the tumor-initiating cells. In addition to acinar 
cells and ductal epithelial cells, it also remains to be seen if there are pancreatic stem or 
progenitor cells in adults that could be the “tumor-initiating cells” for PDAC. Understanding the 
properties of cell of origin could help addressing sell-autonomous mechanisms by which PDAC 
evades cancer surveillance and therapeutic targeting. 
Genetic mutations not only drive a series of cellular activities that govern proliferation, 
metabolism, and invasiveness, but also alter the way the cells shape their tissue 
microenvironment to promote tumor progression through non-sell-autonomous mechanisms. 
This will be discussed in the following sections. 
 
1.1.2 Cancer and Cancer Microenvironment 
Cancers are characterized by uncontrolled growth of transformed cells with genetic 
mutations. While encompassing a wide range of diseases covering almost all mammalian organs, 
cancers share some common features that help us understand the biology of these diseases. They 
acquire several biological traits that confer advantages of tumor cells at the expense of host 
fitness; these traits include self-sufficiency in growth signals, insensitivity to growth inhibition, 
resistance to programmed cell death, and unlimited replication potential.  
First, cancer cells are self sufficient in growth signals. Normal cells require exogenous 
growth factors in order to exit a quiescent state and enter active proliferation. Such signals are 
transduced usually through transmembrane receptors, which trigger downstream signaling 
pathways that promote cell division. This way, cell division is orchestrated within a larger tissue 
context that enables optimal organ functions by meeting various cellular needs within different 
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tissue components. However, cancers generate their own growth signals independently of the 
extracellular milieu. Their altered oncogenic program takes over the proliferative system, usually 
making cells constitutively cycling, thereby reducing their dependence of stimulation from the 
external microenvironment. 
On the other hand, multiple inhibitory signals are usually able to maintain tissue 
homeostasis by inhibiting cell proliferation within normal tissues. These signals could block the 
potential of the cells to proliferate, or force cells out of active division cycles back into quiescent 
states. Cancer cells can often disrupt the elements that mediate these negative regulatory 
pathways. This mechanism, coupled with growth signal autonomy, contributes to the hyper-
proliferative features of neoplastic cells.  
Fundamentally, tumor growth is the net result of cell production and cell loss. Abilities to 
proliferate autonomously and to evade growth inhibition are not sufficient to drive tumor growth, 
because higher rates of cell death can also compromise the ability of the cancer cell population to 
expand. Programmed cell death, or apoptosis, is essential to the homeostasis of most 
multicellular organisms due to its importance in eliminating unnecessary or harmful cells and 
cellular debris. Normal cells have sensors to detect apoptosis-inducing signals, either from 
intracellular molecules that indicate irreversible cellular damages, or from extracellular sources. 
However, cancer cells often develop strategies that render them resistant to programmed cell 
death, which is a hallmark of most types of tumors. They become resistant to apoptosis through 
several mechanisms, such as upregulating pro-survival effector molecules, downregulating 
“death receptors” that can engage apoptosis signals, and inhibiting the production or activities of 
pro-apoptotic effector molecules, such as caspases.  
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Moreover, cancer cells have limitless replication potential. Normal cells have limited life 
span, i.e. they could undergo a finite number of cell division cycles before entering a crisis state 
and undergo senescence. This phenomenon is termed “Hayflick limit”. Genetic mutations within 
cancer cells often allow them to evade the Hayflick limit. Under homeostatic conditions, normal 
cells undergo senescence often due to the shortening of telomeres, regions of repetitive 
nucleotides at the end of a chromosome. Cancer cells often utilize alternative programs to 
replicate their chromosome ends, such as upregulating telomerase that promotes telomere 
lengthening, which could dramatically or indefinitely delay the occurrence of senescence.  
While a lot of initial attention in cancer research was directed towards the transformed 
cells themselves, in the past decade or so it has become well appreciated that tumors are not 
malignant cells growing in isolation. Instead, cancer cells are embedded within a very complex 
organ system that is composed of a wide range of cellular and non-cellular components. 
Fibroblasts, blood vessels, neurons, and immune cells are examples of key cellular components 
of the tumor microenvironment.  
Fibroblasts are essential stromal components of the tumor microenvironment. One of the 
major functions of fibroblasts is to produce, deposit, and remodel the extracellular matrix (ECM), 
which in normal tissues ensures the integrity of the organ system. While cancer-associated 
fibroblasts (CAFs) carry out the same functions as their normal fibroblast counterparts, their 
activities are severely disrupted. Tumor cells recruit fibroblasts, promote fibroblast proliferation, 
and induce an activated myofibroblast phenotype. Activated fibroblasts in tumors could produce 
ECM molecules in an unrestrained fashion, therefore laying out excessive amount of ECM that 
leads to tissue fibrosis. The growth of fibrous part of the tissue, or desmoplasia, was originally 
considered to a protective mechanism by encapsulating, constraining, or even rejecting the tumor. 
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However, accumulating amount of evidence suggests a strong correlation between desmoplasia, 
tumor progression, and poor patient outcome. Excessive amount of ECM in the tissue activates 
cancer cell proliferation, suppresses apoptosis, and promotes the invasion and metastasis of 
tumor cells. Fibrosis also increases interstitial pressure and leads to poor tumor vascularization. 
These altogether lead to hypoxia and pose a barrier to effective therapy delivery. In parallel to 
ECM remodeling, CAFs can secrete a large amount of inflammatory cytokines that can further 
modulate the local environment through the recruitment of immune cells and modulation of 
tumor vasculature. 
Blood vessels are also abundant in many kinds of tumor tissues. Despite their self-
sufficiency in growth signals, tumor cells still require oxygen and nutrients to sustain their 
metabolic activities. As tumors reach the size of a few millimeters in diameter, tumors would 
experience low oxygen tension, known as hypoxia, and nutrient deprivation. To meet their 
metabolic needs, tumor cells would trigger vasculature generation and remodeling, a series of 
events collectively called “angiogenesis”. In addition to hypoxia, other events during tumor 
expansion, such as the buildup of extracellular matrix and inflammation, are also able to trigger 
angiogenesis. These players in the tumor stroma could trigger sprouting/branching of pre-
existing blood vessels by promoting the protrusion of a selected endothelial cell. Alternatively, 
endothelial progenitor cells could be recruited from the circulation system to the tumor site, 
differentiate to new endothelial cells that line up blood vessels; this process is called 
“vasculogenesis”. Moreover, a subset of cancer cells could differentiate and adopt an endothelial 
cell-like phenotype and form bona fide blood vessels. Tumor cells can also line up blood vessels 
by mimicking, rather than differentiating into, endothelial cells. Tumor neo-vasculature is often 
morphologically and functionally distinct from normal vasculature. They appear disorganized 
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and tortuous. They are more leaky than normal blood vessels. Endothelial cells can demonstrate 
abnormal cell morphologies, such as aneuploidy, multiple chromosomes, and multi-centrosomes. 
The generation and remodeling of vasculature in the tumor not only allows the transport of 
oxygen and nutrients, but also produces or allows the supply of growth factors that further 
enhance tumor cell proliferation. 
Nerves are also important components of the tumor stroma. Cancer cells can attract 
nearby nerves through the secretion of axon guiding molecules, thereby increasing the number 
and extensions of axons. Such process is called “axonogenesis”, which is very similar to 
angiogenesis. Adrenergic signals from sympathetic nerve cells can directly stimulate cancer cells, 
rendering resistance to apoptosis, promoting invasive potential and migratory capacity. Neural 
activation of tumor cells can also lead to increased secretion of angiogenesis promoting 
cytokines. Cholinergic signals from parasympathetic nerve cells have also been shown to 
promote “cancer stem cell” properties. In addition, the nervous system can also act on other 
stromal components in the tumor, including vasculature and immune cells.  
It is important to note that reorganization or disruption of the tissue microenvironment 
not only is a consequence of tumor development, but also occurs prior to malignant 
transformation and contributes to tumorigenesis. For example, while tumor cells secrete a wide 
range of inflammatory cytokines to recruit immune infiltration, chronic inflammation during 
premalignant stages can cause cell damages and facilitates tumorigenesis. Similarly, while tumor 
cells activate fibroblasts to promote fibrosis and inflammation, aberrant fibroblast activation can 
secrete factors that promote inflammation and facilitate cancer cell transformation. In addition, 
human beings that have chronic depression or have suffered traumatic life events are more likely 
to develop cancers, which suggests the possibility that neural deregulation may promote cancer 
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transformation. Indeed, adrenergic signaling in tumor stroma was shown to be essential for 
tumor initiation in murine transplantation models.  
Taken together, tumors are malignant cells with aberrantly regulated proliferative 
programs that reside within a complex tissue microenvironment. Cancer cells remodel various 
aspects of the tissue environment, which in turn facilitate tumor progression. This dissertation is 
focused on understanding how tumors, in particular pancreatic ductal adenocarcinoma (PDAC), 
interact with the immune components of the stroma.  
 
1.2 Overview of the Immune System 
1.2.1 Overview of the Innate Immune System 
The immune system plays an essential role in both defending organisms against pathogen 
invasion and protecting against abnormalities that rise within the host. It is a tightly regulated 
system composed of several lines of defense.  
Anatomical barriers form the first line of defense that includes the skin, tears, and mucus. 
These are the initial sites of encounter as pathogens attempt to enter the body. Physical, 
biological, and chemical components exist in these sites to maintain barrier integrative in order 
to minimize the penetrance of pathogens into host organisms. For example, epidermal cells in the 
skin form a waterproof and airtight keratinized layer that is impermeable to most foreign 
organisms. Sweat glands in the skin also secrete bactericidal peptides such as dermicin to kill 
microbes. Cells in sebaceous glands also produce oily substances such as sebum to cover hair 
and the keratinized layer, preventing the cracking and drying of the barrier. Similarly, in other 
barriers, such as the digestive tract and the respiratory system, different components also 
function to deter ingested or inhaled pathogens. 
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External barriers are not perfect. As pathogens pass through and penetrate into the host 
organisms, innate immune system constitutes the second line of defense. The major functions of 
the innate immune cells are to (1) quickly recognize, contain, inactivate, and eliminate invaders, 
(2) remove debris, and (3) prepare the body for subsequent events that bring the organisms back 
to homeostatic conditions. Innate immunity can be further classified into cellular immune 
responses and humoral immunity, which are immune responses mediated by macromolecules 
present in the humors, or body fluid.  
The major cellular components of the innate immunity are phagocytic cells, including 
macrophages, neutrophils, and dendritic cells. They recognize foreign materials by binding to 
pattern-associated molecular patterns (PAMP), which are molecules associated with pathogens 
but not host cells. Examples of PAMPs include lipopolysaccharides, double-stranded RNA, and 
unmethylated CpG motifs, all of which signal to the phagocytes the presence of “non-self”. In 
addition, phagocytes can detect pathogens by sensing damage-associated molecular patterns 
(DAMP), which are host molecules expressed or released during inflammatory responses. 
Examples of DAMPs include heat shock proteins, extracellular matrix (ECM) proteins, DNA, 
and ATP, which signal cellular damages or cell death caused by infectious or non-infectious 
inflammation. PAMPs and DAMPs are recognized by pattern recognition receptors (PRRs), 
whose engagement on phagocytes lead to the activation of these cells. Upon activation, 
phagocytes could engulf pathogens or pathogen-infected cells, and subsequently eliminate 
pathogens through several mechanisms. For example, phagocytes would increase oxygen 
consumption upon phagocytosis, causing a respiratory burst, which produces reactive oxygen 
species that could effectively kill the microbes. Alternatively, phagocytes could eliminate 
pathogens through lysozymes, proteases, lactoferrins, among others, to destroy the key 
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components of the microbes. In addition, phagocytes could release chemicals such as nitric oxide 
to eliminate microbes in adjacent locations. Moreover, certain types of phagocytes, such as 
macrophages and dendritic cells, could transport specific fragments of the engulfed antigens to 
their cell surface, and present these molecules to lymphocytes, a key component of the adaptive 
immune system that could initiate specific defense reactions against pathogens of interest.   
In addition to phagocytosis, certain innate immune cells could kill pathogens through 
other mechanisms. A class of innate immune cells called granulocytes (such as neutrophils, 
eosinophils, and basophils) and mast cells could undergo a process called degranulation, during 
which antimicrobial and cytotoxic molecules, such as myeloperoxidase, cathepsins, and 
histamines, are released to the extracellular space to combat infection. Neutrophils are also 
known for their abilities to secrete neutrophil extracellular traps (NETs), fibers composed of 
chromatin and proteases, that participate in the trapping and killing pathogens.  
A third kind of innate immune cells are natural killer (NK) cells. Instead of directly 
killing the invading pathogens, NK cells target a type of infected cells that lack major 
histocompatibility complex (MHC) I, whose expression on the cell surface labels the cell as 
“self”. NK cells kill by (1) natural killing, (2) antibody-dependent cellular cytotoxicity, (3) 
redirected lysis, and (4) lectin facilitated killing. They can also produce cytokines to amplify the 
immune responses by recruiting and/or activating other leukocytes. 
In addition, a recently discovered class of immune cells, called innate lymphoid cells 
(ILCs), also constitute another key cellular component of the innate immune system (Klose and 
Artis, 2016). Unlike many other innate immune cells, ILCs lack pattern recognition receptors 
(Robinette et al., 2015). Instead, they sense cytokines and inflammatory mediators secreted by 
parenchymal cells or myeloid cells. Upon engagement, ILCs promote immune responses by 
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secreting soluble factors, such as classic T helper cytokines including IFNγ and TNF for type 1 
ILCs (ILC1s), IL-5, IL-9, and IL-13 for ILC2s, and IL-17, IL-22, and GM-CSF for ILC3s. In 
addition, some previously unknown “ILC-specific” effector molecules are also secreted, such as 
amphiregulin (Monticelli et al., 2011; Robinette et al., 2015) and methionine-enkaphalin 
(Brestoff et al., 2015), which mediate epithelial cell repair and adipocyte beiging respectively. 
In addition to the cellular components discussed above, the complement system is also a 
key component of innate immunity that, together with B lymphocytes of the adaptive immunity, 
forms the humoral immune system (Dunkelberger and Song, 2010). It is composed of more than 
30 proteins circulating in the plasma that initiate a sequence of events on the surface of the 
pathogen to help eliminate the infection. The complement system can be engaged either upon 
identification of pathogen surface molecules, such as certain polysaccharides, or upon 
recognition of antibodies that bind to the pathogen surface. Upon activation, protein components 
will initiate a cascade of proteolytic cascades that eventually lead to the production of active 
opsonin and assembly of membrane attack complexes (MACs). Opsonins coat the pathogen 
surface, allowing either the phagocytosis of pathogens or membrane permeabilization by MACs 
that kill the invading bacteria. During the proteolytic events, a series of proinflammatory 
mediators are produced, leading to the amplification of immune responses by recruiting other 
effector cells.   
Collectively, phagocytes, granulocytes, natural killer cells, and innate lymphoid cells 
altogether build up the cellular arm of the innate immune system. These innate immune cells, 
along with humoral components such as the complement system, initiate immediate responses 
against invading pathogens in order to maintain the fitness of host organisms.  
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The innate immune system is evolutionarily conserved from vertebrate animals to plants. 
It relies on germline-encoded receptors to recognize microbes bearing conserved surface 
molecules that are shared by many organisms. Therefore, the innate immune system does not 
require an extended phase to initiate responses and could elicit rapid responses to combat 
pathogens. However, the range of pathogens that can be recognized by the innate immune system 
is limited, due to the restricted diversity of recognition machinery. Moreover, the efficiency of 
the innate immune system to eliminate recognized pathogens is constrained because microbial 
organisms could evolve more rapidly than the infected hosts and develop strategies to evade 
these defense mechanisms. For example, many bacteria adopted strategies that allow them to 
hide pattern recognition molecules from being recognized by the immune system. To address the 
limitations of the innate immune system, vertebrates developed the adaptive immunity with 
higher levels of specificity and diversity.  
 
1.2.2 Overview of the Adaptive Immune Responses 
Similar to the innate immune system, the adaptive immune system is also composed of 
both cellular and humoral immunity. The major components of the cellular arm of adaptive 
immunity are T lymphocytes, whereas B lymphocytes are the central players of the humoral 
immune system. “T” designates “thymus”, named so based on the observation that T cells 
undergo the maturation process in the thymus. “B” stands for “bursa of Fabricius”, the site of B 
cells production in birds. Mammals do not have the organs equivalent of bursa of Fabricius; 
instead, B cells in mammals are produced in the bone marrow.  
Unlike innate immune cells that can recognize a wide range of molecules commonly 
expressed by multiple pathogens, T and B lymphocytes recognize epitopes that are usually 
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unique to specific antigens. Both types of lymphocytes rely on their unique membrane receptors, 
termed T cell receptors (TCRs) and B cell receptors (BCRs) in the respective cell types, for this 
recognition. T cell receptors in most T cells are heterodimers of two chains designated alpha (α) 
and beta (β). Though a small fraction of T cells express TCR composed of gamma (γ) and delta 
(δ) chains. B cells express BCRs that are composed of cell surface-bound antibodies and signal 
transduction moieties. Each antibody is a Y-shaped molecule consisting of two identical 
polypeptide heavy chains and two identical light chains. Each heavy chain or light chain contains 
constant regions and variable regions. To generate TCRs and BCRs, a series of genetic 
recombination, known as V(D)J recombination, occurs in developing T cells and B cells 
respectively. The process involves somatic recombination events that occur at the locus of TCR 
genes and immunoglobulin genes, generating highly diverse products of TCRs and 
immunoglobulins that specifically recognize certain unique amino acid sequences. Therefore, 
both T and B cell responses are highly antigen-specific, which is one of the hallmarks of the 
adaptive immune system.  
T cells are present in several categories and accomplish their defense responses through 
different mechanisms. Broadly speaking, T cells can be classified into effector T cells, regulatory 
T cells, and memory T cells. Effector T cells are activated cells that are relatively short-lived. 
These cells are responsible for eliminating pathogens upon activation by the innate immune 
responses. Memory T cells do not immediately become active, even though they are usually 
produced at the same time as effector T cells. Instead, they are long-lived, persist after the 
resolution of inflammation, and could mount quicker immune responses upon secondary 
exposure to the same antigen. On the other hand, the role of regulatory T cells (Tregs) is to 
modulate and prevent excessive immune responses. Tregs ensure the balance between effective 
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immunity that damages the invaders and immunopathology that damages the host, keeping other 
immune cells at bay so that effectors do not cause unnecessary tissue damages as they control or 
eliminate infections.  
T cells activation is a tightly regulated process that requires multiple signals integrated 
together. First signal is initiated when TCRs recognize pathogen-specific peptides that are 
presented by MHC molecules on antigen presenting cells. It is important to note that T cells do 
not recognize free-floating antigens, but can only recognize peptide-MHC (pMHC) complex. 
This TCR-pMHC binding requires co-receptors that include at least CD3 along with either CD4 
or CD8. In addition, T cell activation requires a second “co-stimulatory” signal, without which T 
cells would be rendered “anergic”, or non-functional, by TCR-pMHC engagement alone. One of 
the best-characterized co-stimulatory molecules on T cells is CD28, which binds to CD80 or 
CD86 on antigen presenting cells and then triggers downstream signaling pathways to enable T 
cell expansion and differentiation. To ensure a proper T cell differentiation program that caters to 
the need of the pathogenic challenge, a third signal is triggered by inflammatory cytokines within 
the local environment. The cytokine milieu not only has a key influence on the kind of T cells 
being produced, but also determines if the first two signals lead to tolerance, effector T cell 
activities, or immune memory. The three signals are highly integrated to ensure proper T cell 
activation. 
Effector T cells are predominantly composed of cytotoxic T cells and helper T cells. 
While other less abundant populations, including natural killer T cells, gamma delta T cells, and 
mucosal associated invariant T cells, are also subclasses of effector T cells. Cytotoxic T cells 
express CD8 molecules on their cell surface; they are activated by antigen presenting cells that 
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present antigens on surface MHC class I molecules (MHCI). Helper T cells express CD4 on their 
surface and are activated by peptides on MHC class II molecules (MHCII).  
Cytotoxic T cells, or CD8+ T cells, kill pathogen-infected cells mainly through two 
mechanisms. When confronting infected cells, CD8+ T cells can release a series of cytotoxic 
granules including perforin, granzymes, and granulysin. Perforin and granulysin could form 
pores on the target cells, allowing granzymes, a family of serine proteases, to enter and initiate a 
cascade of apoptotic events.  CD8+ T cells can also upregulate Fas ligand upon encounter with 
and recognition of infected cells. Fas ligand can bind to Fas molecule of the target cells and 
initiate receptor-mediated extrinsic apoptosis pathways.  
T helper cells, or CD4+ T cells, do not directly kill pathogen-infected cells. Instead, their 
functions are mainly carried out through the release of cytokines that help the activities of other 
immune cells. These include mediating class switching in B cells, activating cytotoxic T cells, 
and modulating phagocytosis in macrophages. The type of cytokine milieu has a direct influence 
on what type of T helper cells are generated during CD4 activation, and different types of CD4+ 
T cells are able to produce different kinds of cytokines to respond to the challenges brought forth 
by various pathogens. The major classes of T helper cells are Th1 and Th2 cells. Th1 cells are 
mainly responsible for combatting against intracellular bacteria and protozoa. They are activated 
by IL-12 and IL-2 that trigger downstream signaling that converge to transcription factors 
STAT4 and T-bet. Th1 cells predominantly produce IFN-γ, which triggers macrophage 
phagocytosis and activates iNOS to produce bactericidal radicals. Th1 cells are also potent at 
activating CD8+ T cells to produce cytotoxic molecules to kill compromised cells. Th2 cells are 
responsible for defending against extracellular parasites, including helminthes. They are 
activated by IL-4, through STAT6 and GATA3, and produce IL-4, IL-5, IL-9, and IL-13 as 
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effector cytokines. These effectors activate eosinophils, basophils, and mast cells to attack 
parasites. IL-4 also stimulates B cell to produce immunoglobulin E (IgE) that further stimulates 
mast cells to produce inflammatory mediators. IL-4 also acts in an autocrine fashion to enhance 
Th2 responses. Th2 cells can also produce IL-10 that suppresses Th1 differentiation. In addition 
to Th1 and Th2 cells that make up the majority of the CD4+ effector T cell populations, there are 
also other T helper cell types. Th17 cells play a role in clearing extracellular bacteria and fungi 
mostly at the skin and mucosal surfaces. Th22 cells are involved in wound healing responses in 
the skin by acting on keratinocytes, myofibroblasts, and epithelial cells. Folicular helper T cells 
(TFH) regulate the development of antigen-specific B cells in secondary lymphoid organs. There 
are also other less well-established helper T cells, such as Th9 cells, which may constitute their 
own distinct lineages. 
Responses by effector T cells are tightly regulated to ensure that the system could 
discriminate between self and non-self and that the adaptive immune responses do not overshoot 
to cause autoimmunity. Regulatory T cells, or Tregs, play a critical role in regulating effector T 
cell activities. These cells are characterized by high level of IL-2 receptor and glucocorticoid-
induced TNFR family related gene (GITR) on their surface, and unique expression of the 
transcription factor FoxP3. Tregs regulate or suppress effector T cells (and potentially other 
immune cells) through several possible mechanisms. First, Tregs have high levels of IL-2 receptor 
expression on their cell surface, which could serve as a reservoir that deprives the other T cells of 
this activating cytokine. In addition, Tregs are potent producers of transforming growth factor 
beta (TGFβ) and IL-10, which could either suppress the abilities of antigen presenting cells to 
activate effector T cells or downregulate T cell effector activities. Cell-cell contact-based 
mechanisms could also mediate Treg-based immune suppression.  
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In addition to effector T cells and regulatory T cells, a third class of T cells constitute 
memory T cells, which are long lived T cells generated during primary immune responses and 
respond to cognate antigens during secondary encounters. Memory is the second hallmark of the 
adaptive immune system.  
The principal function of B cells is to generate antibodies against soluble antigens. Unlike 
T cells that can only recognize peptides presented on MHC molecule, antibodies can recognize 
free-floating antigens. Antibody functions are several fold: first, antibodies can block and 
neutralize parts of the pathogen surface, rending the pathogen incapable of effective attacks. 
Second, antibodies can perform agglutination, a process in which invading cells are glued into 
clumps that are processed for phagocytosis. Similarly, antibodies can precipitate serum-soluble 
antigens out of solution, rendering them recognizable by phagocyte. In addition, antibodies that 
bind to foreign microbes can activate the complement system, allowing the formation of 
membrane attack complexes that lead to the lysis of the invaders. In a similar process, antibody-
bound pathogen can also be recognized by cellular immune components, such as NK cells.  
Like T cells, B cells are activated by several signals. First signal comes when BCRs bind 
to antigens. B cells then endocytose the antigen along with BCR, process the antigen that is then 
presented onto surface MHCII molecules, which subsequently act as antigen presenting cells and 
interact with cognate CD4+ T cells. These T cells would then provide the second signal to B 
cells for further activation. Upon activation, B cells would proliferate and form germinal centers 
in secondary lymphoid organs. In the germinal centers, activated B cells would differentiate into 
antibody-secreting plasma cells and memory B cells. Similar to the T cell counterpart, plasma 
cells would serve as immune effectors and carry out their functions by secreting antibodies, 
while memory B cells would persist for future infections.  
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In conclusion, T and B lymphocytes constitute the cellular and humoral aspects of the 
adaptive immune system. With unique features of antigen specificity and memory, adaptive 
immunity cooperates with innate immune players to form a tightly regulated defense system. 
This system not only plays a key role in defending the host organisms against foreign pathogens, 
but also protects the organisms against attacks arisen within the “self”. Cancer is a classical 
example of such self-attacks. 
 
1.2.3 Immune Responses in Cancer 
The presence of immune cells in cancer was observed a long time ago, with the earliest 
known report by Rudolf Virchow in the 19th century. Ever since, the immune system was 
postulated to play a role in protecting organisms against malignant diseases. In the last two 
decades, these postulations were corroborated by experimental evidence in mouse models, as 
mice deficient in various aspects of the immune system are more prone to develop carcinogen- or 
oncogene-induced tumors or even spontaneous tumors. These pieces of evidence led to the 
generation of the “immune surveillance” theory, which proposes the protective role of the 
immune system. Indeed, mice deficient in the generation of functional T and B lymphocytes 
have higher chances of developing tumors upon induction (Shankaran et al., 2001). This is 
exacerbated when natural killer cells are also depleted, suggesting the involvement of innate 
immunity in cancer surveillance (O'Sullivan et al., 2012). Deficiencies of certain molecules in 
myeloid cells, as exemplified in CD80 and CD86 double knockout mice that lack co-stimulatory 
signals, are also more susceptible to carcinogen-induced sarcoma development (Loser et al., 
2005), which further illustrates an integrated defense mechanism that involves interactions 
between innate and adaptive immune components. Cytokines likely play an important role 
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during this coordination, especially type I cytokines. Mice lack interferons (Dunn et al., 2005; 
Kaplan et al., 1998), interferon receptors (Kaplan et al., 1998), and certain type 1 interleukins, 
such as interleukin (IL)-12 and IL-23 (Langowski et al., 2006; Liu et al., 2004), are all prone to 
tumorigenesis. While being supported by a large number of mouse studies, the surveillance 
theory adopts a one-dimensional and static view of the role of the immune system. Later 
evidence suggested that the interactions between cancer and the immune system are rather 
dynamic. Therefore, a newer “immune editing” theory was developed, which adds the dimension 
that the immune system also sculpts the tumors. The immunoediting process is composed of 
three distinct phases: elimination, equilibrium, and escape. The elimination phase is evidenced 
by the experimental approaches that corroborate the “surveillance” mechanisms. Equilibrium 
phase occurs when the immune system fails to eliminate cancer cells but is able to suppress their 
outgrowth. This phase was mostly inferred from clinical observations, but later supported by a 
number of experimental animal models. The first piece of evidence came from a lose dose 
carcinogen treatment, where the majority of the mice do not develop tumors. However, if T cells 
were depleted after a prolonged tumor-free period after carcinogen treatment, mice would 
develop malignant diseases (Koebel et al., 2007). This suggests the capabilities of the immune 
system to suppress the outgrowth of tumor cells for an extended period of time. This equilibrium 
regulates both the primary tumor development and the occurrence of metastasis (Eyles et al., 
2010). Unlike the elimination phase, in which both the innate and adaptive immune systems are 
important, equilibrium seems to rely mostly on adaptive immunity, which likely contains tumor 
cells in an antigen-specific manner. As tumors exit the equilibrium phase, they would escape 
immune regulation. Cancer patients present diseases that are in the “escape” phase.  
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Tumors escape immune attacks through both the suppression of anti-tumor immunity and 
the augmentation of pro-tumor immune responses. To negatively suppress inhibition by the 
immune system, tumor cells can suppress dendritic cell activities through the secretion of a series 
of cytokines and factors, such as adenosine (Novitskiy et al., 2008) and prostaglandin E2 (Lee et 
al., 2002). They can also evolve strategies that evade the recognition or phagocytosis by 
dendritic cells or macrophages. For example, multiple types of tumors have upregulated level of 
CD47, a molecule that delivers “do-not-eat-me” signals to phagocytes. These disruptions in 
myeloid cell activities lead to the prevention of antigen processing. As a consequence, antigen 
presentation becomes compromised in secondary lymphoid tissues. Therefore, anti-tumor T cells 
do not become activated or traffic to the tumor site. Even when confronting the activated and 
infiltrated T cells, tumor cells also have strategies to avoid attacks. They could downregulate 
MHCI molecules on their cell surface or alter their own antigen presentation machinery, both of 
which help hiding tumor antigens from T cell recognition. They can suppress lymphocyte 
activities through paracrine mechanisms, such as the upregulation of PD-L1 or shedding of 
NKG2D ligands, which renders anergy and suppress T cell/NK cell effector functions (Nausch 
and Cerwenka, 2008).  
On the other hand, tumors often augment the myeloid compartment and the inhibitory 
arm of the adaptive immune system to allow immune escape. One of the hallmarks of many 
types of cancers is the extensive infiltration of immune cells. These include cells from both the 
myeloid lineage (such as macrophages, neutrophils, immature dendritic cells (DCs)) and the 
lymphoid lineages (such as regulatory T cells). Myeloid cells, including macrophages and 
neutrophils, have plastic phenotypes. Even though they could be equipped with cytotoxicity and 
anti-tumor activities, they are polarized in the tumor microenvironment to promote cancer 
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progression through various mechanisms. They do so by secreting growth factors that sustain the 
proliferation and survival of cancer cells, promoting angiogenesis, and metabolically inhibiting 
anti-tumor adaptive immune responses. Similarly, the dendritic cell compartment is 
reprogrammed. Conventional dendritic cells that are able to functionally activate CD8+ T cells 
are scarce in many tumors, due to a combination of defects in DC recruitment and tumor-induced 
DC apoptosis (Ma et al., 2013). Instead, tumors could recruit DCs with immature phenotype 
characterized by low MHC molecules and co-stimulatory molecules, such as CD80 and CD86, 
and inefficient motility (Kim et al., 2006; Mahnke et al., 2002; Palucka and Banchereau, 2012). 
Activation by these DCs lead to tolerogenic T cell activation, as evidenced by the induction of 
regulatory T cell responses (Jonuleit et al., 2000) instead of antigenic activation. Cancers often 
upregulate the infiltration of regulatory T cells to suppress the functions of CD8+ cytotoxic and 
Th1 T cells, thereby rendering the tumor cells tolerated by the immune system. 
One of the corollaries of the immunoediting theory is that the immune system only 
attempts to sequester tumor initiation. While this may truly be the function of effector CD4+ and 
CD8+ T cells, other components of the immune system could promote the growth of nascent 
tumor cells instead. This is evidenced the demonstration of chronic inflammation as a significant 
risk factor for cancer (Hussain and Harris, 2007). During inflammation, tissue-infiltrating 
leukocytes could produce a large number of inflammatory mediators, such as reactive oxygen 
species, reactive nitrogen species, and cytokines, which could disrupt the environment that is 
suitable for the homeostasis of parenchymal cells. Possible disruptions include tissue damage, 
fibrosis, angiogenesis, and hypoxia (Mantovani et al., 2008; Multhoff et al., 2011). Inflammatory 
mediators, along with tissue disruptions caused by these factors, could promote genome 
instabilities and genetic alterations that lead to the initiation of tumorigenesis (Grivennikov and 
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Karin, 2010). In addition, epigenetic changes could be induced in premalignant cells. Stress 
could also disrupt proteostasis, by stimulating the over-production of heat shock proteins for 
example, that overwhelms the healthy cellular activities. While surveillance mechanisms exist to 
eliminate transforming cells, inflammation could supply pro-survival factors and nutrients that 
even overcome transformation-induced stress, such as oncogene-induced senescence. Moreover, 
a number of inflammatory cytokines could promote epithelial-to-mesenchymal transition, which 
upregulates the invasiveness and mobility of transformed or transforming cells.  
In conclusion, the interactions between the tumor and the immune system are dynamic 
and complex. The immune system could restrain and eliminate nascent tumor cells, while 
chronic inflammation could participate in the promotion of tumorigenesis. Established tumors 
could evade immune recognition, while the immune system could also be utilized to target tumor 
cells. In order to better target the immune system to treat cancer, it is imperative to have a better 
understanding of how the immune system could function and how these processes could go awry 
in cancer-bearing organisms. This dissertation focuses on one of the most abundant innate 
immune cells in many types of tumors, macrophages.  
 
1.3 Overview of Macrophage Biology 
1.3.1 Macrophages in Pathogen Infection  
Macrophages were originally discovered by Ellie Metchnikoff. Named after Greek words 
“makro” (large) and “phagein” (eat), these cells are known for their abilities to engulf and digest 
pathogens, cellular debris, and infected or transformed host cells. As a key component of the 
innate immune system, macrophages play important roles in the clearance of pathogen during 
infections by bacteria, viruses, fungi, and parasites. 
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Macrophages are present in almost all mammalian organs, including the sites that are 
susceptible to the initial attacks of invading pathogen. Because of their locations, tissue resident 
macrophages are often a key player in the initial phase of the combat against pathogens. 
However, tissue resident macrophages alone may not be sufficient to mount a sufficient defense. 
To ensure a sufficient number of defense effector cells, affected tissues would also send signals 
to recruit more inflammatory monocytes from circulation that differentiate into macrophages 
upon infiltration into affected tissues. In most infectious diseases, recruitment provides the major 
source of macrophages. The C-C motif chemokine ligand 2 (CCL2) and CCL2 receptor 2 
(CCR2) signaling pathway is essential for monocyte recruitment (Pierce et al., 1990). Other 
cytokines and chemokines also demonstrated monocyte-attracting activities. These include 
macrophage colony-stimulating factor (M-CSF, also known as CSF-1), granulocyte-macrophage 
colony-stimulating factor (GM-CSF, or CSF-2), CCL3, CCL5, CCL8, vascular endothelial 
growth factor (VEGF), placental growth factor (PlGF), and CXC-motif ligand-12 (CXCL12) 
(Coffelt et al., 2009), although their relevance in vivo is less well established. Deficiency in 
monocyte recruitment compromises immune responses against bacteria including Listeria 
monocytogenes, Toxoplasma gondii, and Mycobacterium tuberculosis, viruses including 
influenza, and fungi infections (Serbina et al., 2008; Shi and Pamer, 2011; Zhang and Wang, 
2014). On the contrary, during helminth infections, macrophages undergo proliferation at the site 
of infection independently of blood recruitment (Jenkins et al., 2011). However, in certain 
helminth infection models, such as Schistosoma mansoni infection, in situ proliferation occurs in 
monocyte-derived macrophages instead of tissue resident macrophages (Nascimento et al., 2014). 
These data suggest that recruitment and local proliferation may occur sequentially or 
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simultaneously to supply sufficient quantities of macrophages for defense against foreign 
pathogens. 
At the infection site, macrophages become activated and contribute to the clearance of 
pathogens by a range of effector mechanisms. To recognize pathogens or pathogen-affected cells, 
macrophages are equipped with pattern recognition receptors (PRRs) to recognize pathogen-
associated molecular patterns and damage-associated molecular patterns. These PRRs include 
membrane-bound toll-like receptors (TLRs) and C-type lectin receptors (CLR2), and 
cytoplasmic NOD (nucleotide-binding oligomerization domain)-like receptors (NLRs) and RIG 
(retinoid acid-inducible gene)-I-like receptors (RLRs) (Takeuchi and Akira, 2010). Altogether, 
these pattern recognition receptors recognize molecules associated with microbes (such as 
lipopolysaccharides, flagellin, and single-stranded or double-stranded RNA), and molecules 
associated with cellular damages that represent the “danger” signal (such as extracellular 
adenosine triphosphate (ATP) and high motility group box 1 protein, both of which are released 
by injured cells). Upon the engagement of PPRs, the intracellular signaling pathways triggered 
downstream will lead to transcriptional activation of inflammatory mediator genes followed by 
the production and secretion of these factors. In addition to PRRs, macrophages are also armed 
with a wide range of receptors for immunomodulatory cytokines. Engagement of different 
cytokine receptors could lead to differential activation of macrophages (Mosser and Edwards, 
2008). An over-simplistic classification categorizes macrophage activation status into M1 and 
M2, corresponding to classically activated macrophages and alternatively activated macrophages. 
This nomenclature was proposed to parallel the classification of T cell differentiation into Th1 
and Th2 cells. Cytokines such as interferon gamma (IFNγ) and tumor-necrosis factor (TNF) 
activate M1 macrophages, which then produce pro-inflammatory cytokines, promote Th1 
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responses, and cause extracellular matrix (ECM) destruction and apoptosis. Exposure to 
cytokines such as interleukin (IL)-4 leads to the activation of M2 macrophages, which promote 
Th2 responses, ECM construction, and wound healing. However, this simplistic scheme 
underestimates the variety of cytokines available in the tissue environment; macrophages are 
usually exposed to a large number of factors of different flavors at the infection sites. Indeed, 
increasing amount of data demonstrate a large spectrum of activation status that fits between and 
beyond the M1 and M2 dichotomy (Murray et al., 2014; Xue et al., 2014), which allows 
macrophages to carry out different functions tailored to the needs of specific pathogenic 
challenges.  
To clear pathogens, activated macrophages perform phagocytosis, engulfing not only 
microbes but also microbe-infected cells. As discussed earlier, macrophages could initiate a 
series of microbicidal activities following phagocytosis, such as producing ROS during 
respiratory burst and synthesizing proteolytic enzymes to digest microbial components. Other 
than killing engulfed microbes, macrophages could kill extracellular pathogens or infected cells 
in proximity through the secretion of metabolites that have microbicidal activities. These 
metabolites include indoleamine-pyrrole 2,3 dioxygenase (IDO) and nitric oxide. Macrophages 
could also upregulate apoptosis-inducing molecules, such as Fas ligand, which gets rid of 
infected cells in a paracrine manner. In addition to direct microbicidal mechanisms, macrophages 
also secrete various proinflammatory cytokines and chemokines that recruit other effector 
leukocytes to the infection sites to clear pathogens. For example, CXC-motif ligand-10 (CXCL-
10) and CXCL-11 secretion induces the infiltration of CD8+ T cells and Th1 cells to control 
virus and intracellular bacteria infections. Secretion of IL-17 could attract Th17 cells to fight 
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fungus infections at certain sites. IL-4 and IL-13 could attract granulocytes such as eosinophils to 
combat parasites. 
During the clearance of infection, immune responses cause tissue damages due to the 
release of cytotoxic molecules and metabolites. A functional immune response dictates the 
inevitable consequence of immunopathology, compromising the short-term health of the host in 
exchange for long-term fitness of a pathogen-free organism. However, upon elimination of 
invading pathogens, uncontrolled inflammation needs to be avoided. Macrophages play a critical 
role in the resolution of immune responses against infections. They engulf effector immune cells 
that have accomplished their microbicidal functions. They adopt the “M2” activation state and 
secrete immunosuppressive cytokines that inhibit potentially excessive cytotoxic activities. They 
can also initiate the wound-healing process through actions on non-hematopoietic cells. For 
example, macrophages secrete factors such as transforming growth factor-beta (TGFβ) and 
metalloproteinases to activate fibroblast cells, which in turn lay out ECM molecules to serve as a 
scaffold for tissue repair (Ortega-Gomez et al., 2013).   
 
1.3.2 Macrophages in Development and Homeostasis 
In addition to defending the host against pathogen infections, another important function 
of macrophages is to maintain tissue integrity of an organism. First, they are necessary in 
embryonic and neonatal development, during which organs develop into functional units that 
perform designated activities of an organism. In adult organisms, macrophages are also involved 
in the maintenance of homeostasis.  
The necessity of macrophages during development was manifested by a series of tissue 
abnormalities in mice that have a deficiency in macrophage colony-stimulating factor (MCSF, 
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also known as CSF1). Abnormalities cover a wide range of tissues, including the bone, 
mammary gland, kidney, and pancreas (Pollard, 2009). More dramatically, PU.1 deficient mice 
that lack macrophages are embryonically/neonatally lethal, which further suggests the 
importance of macrophages during development.  
Macrophages regulate proper tissue development through several mechanisms. First, they 
provide factors that sustain the survival and proliferation of tissue parenchymal cells during 
development. This is best studied in brain development, where neuron viability relies on the 
presence of macrophages. In addition to supplying pro-survival factors, macrophages are also 
involved in fine-tuning and promoting the functions of parenchymal cells. Brain resident 
macrophages, called microglia, have also been indicated to modulate neuron activities, prune 
synapses during development, and maintain neural circuits and brain structure (Erblich et al., 
2011). In addition to the regulation of terminally differentiated cells, microglia may also regulate 
neural stem cells during development (Nandi et al., 2012). Similarly, macrophages are also 
important in maintaining the viability and functions of mammary gland stem cells (Gyorki et al., 
2009) during development. 
In addition to its actions on parenchymal cells and/or tissue stem cells, macrophages are 
also important for remodeling the tissue structure. They do so through modifications of the 
extracellular matrix and vasculature. Moreover, processing cell death and cellular debris is 
another key mechanism by which macrophages oversees proper development. Development is 
accompanied by constant tissue remodeling, during which a lot of cells and structures that form 
temporarily will need to be recycled. These cells would receive signals to undergo apoptosis. 
Macrophages play a critical role at clearing apoptotic cells, both to avoid unnecessary or 
detrimental inflammation, and to clear space for further construction/reconstruction. A best-
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known example is the disappearance of interdigital webs that formed during limb development, 
in which macrophages have been shown to actively scavenge the apoptotic cells (Gregory and 
Devitt, 2004). Not only are macrophages necessary for the recycling of apoptotic cellular debris, 
they are also active inducers of apoptosis. For example, during eye development, macrophages 
induce apoptosis through Wnt-dependent pathways in order to optimize the patterning of 
vasculature in the developing eye (Lobov et al., 2005).  
Even though the vast majority of data defining the functions of macrophages were 
obtained from development and pathological conditions, these cells are also essential for the 
maintenance of organismal homeostasis. Homeostasis is not a static condition, but instead 
involves various events occurring in a very dynamic manner. Maintenance of hair is a great 
example, in which hair follicles undergo various phases to allow hair to grow. Hair follicle 
cycling not only happens in response to hair loss but is also involved during the homeostatic hair 
turnover. Macrophages can be activated to secrete factors that stimulate the active cycling of hair 
follicle stem cells to promote hair growth (Castellana et al., 2014). In the hematopoietic system, 
depletion of macrophages led to impaired generation of erythroblasts and caused peripheral 
blood anemia (Chow et al., 2013). This suggests that macrophages are important for the 
maintenance of the blood system that provides oxygenation to all organs, potentially through 
interactions between bone marrow resident macrophages and hematopoietic progenitor cells. In 
extramedullary hematopoietic sites, macrophages were shown to retain hematopoietic stem cells 
(HSCs) in the splenic niche, which is essential for maintaining HSC functions (Dutta et al., 2015). 
Macrophages have also been reported to interact with tissue stem cells in various organs, 
including the liver (Boulter et al., 2012), heart (Ben-Mordechai et al., 2013), mammary gland 
(Gyorki et al., 2009), colon (Pull et al., 2005), and intestine (Saha et al., 2016). More 
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experimental evidence is needed to define to what extent are these interactions involved in the 
regulation of tissue homeostasis needs.  
In addition to activating cellular activities, macrophages can also participate in 
homeostasis by maintaining immune quiescence, i.e. inhibiting the activation of immune cells. A 
classic textbook example is the participation of macrophages in clearing out apoptotic cell 
products in a process called “efferocytosis”. Apoptotic cells undergo membrane flipping, where 
the inner leaflet of the cell membrane becomes exposed to the outside. Inner membrane 
phosphatidylserine was also translocated to the outer membrane, which is recognized by 
macrophages. Upon the receipt of this “eat me” signal, macrophages engulf apoptotic cells, 
which limits the non-discriminatory release of cellular materials that could trigger unnecessary 
inflammation (Arandjelovic and Ravichandran, 2015). Efferocytosis is essential for maintaining 
the non-phlogistic (not causing inflammation) nature of apoptosis, which is distinguished from 
necrosis. In a similar fashion, macrophages also get rid of senescent cells, as exemplified by the 
clearance of senescent red blood cells by splenic macrophages (Kohyama et al., 2009). In 
addition, macrophages can secrete other immune dampening factors, such as complement 
component 1q, resolven E1, protectin D1, and galectin, among others, to alleviate unnecessary 
immune responses (Pinto et al., 2014).  
Moreover, macrophages are important for maintaining metabolic homeostasis in response 
to environmental changes, such as temperature decrease and caloric intake. Brown adipose tissue 
(BAT) is the primary thermogenic organ upon exposure to low temperature. BAT resident 
macrophages are required for metabolic adaptation to cold. Upon alternative “M2” activation, 
these macrophages secrete norepinephrine that stimulates sympathetic nerve cells to activate the 
thermogenic programs within the BAT (Nguyen et al., 2011). White adipose tissue is responsible 
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for long-term storage of nutrients and regulates systemic metabolic activities through hormone 
release. In lean animals, alternatively activated macrophages maintain insulin sensitivity in 
adipocytes, partially through the secretion of IL-10 (Odegaard and Chawla, 2013). As mice 
develop from lean into fat physique under the influence of high fat diet, classically activated 
macrophages infiltrate WATs and remodel these tissues during their enlargement (Lumeng et al., 
2007). High fat diet also causes increased lipid storage in hepatocytes; liver resident 
macrophages, or Kupffer cells, participate in this process by regulating fatty acid oxidation in 
hepatocytes. Disruption in the alternative activation of Kupffer cells led to insulin resistance and 
steotosis (Kang et al., 2008).  During the increased uptake of fatty acid mentioned above, 
macrophages act as lipid sensors and trigger the corresponding responses through the activation 
of peroxisome proliferator activator receptors (PPAR) (Jantsch et al., 2014). Similarly, 
macrophage activation is also altered to respond to changes glucose levels (de Souza et al., 2008). 
Another critical aspect of homeostasis is the balance in body fluids. While kidney is the 
principal organ that regulates salt and water in an organism, the skin does not equilibrate readily 
with the plasma, and therefore is less susceptible to renal homeostatic control (Titze, 2014). 
Interestingly, macrophages infiltrate to hypertonic sites of the skin where sodium and chloride 
levels are above the normal threshold. These macrophages sense interstitial electrolytes, possibly 
through the engagement of pattern recognition receptors, which trigger inflammasome activation 
(Ip and Medzhitov, 2015). Consequently, nuclear factor of activated T-cells 5 (NFAT5) is 
activated to initiate essential transcription programs in response to the osmotic stress (Muller et 
al., 2013).  
In conditions where homeostasis is disrupted, macrophages are important for restoring 
the normal functions of a tissue, in processes such as tissue regeneration. This is evidenced by 
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delayed tissue repair upon macrophage depletion. A key mechanism relies on the ability of 
macrophages to clear senescent cells and cellular debris through phagocytosis, which is believed 
to create an environment that is permissive to regeneration (Yun et al., 2015). For example, in a 
non-inflammatory lung injury model that mimics damages caused by respiratory stress, 
macrophages selectively deplete the dysfunctional type II lung epithelial cells, therefore 
alleviating the consequences of injury (Miyake et al., 2007). In addition, angiogenesis can also 
compensate for the lack of oxygenation at the injury site and facilitate tissue repair; macrophages 
have been shown to provide critical signals for angiogenesis. This has been shown in multiple 
pathophysiological processes, such as the repair during myocardial infarction (Aurora et al., 
2014) and peripheral nerve damage (Cattin et al., 2015).  	  
1.3.3 Macrophages in Malignant Diseases 
Macrophages can promote the initiation of tumorigenesis by promoting chronic 
inflammation as discussed in Section 1.2.3. Chronic inflammation may cause DNA damages, 
lead to genome instabilities, and generate a hostile tissue environment. In addition, depletion of 
macrophages in pancreatic ductal adenocarcinoma correlated with significantly reduced number 
of cells with tumor-initiating properties, suggesting that macrophages could also promote tumor 
development through actions on “cancer stem cells” (Yang et al., 2013). Such activities could be 
executed through the activation of the signal transducer and activator of transcription 3 (STAT3) 
signaling pathway within the neoplastic compartment (Mitchem et al., 2013). 
Beyond the inception of tumorigenesis, macrophages can also promote the progression of 
established tumors. They are highly abundant in tumor tissues in many types of cancers. High 
levels of macrophage infiltration in the tumor tissue, also called “tumor-associated macrophages” 
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(TAMs), correlate with worse patient outcome in most types of cancers. One exception is 
colorectal cancers, where contradictory roles of macrophages have been reported (Khorana et al., 
2003; Lackner et al., 2004; van Netten et al., 1993). These inconsistencies could be due to 
variations in the timing of the disease progression and the location of macrophages that were 
examined in different studies. Other than colorectal cancer, TAMs tends to play pro-tumorigenic 
roles through various mechanisms that facilitate tumor progression. 
First, TAMs can produce growth or survival factors that enhance the proliferation and 
viability of tumor cells. A classic example came from studies looking at the MMTV-PyMT 
breast cancer mouse model, in which macrophages recruited in a CSF1-dependent manner 
secrete epidermal growth factor (EGF) that stimulates the division of neoplastic cells. In this 
model, EGF also enhances the invasiveness of the cancer cell (Goswami et al., 2005; Patsialou et 
al., 2009).  
Second, macrophages can remodel the stromal components that are normally present in 
the tissue to support organ functions, and skew their activities to facilitate tumor development. 
Two examples are blood vessels and fibroblast cells, whose activations by TAMs lead to 
angiogenesis and fibrosis respectively. The involvement of TAMs in promoting angiogenesis has 
been demonstrated in mice deficient in macrophage recruitment, which have reduced vasculature, 
increased hypoxia and reduced tumor growth and metastasis (De Palma et al., 2005; Pucci et al., 
2009). TAMs secrete an extended list of cytokines, such as VEGF, CXCL12, which promote 
angiogenesis and vascularization through several mechanisms: they could trigger 
sprouting/branching of pre-existing blood vessels by promoting the protrusion of a selected 
endothelial cell. Alternatively, endothelial progenitor cells could be recruited from the 
circulation system to the tumor site and differentiate to new endothelial cells that line up blood 
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vessels; this process is called “vasculogenesis”. In a fashion similar to angiogenesis, TAMs can 
also remodel the lymphatic vessels through lymphangiogenesis, which will not be discussed here. 
As tumor vasculature is remodeled, basement membranes underlining the endothelial cells also 
need to be remodeled. TAMs can accomplish this remodeling function through the secretion of 
metalloproteinases (MMPs), such as MMP-9 (Coussens et al., 2002).   
TAMs, especially the “M2” polarized macrophages, are well known for their abilities to 
promote fibrosis through the secretion of profibrotic cytokines that activate fibroblast cells. 
Quiescent fibroblasts would then become myofibroblasts and lay down extracellular matrix 
molecules. The best-studied cytokine involved in this process is TGFβ, which induces fibroblast 
proliferation and upregulates the transcription of profibrotic genes, including collagens and 
fibronectin (Border et al., 1990; Haberstroh et al., 1993), through the phosphorylation of Smad 
molecules (Meng et al., 2016). In addition to inducing the differentiation of fibroblasts into 
myofibroblasts, macrophages also play a role in sustaining myofibroblast survival through the 
stimulation of nuclear factor kappa B (NF-κB) activities (Pradere et al., 2013). In a similar 
mechanism, macrophages can produce factors that promote epithelial-to-mesenchymal transition, 
during which epithelial cells lose their identity and adopt a fibroblast phenotype and lay down 
ECMs (Usunier et al., 2014). Surprisingly, TAMs could also promote fibrosis by directly 
producing ECM molecules without involving the activation of fibroblasts. A recent proteomic 
study in colorectal cancer models demonstrated that TAMs produced a wide range of collagens, 
peoteoglycans, glycoproteins, and ECM modulators (Afik et al., 2016). It remains to be seen if 
TAMs in other cancers can also directly lay down ECM molecules. As a side note, though the 
angiogenic and pro-fibrotic functions of macrophages have been shown in multiple tissue 
contexts, it is not clear if all macrophages have the same potential to execute these activities, or 
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if only a subset of macrophages are capable of doing so. Characterization of angiogenic TAMs 
led to the identification that these cells represent a TIE2-expressing subset of macrophages (De 
Palma et al., 2005; Lewis et al., 2007). More recently, an atypical progenitor-like 
monocyte/macrophage population was identified to be necessary for fibrosis (Satoh et al., 2017). 
It remains to be seen to what extent in vivo are different macrophage subsets involved in these 
processes.  
The third tumor-promoting mechanism involves the suppression of anti-tumor immune 
responses. Macrophages can secrete anti-inflammatory cytokines to inhibit the recruitment of 
CD8+ and Th1-biased CD4+ T cells. They can metabolically suppress the activities of anti-
tumor T cells, by depleting the L-arginine in the environment that is necessary for T cell 
functions, through the secretion of L-arginine processing enzymes, nitric-oxide synthase and 
arginase I. TAMs could also chemically modify T cell receptors to inhibit their recognition of 
tumor antigens through molecules such as peroxynitrite. TAMs can also engage with T cells in a 
paracrine manner through surface markers such as co-stimulatory molecules. Upon engagement 
with macrophages, T cells could activate signaling pathways downstream of cytotoxic T 
lymphocyte antigen-4 (CTLA4) and programmed death-1 (PD1), which drive the cells towards 
an anergic or exhausted phenotype, rendering T cells non-functional. Macrophages also produce 
chemokines to recruit immunosuppressive regulatory T cells, through the secretion of CCL-17 
and CCL-22 for example.  
Through these integrated actions on tumor cells, fibroblasts, endothelial cells, and 
adaptive immune cells, macrophages create an environment that facilitates tumor growth and 
invasion but deters effective immune responses, thereby facilitating tumor progression.  
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Macrophages not only promote primary tumor growth but also accelerate metastasis. This 
could occur during both the intravasation process at the primary tumor site and the extravasation 
process at the metastatic/pre-metastatic site. TAMs at the primary tumor site promote the 
invasion of tumor cells through the secretion of factors such as EGF and vascular endothelial 
growth factor (VEGF) (Qian et al., 2011), thereby allowing tumor cells to enter circulation and 
home to distant organs. Metastasis-associated macrophages (MAMs) can capture circulating 
tumor cells and retain them at the pre-metastasis site, which extends the duration at which newly 
arrived tumor cells could interact with the pre-metastatic niche. This extended duration could 
allow further modifications to the tissue, and increases the possibilities of neoplastic cell 
extravasation to form a metastatic site (Kitamura et al., 2015). Similar to TAMs, MAMs can also 
produce growth factors to accelerate the expansion of tumor cells (DeNardo et al., 2009). In 
addition, even before the arrival or disseminated cells, macrophages can already contribute to the 
creation of a pre-metastatic niche, in part through the downregulation of dendritic cells and anti-
tumor T cell infiltration (Sharma et al., 2015) and the induction of fibrosis at the pre-metastatic 
site (Nielsen et al., 2016). 
Macrophages not only participate in the natural courses of tumor initiation and 
progression, but also affect how tumors respond to therapeutic interferences. This is usually 
accomplished through (1) secretion of pro-survival factors that blocks the apoptosis pathways 
induced by chemotherapies, (2) production of molecules involved in the metabolism of 
chemotherapeutic drugs, which are converted to a form that is less toxic to tumor cells, and (3) 
modulation of other stromal cells, such as dendritic cells (Ruffell et al., 2014), to suppress 
chemotherapy-induced activation of anti-tumor immune responses. 
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Taken together, macrophages infiltrating primary tumors and metastatic or pre-metastatic 
tissues promote tumor progression, metastasis, and therapy resistance through various 
mechanisms, therefore posing a significant barrier to effective anti-cancer treatments. 
Understanding the biology of TAMs and MAMs is essential for the development of trials that 
target these myeloid cells. While a lot of research has been done to elucidate the mechanisms by 
which macrophages regulate tumor growth, available strategies to target these cells are very 
limited, with the majority of the approaches focused on depleting these cells. Improving the 
clinical efficacy in these strategies requires in-depth understanding of the sources that supply 
macrophages to the tumor tissue. However, ontogeny of tumor-associated macrophages is not 
well defined. 
 
1.3.4 New Paradigm of Macrophage Ontogeny 
As part of the mononuclear phagocytes system (MPS), macrophages in tissues were 
considered to originate from the adult hematopoietic system. A four-decade-old dogma of 
macrophage ontogeny held that hematopoietic stem cells in the bone marrow give rise to 
monocytes through stepwise lineage specification; monocytes then enter circulation and further 
differentiate into macrophages upon extravasation into tissues. In other words, this paradigm 
proposed that monocytes in circulation constitute a mobile pool of intermediately differentiated 
progenitors that are on their way between their origin (bone marrow) and their destination 
(tissue). This dogma was proposed based on the initial observation that adoptively transferred 
monocytes differentiate into macrophages as they circulate into the inflamed peritoneum. It was 
later supported by a large number of similar observations in various tissues under different 
pathological conditions (Ginhoux and Guilliams, 2016).  
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This paradigm has been challenged in the past decade. As this model was based solely on 
observations under inflammatory conditions, several lines of evidence looking at the homeostasis 
of macrophages in non-pathological conditions raised discrepancies with the concept that the 
adult hematopoietic system provides the only source of tissue macrophages. For example, 
irradiation causes the ablation of the hematopoietic stem cells but does not wipe out tissue 
resident macrophages, which can be minimally affected, as is the case with skin Langerhans cells 
(Merad et al., 2002) and brain microglia (Ginhoux et al., 2010). Furthermore, patients who have 
severe monocytopenia could have normal numbers of macrophages in many tissues (Collin et al., 
2006), a phenotype also recapitulated in mouse models. In addition, monocyte-derived cells tend 
to have a shorter life span and high turnover rate, which does not explain the long half-life of 
tissue resident macrophages. Moreover, the original MPS ontogeny paradigm views monocytes 
as a cell type with transition roles but little other functionality; differentiation in macrophages is 
their fate by default. This view has also been challenged. Monocytes were shown to be able to 
traffic out of the blood into multiple tissues constitutively without contributing to the 
macrophage pool. Instead these monocytes can sample antigens in a similar fashion as dendritic 
cells (Jakubzick et al., 2013). These observations led to the rewriting of the paradigm of MPS 
ontogeny. 
An extensive list of parabiosis studies investigated the contribution of circulating Ly6CHi 
monocytes to the turnover of tissue resident macrophages. Some tissues, including the colon and 
intestine (Bain et al., 2014), dermis (Tamoutounour et al., 2013), and pancreatic islets (Calderon 
et al., 2015) rely on monocyte infiltration for macrophage maintenance. On the other hand, 
macrophages in a wide range of organs, including the lung, red pulp, pancreatic stroma, and 
brain, do not show significant exchange with the blood for even after up to 5 months of 
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parabiosis (Hashimoto et al., 2013). These data uncoupled the adult hematopoietic system with 
the maintenance of tissue resident macrophages in many organs, suggesting the existence of an 
alternative source that sustains these cells.  
In addition to maintenance, the development of macrophages could also be independent 
of HSCs. One of the first pieces of evidence to uncouple the ontogeny of tissue resident 
macrophages with HSCs was based on the observation that macrophage development and 
hematopoiesis had differential transcriptional requirements. Hematopoietic stem cell 
differentiation requires the transcription factor c-Myb for proliferation and differentiation 
(Sandberg et al., 2005). However, subsets of tissue resident macrophages in a wide range of 
organs still develop in mice that lack this transcription factor (Schulz et al., 2012). This suggests 
that HSCs are not the only developmental source of macrophages. Moreover, Flt3-based lineage 
tracing experiments added further confirmation. Flt3 is a receptor tyrosine kinase that is 
expressed in multipotent hematopoietic progenitors. Its expression is activated during early 
stages of HSC differentiation (Boyer et al., 2011). Therefore, all hematopoietic cells in 
circulation are labeled by Cre recombinase. However, macrophages in a number of tissues, 
including epidermis Langerhans cells, liver Kupffer cells, spleen and kidney resident 
macrophages, and brain microglia, demonstrated low levels of recombination. These data 
suggested that an alternative hematopoietic source is responsible for the development of tissue 
resident macrophages.  
A series of tamoxifen-inducible lineage tracing models provided crucial data that helped 
defining the origin of tissue resident macrophage: transgenic or knock-in mouse models that 
have the Cre recombinase genes driven by various promoters took advantage of the early 
expression of these promoter genes that precedes the emergence of HSC-initiated hematopoiesis, 
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also called “definitely hematopoiesis”. Before the appearance of HSCs and the occurrence of 
definitive hematopoiesis, the embryo undergoes several waves of blood production (Franklin and 
Li, 2016; Ginhoux and Guilliams, 2016). First wave is called “primitive hematopoiesis”, in 
which blood cells arise from the blood islands of extra-embryonic yolk sac. In mice this occurs 
around embryonic day 7.0. During primitive hematopoiesis, a progenitor population called 
“erythro-myeloid progenitors” (EMPs) arises around E7.25 and produces nucleated erythrocytes 
and macrophages, which respectively provide oxygenation and participate in tissue structuring. 
Following primitive hematopoiesis, a second wave of hematopoiesis occurs. During this period, 
a slightly larger variety of leukocytes could be produced. In addition to EMPs, a population of 
progenitors with lympho-myeloid potential is also produced. This wave of blood production 
occurs in the hemogenic endothelium of the yolk sac; therefore the EMPs produced during this 
wave are named “late EMPs” which distinguishes them from the EMPs that arise within the yolk 
sac blood islands. “Early” EMPs express CSF1R but is c-Myb independent, while the “late” 
EMPs appear to express c-Myb. Before the formation of the circulatory system, yolk sac serves 
as the primary site of blood production for the embryo. Concomitant with the emergence of late 
EMPs, a third wave starts within the hemogenic endothelium of the embryo proper around E8.25. 
Coinciding with this, the embryo develops a functioning circulation system by E8.5. During this 
wave of hematopoiesis, immature hematopoietic stem cells are generated within the para-aortic 
splanchnopleura (P-Sp) region. Subsequently, HSCs were observed in the aorta gonads and 
mesonephris (AGM) region at E10.5, and then in the fetal liver. Though still controversial, the 
immature HSCs observed in the P-Sp region were considered to be the progenitors of HSCs that 
later migrate to the AGM region and then ultimately settle in the fetal liver (Cumano and Godin, 
2007). Fetal liver becomes the major site of hematopoiesis starting at E12.5 and peaks at E16.5 
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in mice, before bone marrow takes over the hematopoietic function at perinatal stages (Orkin and 
Zon, 2008).  
Despite the agreement on the embryonic contribution to tissue resident macrophages, 
controversies still exist regarding the precise nature of the embryonic progenitors that give rise to 
these cells. This is partially due to differences in the mouse models used for lineage tracing and 
the labeling variations by promoters driven by different genes. Runx1-CreER took advantage of 
the early expression of Runx1 starting at E6.5. Tamoxifen pulse at E7.0 specifically labeled up to 
30% of brain microglia while sparing hematopoietic stem cells (Ginhoux et al., 2010). CSF1R-
CreER has also been used, whose expression comes later than Runx1, therefore allowing a 
longer time window for labeling. E8.5 tamoxifen treatment leads to the labeling of various tissue 
macrophages, including those in brain, epidermis, liver, and spleen (Schulz et al., 2012), and 
subsets of macrophages in the pancreas and heart (Calderon et al., 2015; Epelman et al., 2014; 
Gomez Perdiguero et al., 2015). These findings, along with the presence of these cells in Myb 
knockout mice, led to the model in which yolk sac EMPs differentiate into macrophages that 
persist into adulthood.  
However, whether these data above supports this “yolk sac exclusive” ontogeny model is 
questionable. Persistence of macrophage populations in Myb knockout mice only suggests the 
ability of progenitors to contribute to these cells when HSC differentiation is deficient, but does 
not suggest that this is what actually happens in unperturbed situations. These observations could 
be the mechanisms by which “early” EMP differentiation compensates for the deficiencies of 
hematopoiesis induced by Myb-dependent “late” EMPs or HSCs. Along the same lines, 
depletion of yolk sac-derived macrophages, through the treatment of CSF1 receptor depleting 
antibodies on E6.5, did not lead to irreversible reductions in fetal macrophages in most organs. 
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The only tissue resident macrophages that were irreversibly depleted were macrophages. Indeed, 
kinetics studies using CSF1R- and Runx1-CreER fate mapping models demonstrated the 
replacement of yolk sac derived macrophages as hematopoiesis progresses to the fetal liver stage. 
In a novel S100A4-Cre model that specifically traces fetal monocytes, Cre labeling started to be 
observed at E12.5 in macrophages in lung, liver, spleen, and skin, and the labeling efficiency 
progressively increased to an average of 60% in neonates, which was maintained into adulthood. 
Going back to the Runx1-CreER model, tamoxifen treatment at a later time point (E8.5) led to 
the labeling of a myb-expressing EMP population that entered circulation and colonized the fetal 
liver. These “late” EMPs were distinct from the “early” EMPs, which lack Myb expression and 
differentiate into macrophages without going through the monocyte stage (Hoeffel et al., 2015). 
These data suggest that fetal liver progressively replace yolk sac derived cells, and led to the 
proposal of a new model in which late EMP-derived fetal liver monocytes are the major sources 
of most tissue resident macrophages, while early EMPs in the yolk sac provide the source for 
microglia. 
In addition to early EMPs in the yolk sac and late EMPs in the fetal liver, fetal HSCs 
were also proposed to contribute to the generation of resident macrophages. This was based on 
the c-Kit-CreER model. In this model, E7.5 tamoxifen treatment led to significant amount of 
labeling in brain microglia but not in the resident macrophage populations from other major 
organs (Sheng et al., 2015). On the other hand, pulsing at later time points (E8.5 and E9.5) 
labeled macrophages that are resident in the liver, lung, spleen, kidney, dermis, and peritoneum. 
Because the kinetics of the labeling coincides with the occurrence of HSCs, these data led to the 
proposal of fetal HSCs as sources of resident macrophages other than microglia. Moreover, the 
labeling of other hematopoietic cells, including neutrophils and lymphocytes, led to the 
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hypothesis that c-Kit+ cells pulsed at E8.5 or E9.5 are HSCs. However, further confirmations of 
the identity of these cells are still needed to validate this model. Moreover, these data are still 
consistent with the EMP model.  
In addition to embryonically derived populations, regardless of the precise nature of the 
progenitors, HSCs are also shown to be a significant contributor to many tissue resident 
macrophages shortly after birth. For example, infiltration of monocytes replenished macrophages 
in the colon during weaning. This was shown by the decrease of macrophages labeled on E8.5 by 
CSF1R-CreER concomitant with an increase in Flt3-Cre labeled cells (Bain et al., 2014). This 
replenishment was stimulated by microbiota in the neonates, suggesting that environmental 
stimuli could interact with the tissue to shape the ontogeny of local macrophages. While the 
contribution of perinatal hematopoiesis is best studied in organs that are exposed to the 
environment, such as the lung and colon, it can also happen in internal tissues, such as the 
arteries. Unlike the mouse models mentioned above, CX3CR1-CreER does not label significant 
amount of inflammatory monocytes, therefore allowing the investigation into the contribution of 
embryonic hematopoiesis to macrophages that do not express CX3CR1. E18.5 labeling in 
CX3CR1-CreER reporter mice led to the labeling of most macrophages in neonatal arteries. 
Interestingly, two weeks after birth, a significant portion of artery associated macrophages are 
replaced by unlabeled monocytes, suggesting the contribution of HSCs to cardiarc macrophages 
at the neonatal period (Ensan et al., 2016). Similarly, the MHCII+ macrophages in the 
peritoneum also develop within the first week after birth, in a CCR2-dependent manner, 
suggesting the perinatal contribution of HSCs to the development of this population (Kim et al., 
2016).  
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Unlike the differentiation of macrophages from adult HSCs, embryonic macrophage 
differentiation before the formation of fetal liver HSCs does not appears to involve monocyte 
intermediates (Ajami et al., 2007). A question raised by this model is the mechanisms by which 
tissue macrophages generated their phenotypic and functional diversity across various organs. 
One possibility is that the diversity could be generated already upon differentiation at the 
hematopoietic sites. Variable “clones” of macrophages could be armed with differing repertoire 
of chemokine receptors that drive their unique migration pathways towards different organs or 
even different sites within an organ. This “pre-determinism” model resembles the generation of 
the homing of tissue resident memory T cells, which are activated uniquely in secondary 
lymphoid sites and home to unique tissues. An alternative but related possibility is that 
heterogeneous EMP populations give rise to different macrophages that home to their target 
organs. This model might be unlikely, because the generation of a diverse progenitor population 
may be costly. However, characterization of EMPs is relatively simplistic. We may 
underestimate the heterogeneity of the “primitive” progenitors that may exist. Moreover, in all 
lineage-tracing models mentioned above, the labeling of various mature macrophages 
populations by a single promoter does not mean they share the same progenitor. E8.5 tamoxifen 
pulse may label various CSF1R+ progenitors, each of which later gives rise to different resident 
populations. This “progenitor heterogeneity” model also implies the concept of pre-determined 
diversity and pre-determined destination. 
Alternatively, progenitors such as EMPs could directly differentiate into macrophages, 
which then settle into embryonic organs or organ primordial, and quickly achieve organ-specific 
program upon the receipt of tissue specific niche signals. However, to accomplish this “fast 
maturation”, macrophages may also need to develop unique receptors or signaling machineries 
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that allows them to respond to environmental signals. Another possibility involves the 
differentiation of embryonic progenitors into intermediate precursors, similar to monocytes in 
adult hematopoiesis, which then differentiate into macrophages and obtain organ-specific 
transcriptional program upon tissue entry. This “step-wise diversification” model was supported 
by the profiling of a CD45+cKit-Lin-F4/80- population, whose surface markers and 
transcriptional profiles are intermediary between EMPs and mature macrophages (Mass et al., 
2016). While these transition-state “pre-macrophages” could explain the generation of 
phenotypic diversity among tissue macrophages, further studies are needed to validate their 
existence and contribution to the macrophage ontogeny. 
The contribution of multiple progenitors to macrophage ontogeny raised an important 
“nature vs. nurture” debate. Multiple studies demonstrated a wide range of diversity among 
various tissue macrophages. Macrophages resident in each tissue seem to demonstrate a distinct 
signature in terms of transcriptional activities (Gautier et al., 2012), enhancer landscape 
(Gosselin et al., 2014; Lavin et al., 2014), and chromosome modification profiles. A common 
theme of these studies is a focus on the importance of environment in the regulation of 
macrophage activities. To what extent does ontogeny contribute to the shaping of macrophage 
functionality? Answer to this question requires investigations into macrophages of different 
origins that co-exist within the same tissue. A number of studies used artificial systems by 
partially depleting the tissue resident population to induce their replacement by monocytes, 
followed by profiling the transcriptional signature of monocyte-derived macrophages and 
remaining tissue resident macrophages. In the lung and peritoneal cavity, macrophages derived 
from newly recruited monocytes acquired the majority of the majority of the gene signature of 
their endogenous counterparts. On the other hand, monocyte-derived liver macrophages differ 
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significantly from Kupffer cells in terms of enhancer signature (Lavin et al., 2014). Similarly, 
monocyte-derived microglia also had more than 2,000 differentially expressed genes compared 
from yolk sac-derived microglia (Bruttger et al., 2015). These studies suggest that ontogeny 
could be one of the determining factors that shape the functional properties of macrophages.  
However, these data should be taken with caution, because the depletion strategies involve 
genotoxic irradiation, which could cause alterations in the activities of the endogenous 
populations, even though tissue resident macrophages may be radiation-resistant. Indeed, several 
studies have made similar attempts to enforce the recruitment and differentiation of monocytes 
into tissue resident macrophages, either through shielded irradiation that protects the endogenous 
population, or through transgenic diphtheria toxin receptor-mediated depletion. In both the lung 
and the liver, monocyte-derived macrophages resemble their endogenous counterparts, with very 
little distinction in transcriptional activities that may suggest most overlapping functionalities 
between cells from different origins (Gibbings et al., 2015; Scott et al., 2016). These contrasted 
results in how monocyte-derived liver macrophages resembled endogenous Kupffer cells 
demonstrated how differences in experimental systems could lead to different conclusions, and 
remind us of interpreting these studies with caution. Another important note is that a lot of these 
studies looked at macrophages in the tissue as one homogeneous entity. However, each organ is 
an intricate system with a complicated anatomy; therefore, cells located in different parts of the 
tissue may behave differently. In the pancreas, monocyte-derived macrophages infiltrate the 
islets, while embryonically derived macrophages are enriched in the exocrine stroma. Moreover, 
various subsets of stromal macrophages, as distinguished by the expression of CD206, have 
different gene expression profile (Calderon et al., 2015). These data suggest the possibility that 
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ontogeny and signals from different environmental niches may interact with each other to shape 
the properties of resident macrophages.  
It is important to note that the ontogeny of tissue resident macrophages is not static. 
While embryonically derived macrophages are abundantly populated in almost all organs at birth, 
many cell populations are replaced by monocyte at various rates. On one end of the spectrum, 
brain microglia are the first tissue macrophages derived from yolk sac progenitors, and they 
persist long-term with very minimal contribution from blood monocytes. On the other end of the 
spectrum, macrophages in the colon and intestine are short lived, and rely on constant 
replenishment from the blood. The life spans of epidermis Langerhans cells, lung alveolar 
macrophages, and liver Kupffer cells are more like that of the microglia; dermis MHCII+ 
macrophages are more like colon macrophages. Macrophages in other organs mostly fall into the 
middle of the spectrum, including pancreas and heart. How do various tissue resident 
macrophage populations possess different life span? How do those in the brain, lung alveoli, and 
liver self-maintain through adulthood and aging? These unanswered questions are also worth 
addressing.  
Another important question is whether ontogeny plays a role in determining the fates of 
macrophages during various pathological conditions. Macrophages undergo extensive 
proliferation in Helminth infection, which implies the involvement of tissue resident 
macrophages in Th2 inflammatory responses against pathogens (Jenkins et al., 2011). Local 
proliferation also characterizes macrophages within visceral adipose tissues, suggesting that 
resident macrophages may play a role in the regulation of metabolic diseases (Amano et al., 
2014). Not only can resident macrophages participate in the regulation of these pathological 
conditions, they can also interact with the blood system to promote the infiltration of monocytes 
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to expand the local macrophage pool. In a Listeria monocytogenes infection mode, Kupffer cells 
undergo necroptosis to recruit monocytes that later differentiate into macrophages (Bleriot et al., 
2015). What is the fate of tissue resident macrophages during tumor development? How do they 
contribute to tumor progression and metastasis? These questions are poorly addressed. In a breast 
cancer model, mammary gland resident macrophages seemed to disappear while monocyte influx 
gave rise to tumor-associated macrophages (Franklin et al., 2014). On the other hand, microglia 
appeared to persist in glioblastoma (Chen et al., 2017) and brain metastasis (Bowman et al., 
2016). The limited number of studies suggests that the involvement of tissue resident 
macrophages in tumor development may be organ- and tumor- specific. One organ of particular 
interest to us is the pancreas. Pancreatic cancers can arise within either the exocrine or the 
endocrine portions of the organ; meanwhile, stroma and pancreatic islets are infiltrated with 
macrophages derived from different sources. It would be interesting to see if different 
macrophage sources supply TAMs to different kinds of pancreatic cancers. In addition, cancer 
occurrence in the heart is rare. Since the heart is infiltrated with macrophages of different 
ontogeny, it is also worth asking if these cells contribute differently to cancer 
immunosurveillance in this organ. 
 
1.4 Scope of This Dissertation  
1.4.1 Outstanding Needs for Improvement of Immunotherapies 
Our knowledge of cancer biology is growing at unprecedented speed. In particular, we 
are increasingly appreciative of the role that the tumor microenvironment plays in the regulation 
of cancer development and in the utilities of cancer treatment. In parallel, advancement in the 
development of therapeutics also demonstrates a promising future of cancer treatment by 
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targeting the tumor stroma. A lot of attention has been paid to the immune components of the 
cancer environment, with a focus on targeting the adaptive immune system. The advantage is 
that: (1) the adaptive immune system is capable of combatting cancer in an antigen specific 
manner, thereby allowing the minimization of side effects due to attacks on healthy cells in the 
organisms that are necessary for host fitness; (2) memory is the second hallmark of the adaptive 
immune system, which could build a long lasting anti-cancer arsenal that suppresses tumor 
reoccurrence. Immunotherapies that activate adaptive immune responses have demonstrated 
promising potential in multiple types of malignant diseases; in some cases these therapies even 
showed impressive efficacy at treating late-stage patients with metastasis.  
However, these immunotherapies do not work in all types of cancer. For example, 
checkpoint therapies do not improve patient outcome in pancreatic ductal adenocarcinoma. 
Moreover, even in responsive cancers such as skin melanoma, large cohorts of patients still do 
not sufficiently benefit. Therefore, we need a much better understanding of the tumor 
microenvironment unique in different kinds of tumors and metastasis in order to expand 
treatment benefits to a much larger group of patients.  
Activation of the adaptive immunity is reliant on the innate immune system, in particular 
myeloid cells. Myeloid cells compose the overwhelming majority of leukocytes and far 
outnumber the anti-tumor adaptive immune cells. However, tumor-infiltrating myeloid responses 
are heavily skewed in the tumor to adopt a suppressive phenotype that promotes tumor growth 
instead of inducing effective anti-tumor responses. Therefore, we need to change myeloid 
responses in order to optimize therapies that are targeted towards boosting the adaptive immune 
system. Targeting myeloid components of the tumor stroma is not a new concept in the 
development of cancer immunotherapies. The prevailing strategy is directed towards reducing 
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the amount of immune suppression by reducing the quantity of cells. However, such depleting 
strategies have their own limitations. First, lower quantity of suppressive myeloid cells does not 
equal higher quality of immune responses. Second, without understanding the sources of these 
myeloid cells, depletion of these cells from the tumor stroma could simply induce a positive 
feedback loop that further enhance their production and recruitment to the tumor site. Therefore, 
as we develop therapeutic strategies, we may need to change our thinking from depleting these 
cells to reprogramming these cells. In addition, we need to better understand the cellular origin 
that provides these myeloid cells to the tumor tissue, and cut the supply from the source. 
Furthermore, we can combine the knowledge in both aspects, and design an alternative strategy: 
first depleting pre-existing suppressive myeloid cells to create vacancies that can later be 
occupied by new comers, and then programing or conferring these new comers with anti-tumor 
functions.  
 
1.4.2 Central Questions of This Dissertation 
We choose pancreatic ductal adenocarcinoma (PDAC) as a cancer model due to the high 
lethality and the desperate need for effective immunotherapies. PDAC has a very rich stromal 
environment, which is very scarce in CD8+ T cells but very extensively infiltrated with myeloid 
cells that could be utilized for treatment. Our long-term goal is to understand how neoplastic 
cells in PDAC tissues interact with their microenvironment. The scope of this dissertation 
focuses on macrophages, one of the most abundant immune cells in PDAC tissue. The quantity 
and quality of macrophages in PDAC correlate with patient outcome; therefore we aim to 
develop strategies to reprogram macrophage functions to enable anti-tumor responses. Towards 
that end, we want to understand: (1) how tumor-associated macrophages (TAMs) polarize 
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toward pro-tumor or anti-tumor phenotypes, (2) what tumor-derived signals are responsible for 
programming TAM activities, (3) where do TAMs come from, and (4) how we can utilize the 
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2.1 Summary 
Cancer immunotherapy generally offers limited clinical benefit without coordinated strategies to 
mitigate the immunosuppressive nature of the tumor microenvironment. Critical drivers of 
immune escape in the tumor microenvironment include tumor-associated macrophages (TAM) 
and myeloid-derived suppressor cells (MDSC), which not only mediate immune suppression but 
also promote metastatic dissemination and impart resistance to cytotoxic therapies. Thus, 
strategies to ablate the effects of these myeloid cell populations may offer great therapeutic 
potential. In this report, we demonstrate in a mouse model of pancreatic ductal adenocarcinoma 
(PDAC) that inhibiting signaling by the myeloid growth factor receptor CSF1R can functionally 
reprogram macrophage responses that enhance antigen presentation and productive anti-tumor T 
cell responses. Investigations of this response revealed that CSF1R blockade also upregulated T 
cell checkpoint molecules, including PDL1 and CTLA4, thereby restraining beneficial 
therapeutic effects. We found that PD1 and CTLA4 antagonists showed limited efficacy as single 
agents to restrain PDAC growth, but that that combining these agents with CSF1R blockade 
potently elicited tumor regressions, even in larger established tumors. Taken together, our 
findings provide a rationale to reprogram immunosuppressive myeloid cell populations in the 
tumor microenvironment under conditions that can significantly empower the therapeutic effects 
of checkpoint-based immunotherapeutics. 
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2.2 Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies. 
Current therapies are ineffective at treating late stage disease. The few durable responses to 
therapy seen in PDAC patients are often associated with significant cytotoxic lymphocyte (CTL) 
infiltration into tumor tissue, suggesting that effective immunotherapy would hold promise to 
improve patient outcome (1, 2). However, attempts to use immunotherapeutics as single agents 
have achieved only limited clinical success (3, 4). While multiple factors can contribute to the 
resistance of PDAC to immunotherapies, one dominant player is the presence of a suppressive 
immune microenvironment. Critical drivers of this immunosuppressive microenvironment 
include tumor-associated macrophages (TAMs), monocytic myeloid-derived suppressor cells 
(Mo-MDSCs), and granulocytic MDSCs (G-MDSCs). These leukocytes can also promote tumor 
cell proliferation, confer resistance to cytotoxic stress, and facilitate metastatic dissemination (5, 
6). Therefore, high numbers of tumor-infiltrating myeloid cells often correlate with early local or 
metastatic relapse, leading to poor survival in pancreatic cancer patients (7-9). Therapeutics that 
can reprogram these myeloid responses might overcome immunosuppression to enhance 
responses to immunotherapy. Previous work by our group and others demonstrated that 
combining cytotoxic chemotherapy with the blockade of colony-stimulating factor 1 receptor 
(CSF1R), which is prominently expressed by monocytes, Mo-MDSCs, and macrophages, results 
in improved anti-tumor T cell responses (10-12). These data suggest that CSF1R blockade could 
be effective at alleviating local tumor-induced immune suppression and bolstering the response 
to immunotherapy.  
In this report, we investigate the mechanisms by which inhibition CSF1R signaling 
alleviates immune suppression. We demonstrate that CSF1/CSF1R blockade not only decreases 
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the number of TAMs, but also reprograms remaining TAMs to support antigen presentation and 
bolster T cell activation within the tumor microenvironment. This in-turn leads to reduced 
immune suppression and elevated interferon responses, which restrain tumor progression. 
However, in response to reduced immune suppression programmed death 1 ligand 1 (PDL1) is 
up-regulated on tumor cells and cytotoxic T lymphocyte antigen 4 (CTLA4) on T cells. These 
checkpoint molecules limit the potential of CSF1R inhibition to stimulate anti-tumor immunity. 
While both programmed cell death protein 1 (PD1) and CTLA4 antagonists demonstrate limited 
ability to restrain PDAC growth in this mouse model, similar to reported efficacy as single 
agents in PDAC patients (3, 4). However, CSF1R blockade overcomes these limitations to 
achieve regression in even well-established tumors. These data suggest that reprogramming 
myeloid cell responses via CSF1/CSF1R blockade could improve the efficacy of checkpoint-
based immunotherapeutics. 
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2.3 Methods and Materials 
Pancreatic cancer tissue microarray cohort and analysis 
Tissue microarray (TMA) studies were conducted on surgically resected PDAC specimens from 
60 patients diagnosed in the Department of Pathology at Washington University. Patients 
underwent pancreaticoduodenectomy followed by adjuvant chemotherapy. Fifty-nine of the sixty 
patients did not receive neoadjuvant therapy. To assemble TMAs, clearly defined areas of tumor 
tissue were demarcated and two biopsies (1.0-mm diameter) were taken from each donor block. 
The Washington University School of Medicine ethics committee approved this study. Fully 
automated image acquisition was performed using an Aperio ScanScope XT Slide Scanner 
system with a 20× objective (Aperio Technologies) to capture whole-slide digital images. 
Fluorescent staining analysis was performed using MetaMorph software.  
 
Immunohistochemistry (IHC) 
 Tissues were fixed in 10% formalin, embedded in paraffin, and dehydrated in 70% ethanol. 
Five-mm-thick sections were deparaffinized in xylene, rehydrated in graded ethanol, and 
subjected to antigen retrieval by steam heating in Citra™ antigen retrieval solution (BioGenex). 
CSF1 was stained with clone 2D10 at 1:100 (Thermo) and detected using indirect 
immunofluorescence.  
 
Cell lines and constructs  
KC cells were derived from PDAC tumor tissue obtained from p48-CRE/LSL-KRas/p53flox/flox 
mice (backcrossed C57/B6, n=6 by speed congenic) by our laboratory. Kras-INK (KI) cells were 
obtained from Dr. Hanahan’s laboratory (Collisson et al., 2011; Roy et al., 2011). All cell lines 
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were negative for MAP and mycoplasma. Subsets of these cells were labeled with a polycistronic 
click beetle red luciferase-mCherry reporters.  
 
Orthotopic model and preclinical animal cohorts 
Syngeneic orthotopic PDAC tumors were established by surgical implantation, as previously 
described (Aaltonen et al., 2009). Briefly, we injected 200,000 cells in 50 µl Matrigel (BD-
Biosciences) into each mouse’s pancreas. Cohorts of mice were randomized into different 
treatment groups by either bioluminescence imaging on day 12 or gross palpation of the 
pancreas. Mice were treated with 50 mg/kg Gemcitabine (GEM; Hospira) by intravenous (i.v.) 
injection into the right retro-orbital sinus every 4–5 days. Preclinical studies were conducted with 
10–15 10-week-old female mice per group. Tumor burden was measured by establishing gross 
wet weight of the pancreas/tumor and comparing it to that of five parallel mice sacrificed at the 
beginning of treatment. All studies involving animals were approved by the Washington 
University School of Medicine Institutional Animal Studies Committee. 
 
CSF1R inhibitors, CSF1 neutralizing antibodies, and checkpoint antagonists 
CSF1 neutralizing antibody (clone 5A1, BioXCell) was administered via intraperitoneal (i.p.) 
injection every 4–5 days, with the 1st injection containing 1 mg and subsequent injections 0.5 mg. 
CSF1R inhibitors (CSF1Ri) were provided by Plexxikon Inc. PLX3397 is a selective bispecific 
inhibitor for c-Fms and the c-Kit receptor tyrosine kinases (Artis et al., 2005; DeNardo et al., 
2011; Tsai et al., 2008). GW2580 has been described in detail previously (Conway et al., 2005). 
Both GW2580 and PLX3397 were administered at 800 mg/kg in chow. CTLA4 and PD1 
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antagonists (clones UC10-4F10 and RMP1-14, BioXCell) were given every 4–5 days at 250 and 
200 mg/dose, respectively.  
 
Flow cytometry analysis 
Single-cell suspensions were prepared from dissected pancreatic tumors by manual mincing 
using a scalpel, followed by enzymatic digestion with 3.0 mg/ml collagenase A (Roche) and 
DNase I (Sigma) for 30 min at 37°C with constant stirring. Digestion mixtures were quenched by 
10% fetal bovine serum (FBS), and filtered through 40-µm nylon strainers (Fisher Scientific). 
Cells were incubated for 10 min at 4°C with rat anti-mouse CD16/CD32 mAb (eBiosciences) at 
1:200 dilution. Cells were washed twice in PBS/BSA and incubated for 20 min with 100 µl of 
fluorophore-conjugated anti-mouse antibodies (CD3e (145-2C11), CD4 (6K1.5), CD8a (53-6.7), 
CD11b (M1/70), CD11c (N418), CD19 (MB19-1), Ly6C (HK1.4), CD45 (30-F11), CD115 
(AFS98), F4/80 (BM8), MHCII (M5/114.15.2), FoxP3 (FJK-16s), CD44 (IM7), CD69 (H1.2F3), 
PD1 (J43), PDL1 (MIH5), PDL2 (122), CTLA4 (UC10-4B9), IgG2α/κ (eBR2a), (all from 
eBioscience) and/or Ly6G (1A8, BioLegend), and CD206 (MR5D3, AbDSerotec) using the 
manufacturers’ recommended concentrations. Data acquisition was performed on the LSR-II 
system (BD Biosciences), and FlowJo software version 9.2 (Tree Star) was used for analysis. 
 
Quantitative reverse transcription-polymerase chain reaction (RT-PCR)  
Total tissue RNA was extracted from snap-frozen tumor tissue or lysed tissue culture cells using 
the E.Z.N.A. RNA Kit (Omega). cDNAs were synthesized using qScript cDNA SuperMix 
(QuantaBio). Quantitative real-time PCR Taqman primer probe sets specific for TBP, HPRT, 
GAPDH, CSF1R, CSF1, CCR2, CCL2, CCL5, CCL22, CXCL10, interferon (IFN)-α, IFNβ, 
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interleukin (IL)-1b, IL10, IL12p35, NOS2, ARG1, TGFβ, EGF, PDL1, PDL2, PD1, and CTLA4 
(Applied Biosystems) were used, and the relative gene expression was determined on a StepOne 
PlusTM
 
Real Time PCR System (Applied Biosystems) using Taqman Gene Expression Master 
Mix (Applied Biosystems). The comparative threshold cycle method was used to calculate fold 
changes in gene expression, which were normalized to the expression of TBP, HPRT and/or 
GAPDH as reference genes.  
 
Flow cytometry analysis  
Single-cell suspensions were prepared from dissected pancreatic tumors by manual mincing 
using a scalpel, followed by enzymatic digestion with 3.0 mg/ml collagenase A (Roche) and 
DNase I (Sigma) dissolved in Dulbecco’s modified Eagle medium (DMEM; Gibco) for 40 min at 
37°C with constant stirring. Digestion mixtures were quenched by adding DMEM containing 
10% fetal bovine serum (FBS), and filtered through 40-µm nylon strainers (Fisher Scientific). 
Cells were incubated for 15 min at 4°C with rat anti-mouse CD16/CD32 mAb (eBiosciences) at 
1:200 dilution in phosphate-buffered saline (PBS) containing 1.0% bovine serum albumin (BSA; 
Sigma) to prevent nonspecific antibody binding. Cells were washed twice in PBS/BSA and 
incubated for 20 min with 100 µl of fluorophore-conjugated anti-mouse antibodies (CD3e (145-
2C11), CD4 (6K1.5), CD8a (53-6.7), CD11b (M1/70), CD11c (N418), CD19 (MB19-1), Ly6C 
(HK1.4), CD45 (30-F11), CD115 (AFS98), F4/80 (BM8), MHCII (M5/114.15.2), FoxP3 (FJK-
16s), CD44 (IM7), CD69 (H1.2F3), PD1 (J43), PDL1 (MIH5), PDL2 (122), CTLA4 (UC10-
4B9), IgG2α/κ (eBR2a), (all from eBioscience) and/or Ly6G (1A8, BioLegend), and CD206 
(MR5D3, AbDSerotec) using the manufacturers’ recommended concentrations. This was 
followed by two washes with PBS/BSA. Either 7-AAD (BD Biosciences) or Live/Dead Blue 
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(Invitrogen) was used to identify dead cells. Data acquisition was performed on the LSR-II 
system (BD Biosciences), and FlowJo software version 9.2 (Tree Star) was used for analysis.  
 
Fluorescence-Activated Cell Sorting (FACS)  
Cell suspension and antibody staining were prepared as described above. Sorting was performed 
using the FACSAria-II cell sorter (BD Biosciences) at the FACS Core of Washington University 
Department of Pathology and Immunology. For gene expression analysis, cells were directly 
sorted into the TRK lysis buffer (Omega). For all sorting experiments, post-sort analyses were 
performed to ensure >90% purity.  
 
Gene Signature Survival Analysis  
The full gene lists were matched for human-mouse ortholog by the provided gene symbols for 
human genome annotation (gene symbol and entrez ID); some genes are missing the annotation. 
The genes with human genome annotation were matched in the public datasets and their 
expression was matched with outcomes. We used GSE1501 for survival analysis. For each 
individual gene, the Kaplan-Meier survival curves on the binary gene expression (dichotomized 
by median as low/high) were generated with log-rank test p-values. Top significant individual 
genes log rank p-value included ZBP1, OAS3, PTPN6, SFPI1, IRF9, CDH13, SIGLEC1, STAT1, 
SLC11A1, SH2D2A etc. The up- regulated genes and the down-regulated genes were each 
centered by mean and scaled by standard deviation. The averaged expression of down-regulated 
genes (all available genes or the significant genes only from the previous individual gene 
analysis based on either log-rank test p or Wald test P<0.05) were separately calculated. Each 
sample was categorized into one of the two groups (low, high by median averaged gene 
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expression), then into one of the three groups (low, medium, high by the 33.33% and 66.67% 
quantile of the averaged gene expression). The resulting 2 groups and 3 groups classification was 
each associated with overall survival (OS).  
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2.4 Results 
2.4.1 CSF1 is overexpressed by human PDAC cells. 
Previously, we reported that inhibition of CSF1/CSF1R signaling could improve the 
efficacy of chemotherapy in murine PDAC models by enhancing chemotherapy-induced anti-
tumor immunity (Mitchem et al., 2013). However, the mechanisms by which inhibition of 
CSF1/CSF1R signaling regulates anti-tumor immunity are not well understood. To determine the 
cellular sources of CSF1 and CSF1R in human pancreatic cancer patients, we analyzed TMAs 
constructed from 77 cases of invasive PDAC and 4 samples of normal pancreatic tissue. IHC 
staining showed that CSF1 is frequently, but not exclusively, expressed by malignant PDAC 
cells (Figure 2.1A). In addition, tumors frequently had elevated expression of CSF1 compared to 
normal tissue. PDAC cells in 70% of tumor specimens exhibited moderate to high levels of 
CSF1 expression (Figures 2.1A–C). By contrast, CSF1R was frequently detected in the tumor 
stroma, while only ~10% of the tumors examined had CSF1R expression in the epithelial 
compartment (Figures 2.1A and D). These observations are consistent with other reports (Jiao et 
al., 2012; Pyonteck et al., 2011) and suggest that PDAC tumor cells frequently produce high 
levels of CSF1.  
 
2.4.2 Inhibition of CSF1R signaling reprograms the tumor microenvironment. 
In order to understand the impact of CSF1R signaling on the tumor microenvironment, 
we compared the gene expression profile of PDAC tumor tissue following treatment with either 
CSF1R inhibitors (CSF1Ri) or vehicle. Towards this end, we orthotopically implanted KI PDAC 
tumor cells into syngeneic mice. This cell line produces high levels of CSF1 but does not express 
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CSF1R (Mitchem et al., 2013). Starting on day 14 post-implantation, we treated mice with either 
vehicle or the CSF1R tyrosine kinase inhibitor, PLX3397. Additional details on PLX3397 can be 
found in the Methods section and published elsewhere (Artis et al., 2005; Conway et al., 2005; 
Schubert et al., 2007; Tsai et al., 2008). Eight days of CSF1Ri treatment resulted in a significant 
reduction in the number of tumor-infiltrating CD11b+Ly6G−Ly6CLoF4/80HiMHCII+ 
macrophages and CD11b+Ly6G−Ly6CHi monocytes/ Mo-MDSCs, but not 
CD11b+Ly6G+Ly6C+MHCIILow G-MDSCs (Figure 2.2A, Figure 2.8). Microarray analyses of 
whole tumor tissue mRNA expression revealed 204 downregulated and 158 upregulated genes 
following CSF1Ri treatment (Figure 2.2B, Table S1). As expected, expression of genes 
indicative of macrophage infiltration, including Cd68, Mrc1, Msr1, and Csf1r, were decreased in 
CSF1Ri-treated tumors (Figure 2.2D). The list of downregulated genes was enriched for 
molecules involved in “inflammatory responses, chemotaxis, myeloid leukocyte-mediated 
immunity, and proteolysis,” consistent with the decreased number of infiltrating macrophages 
(Figures 2.2C–D). The list of upregulated genes was enriched for molecules involved in 
“antigen presentation, allograft rejection, interferon responses, and TH1 immunity” (Figure 
2.2C). This is consistent with the idea that CSF1R blockade can overcome immune suppression. 
Corresponding to these altered pathways, genes indicative of cytotoxic T lymphocyte (CTL) 
responses (Ifng, Cd3e, Cd8a, and Prf1), T cell recruitment (Cxcl10, Ccl3, and Ccl4), and 
interferon responses (e.g. Ifng, Stat1, Irf1, and Irf9) were upregulated (Figure 2.2E). Array 
results were also validated by quantitative real-time PCR (qRT-PCR) on a second set of samples 
(Figure 2.2F). To determine the impact of these alterations, we applied these gene lists to 
existing gene expression datasets from PDAC patients (Stratford et al., 2010) and found that the 
core elements of the downregulated gene list were indicative of poor clinical outcomes (Figure 
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2.2G). Taken together, these results suggest that: (1) inhibition of CSF1R signaling in the 
stromal compartment decreases myeloid responses and reprograms the tumor microenvironment 
to support T cell-mediated anti-tumor immunity and (2) these changes could improve patient 
outcomes.  
 
2.4.3 CSF1/CSF1R signal blockade selectively kills CD206Hi TAMs.  
To determine how inhibition of CSF1/CSF1R signaling impacts myeloid responses, we 
treated tumor-bearing mice with CSF1 neutralizing antibodies for 6, 12, 24, or 48 hours or 8 days 
and analyzed tumor-infiltrating myeloid cell composition and cell death at these time points. 
Within the first 6 hours of aCSF1 treatment, total TAM numbers began to decrease. By 8 days, 
TAM numbers had decreased by ~60% (Figure 2.3B). TAMs are a heterogeneous population of 
macrophages with diverse biological activities (Mantovani, 2008; Mantovani and Sica, 2010; 
Martinez et al., 2008; Movahedi et al., 2010; Qian et al.). While classical activation of 
macrophages can restrain cancer development, alternative activation often plays a pro-
tumorigenic role (Martinez et al., 2009; Mosser and Edwards, 2008). Distinct surface markers 
have been used to distinguish between classically and alternatively activated macrophages. 
Murine PDAC tumors contain a distinct subset of CD206Hi TAMs (Figures 2.3A, 2.8), and their 
counterparts in human pancreatic cancer have been associated with poor clinical outcomes (Ino 
et al., 2013). Quantification of CD206Hi and CD206Low TAM subsets revealed that aCSF1 
treatment for 8 days led to a >90% depletion of CD206Hi TAMs, while CD206Low TAMs 
decreased by only ~45% (Figures 2.3C-D). Similar results were seen following CSF1Ri 
treatment (Figure 2.3G). The loss of CD206Hi TAMs could result from either preferential killing 
of this TAM subset or altered CD206 expression. To distinguish between these possibilities, we 
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analyzed the kinetics of macrophage cell death. We found that in PDAC tumors, CD206Hi TAMs 
experienced significantly higher levels of cell death following aCSF1 treatment than CD206Low 
TAMs (Figures 2.3C-E). These data suggest that CD206Hi TAMs are more sensitive to the 
CSF1R signal blockade. Consistent with this differential sensitivity, we found that CD206Hi 
TAMs express higher levels of CSF1R (Figure 2.3F). In addition, while total Mo-MDSCs 
(CD11b+/Ly6G-/Ly6C+) did not demonstrate decreased infiltration until after 8 days of aCSF1 
treatment, CD206Hi Mo-MDSCs were markedly reduced as early as 12 hours after CSF1 
neutralization (Figure 2.9A). By contrast, the number of CD206Low Mo-MDSCs, 
CD11b+/Ly6G+/Ly6C-/MHCII+ mature granulocytes, and CD11b+/Ly6G+/Ly6C+ G-MDSCs 
remained unaffected until after 8 days of CSF1/CSF1R blockade (Figure 2.9B). Taken together, 
these data suggest that the blockade of CSF1/CSF1R signaling preferentially, but not exclusively, 
depletes CD206Hi TAMs and CD206Hi Mo-MDSCs in pancreatic tumors.  
 
2.4.4 CSF1/CSF1R signal blockade reprograms TAMs.  
Despite extensive loss of macrophages and Mo-MDSCs, 40-50% of TAMs remain after 
αCSF1 or CSF1Ri treatment. To determine whether CSF1 blockade reprograms the remaining 
macrophages to support anti-tumor activities, we FACS sorted TAMs from 8-day vehicle or 
aCSF1-treated mice bearing established KI tumors and compared their gene expression profiles. 
TAMs from aCSF1-treated tumors displayed reduced expression of immunosuppressive 
molecules, including Pdcd1lg2, Il10, Arg1, Tgfb1and Ccl22. By contrast, anti-tumor immunity 
genes, such as Il12a, Ifna, Ifnb1, Ifng, Cxcl10, and Nos2, were upregulated (Figure 2.3H). We 
also observed markedly increased surface expression of MHCII after CSF1 or CSF1R inhibition 
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(Figure 2.3I). Taken together, these data suggest that the CSF1/CSF1R blockade reprograms 
remaining TAMs to support anti-tumor interferon responses and T cell activities. 
 
2.4.5 CSF1/CSF1R signal blockade alters the function of TAMs and dendritic cells.  
Based on the observed differences in cytokine profiles among TAMs, we predicted that 
CSF1/CSF1R blockade might also alter the ability of macrophages to suppress T cell functions. 
To address this hypothesis, we assessed the immunosuppressive activity and antigen presentation 
capacity of macrophages in PDAC tumors from mice following CSF1 blockade. Consistent with 
the reduced expression of immunosuppressive factors (Figure 2.3H), we found that 
fluorescence-activated cell sorted TAMs from 8-day aCSF1-treated mice had significantly 
reduced ability to block CD8+ T cell activation in ex vivo assays (Figure 2.4A). These data 
suggest that the TAMs that remain after CSF1 blockade have reduced immunosuppressive 
activity.  
We also analyzed how CSF1 blockade might impact the number and function of antigen 
presenting cells (APCs) in the tumor microenvironment. To identify potential APCs in PDAC 
tumors, we orthotopically implanted mCherry-labeled KI tumor cells. This model allowed us to 
identify potential APCs by their uptake of tumor antigens, based on their mCherry fluorescence 
(Figure 2.4B, (Engelhardt et al., 2012)). We were able to detect tumor-derived mCherry signal 
in granulocytes, monocytes, TAMs, and dendritic cells (DCs) (Figure 2.4B). The highest levels 
of mCherry uptake were observed in TAMs and a subset of CD11blow/-/Ly6G/C-/CD19-
/CD11c+/MHCII+ cells, presumably lymphoid-like DCs (LyDCs). CSF1/CSF1R blockade did not 
affect mCherry uptake. Interestingly, unlike in TAMs, CSF1/CSF1R blockade significantly 
increased the number of tumor-infiltrating LyDCs and their surface expression of MHCII 
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(Figure 2.4C, and Figures 2.9C-E). Because of the high level of tumor antigen uptake by 
TAMs and LyDCs, we tested the ability of these two cell types to present antigen to naïve CD8+ 
T cells and stimulate their proliferation. We isolated TAMs and LyDCs from orthotopic KC 
tumors obtained from mice treated with either vehicle or aCSF1 for 8 days. These leukocytes 
were then loaded with SIINFEKL peptide and assessed for their ability to activate OT1 T cells. 
While macrophages and LyDCs isolated from vehicle-treated tumors had very limited ability to 
activate T cells, aCSF1 treatment significantly enhanced the capacity of these two cell types to 
induce CD8+ T cell proliferation (Figure 2.4D). Taken together, these data suggest that CSF1 
blockade alleviates immunosuppressive activities and enhances APC potential in both TAMs and 
tumor-infiltrating LyDCs.  
 
2.4.6 CSF1/CSF1R blockade modestly increases anti-tumor T cell activity.  
To further understand how the blockade of CSF1/CSF1R signaling might reprogram the 
tumor microenvironment to regulate tumor progression, we assessed alterations in tumor-
infiltrating T lymphocytes and tumor growth following CSF1 or CSF1R blockade in established 
murine PDAC tumors. Mice bearing established (12 days, ~1cm) orthotropic KI or PAN02 
tumors were treated with aCSF1 IgGs or CSF1Ri. Tumor progression was modestly reduced by 
aCSF1 or CSF1Ri treatment as a single agent (Figures 2.5A–C). This reduction in tumor growth 
correlated with increases in CD3+CD8+ CTLs and CD3+CD4+ effectors T cells, decreases in 
CD4+ Foxp3+ T regulatory cells (TRegs), and significantly improved effector-to-TReg ratios 
(Figures 2.5D–E). While the majority of tumor-infiltrating CD8+ CTLs had a CD69+, CD44+, 
and CD62L- activated phenotype, CSF1R blockade led to a modest increase in both the number 
of CD69+ CD8+ T cells (65% to 76%) and the level of CD44 expression (Figure 2.5F). The 
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observed increase in T cell numbers and enhancement of activation status correspond to our 
results from gene expression profiling in Figure 1.2.  
 
2.4.7 CSF1/CSF1R signal blockade alters T cell checkpoint signaling. 
Although the CSF1/CSF1R blockade enhanced T cell infiltration, we hypothesized that 
anti-tumor immunity might be limited via the engagement of T cell checkpoints. We found that 
approximately 70% of activated CTLs had a high level of PD1 expression, which was unaffected 
by CSF1R blockade. By contrast, CTLA4 expression on CD8+ CTLs was significantly 
upregulated by CSF1R inhibition (Figure 2.5F). Along these lines, our array analysis (Figure 
2.2) showed that Cd274 (PDL1) was significantly upregulated following CSF1R blockade. We 
verified these results using qRT-PCR, and found that both Cd274 and Ctla4, but not Pdcd1lg2 
(PDL2), are upregulated in tumor tissues following CSF1 or CSF1R blockade (Figures 2.6A–B). 
These data suggest that while CSF1 blockade reprograms the tumor microenvironment to 
enhance effector T cell infiltration, engagement of T cell checkpoints is also enhanced.  
To determine the cellular sources of these molecules, we analyzed PDL1, PDL2, and PD1 
expression on tumor cells and tumor-infiltrating myeloid cells from vehicle- or CSF1Ri-treated 
mice. We found that TAMs expressed high levels of PD1, PDL1, and PDL2, but consistent with 
a decreased immunosuppressive capacity, tumor-infiltrating macrophages from CSF1Ri-treated 
mice had markedly decreased PDL2 and PD1 expression (Figures 2.6C, 2.6F). CSF1Ri 
treatment also decreased the total number of PD1- and PDL2-positive TAMs (Figure 2.6D). 
Similar effects were also seen with aCSF1 treatment (data not shown). Neither Mo-MDSCs nor 
G-MDSCs expressed significant levels of PDL2. While CSF1R blockade did not alter PD1 or 
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PDL1 expression in G-MDSCs, PDL1 expression was modestly elevated in Mo-MDSCs 
following CSF1Ri treatment.  
Expression of PDL1, PD1, and PDL2 has been reported on human PDAC tumor cells, 
potentially allowing them to evade immune surveillance by suppressing T cell function. To 
determine if CSF1R blockade affects the expression of these molecules on PDAC cells, we used 
mCherry-expressing KI or KC cells to identify tumor cells in vivo. We found that both KI and 
KC cells express PDL1 at modest levels in vivo, but neither cell line expresses PDL2 or PD1 
(Figures 2.6C, 2.6F, and not shown). However, following CSF1 or CSF1R blockade, the 
number of PDL1+ tumor cells and overall expression level of PDL1 was markedly upregulated 
on PDAC tumor cells (Figure 2.6C, 2.6E). These observations correspond with the increased 
mRNA levels of Cd274 identified by array analysis and qRT-PCR validation (Figure 2.2, 2.6A). 
Taken together, these results suggest that while CSF1/CSF1R blockade reprograms macrophage 
responses to bolster CTL responses, this reprogramming also leads to upregulation of PDL1 on 
tumor cells and CTLA4 on T cells. These checkpoints will likely limit the efficacy of observed 
anti-tumor immune responses. 
 
2.4.8 CSF1/CSF1R blockade enhances responses to checkpoint immunotherapy. 
Based on the above data, we hypothesized that CSF1 or CSF1R blockade could enhance 
PDAC responses to PD1- and/or CTLA4-antagonist based immunotherapy. To assess this 
hypothesis, we treated mice bearing established KI tumors with aPD1 or aCTLA4 with or 
without CSF1Ri in combination with gemcitabine (GEM). PD1 and CTLA4 antagonists in 
combination with GEM had only limited efficacy at blunting the progression of established 
tumors (Figures 2.7A–B). By contrast, the combination of CSF1R blockade with either PD1 or 
	   72	  
CTLA4 antagonists reduced tumor progression by more than 90%. Since combined PD1 and 
CTLA4 antagonist therapy is being tested clinically for the treatment of both melanoma and 
PDAC, we also tried this combined therapeutic approach. In the absence of chemotherapy, even 
combined aPD1/aCTLA4 treatment only limited tumor progression by ~50%. However, the 
addition of CSF1R blockade to aPD1/aCTLA4 treatment completely blocked tumor progression 
and even regressed established tumors by 15% (Figure 2.7C). When CSF1 blockade was 
combined with aPD1/aCTLA4 and GEM treatment, we observed complete tumor regression in 
30% of animals and an average tumor regression of ~85% (Figure 2.7D). Similar results were 
seen in orthotopic KC tumors, and when the less potent CSF1R inhibitor, GW2850, was used 
(Figures 2.7B, 2.10A-B). Analysis of T cell responses following combined therapy with aCSF1 
and aPD1/aCTLA4 antagonists demonstrated increased CD8+ CTL and CD4+ effector T cell 
infiltration and decreased CD4+ Foxp3+ TReg numbers (Figure 2.7E). In addition, the number of 
TAMs, Mo-MDSCs, and G-MDSCs decreased following this combined therapeutic regimen 
(Figure 2.7F).  
To determine if alterations in tumor burden in CSF1Ri treatment mice were due to 
increased T cells responses we conducted CD4 and CD8 T depletion studies and found that 
CSF1R blockade no longer improved checkpoint-based therapy (Figure 2.7G). Taken together, 
these results suggest that CSF1/CSF1R blockade improve checkpoint immunotherapy by 
enhancing CD4+ and CD8+ T cell activities.  
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2.5 Discussion 
In this report, we show that blockade of CSF1/CSF1R signaling in pancreatic tumors 
depletes CD206Hi TAMs and reprograms remaining macrophages to support anti-tumor 
immunity. The blockade alone modestly enhances anti-tumor interferon responses, promotes 
CTL infiltration, and slows tumor progression. However, the therapeutic effect is limited by the 
induction of T cell checkpoint molecules, including PDL1 on tumor cells and CTLA4 on T cells. 
Addition of the CSF1/CSF1R blockade markedly improved the efficacy of aPD1 and aCTLA4 
checkpoint immunotherapy and led to the regression of even well-established PDAC tumors. 
These data suggest that CSF1/CSF1R signaling may be an effective therapeutic target to 
reprogram the immunosuppressive microenvironment of human PDAC tumors and enhance the 
efficacy of immunotherapy.  
Recent data from several groups suggest that inhibition of CSF1R signaling alters the 
immunologic responses of tumor-infiltrating macrophages in several cancer types (DeNardo et 
al., 2011; Mitchem et al., 2013; Mok et al., 2013; Priceman et al., 2010; Pyonteck et al., 2013; 
Strachan et al., 2013). Mok et al. targeted CSF1R signaling using the compound PLX3397 in a 
murine melanoma model; PLX3397 treatment depleted >80% of TAMs, leaving behind a small 
population of MHCIIHi macrophages (Mok et al., 2013). These effects led to increased efficacy 
of adoptively transferred T cell based therapies. These data agree with our report here. In 
addition, recent work by Pyonteck et al. has shown that blockade of CSF1R signaling, using the 
small molecule inhibitor BLZ945, significantly blunts murine glioma tumor growth by 
reprogramming macrophage responses (Pyonteck et al., 2013). In contrast to pancreas, 
melanoma and breast models, macrophage numbers in these murine glioma studies were not 
reduced. Instead, TAM survival was sustained by tumor-derived factors. However, in glioma, 
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CSF1R blockade impairs the tumor-promoting functions of TAMs and regresses established 
tumors. Taken together, these results suggest that CSF1/CSF1R signaling can regulate both the 
number and the function of TAMs, but these activities may be highly dependent on tumor-
type/tissue-specific factors.  
One possible mechanism by which CSF1Ri reprograms the remaining TAMs is that 
CSF1R signaling may promote tumor-promoting macrophage phenotypes, while its blockade 
polarizes TAMs into the anti-tumor phenotype. In a study by Fleetwood et al. , macrophages 
cultured in CSF1 or CSF2 demonstrated different cytokine profiles and transcription 
activity(Fleetwood et al., 2007). For example, in response to lipopolysaccharide, CSF2-derived 
macrophages preferentially produce IL-6, IL-12, and TNFα, while CSF1-derived macrophages 
produce IL-10 and CCL-2, but not IL-12. These data suggest that the exact cytokine milieu 
differentially program macrophages to play diverse roles. Intriguingly PDAC tumors can also 
produce high levels of CSF2 (Bayne et al., 2012; Pylayeva-Gupta et al., 2012), which could 
reprogram TAMs toward DC-like phenotypes when unopposed by CSF1R signaling.  
Alternative to TAMs being reprogrammed by CSF1Ri, another possible mechanism is 
that CSF1R signaling blockade selects for a subset of tumor-restraining macrophages that are 
insensitive to the CSF signal kills-off a subset of TAMs that have a pro-tumor phenotype. In 
many physiological and pathological settings, including cancers, macrophages are composed of 
heterogeneous subsets of populations with distinct functions (Movahedi et al., 2010). These 
subsets may depend on different factors for their survival, proliferation, and effector functions. 
Selection pressure due to CSF1 signal blockade may have enriched for subsets of anti-tumor 
macrophages in PDAC tissue that are less dependent on CSF1 signaling for their survival. Our 
analysis of cell death in CD206HiMHCIILow vs. CD206LoMHCIIHi TAM sensitivity to aCSF1 IgG 
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supports this hypothesis (Figure 2.3B). While both CD206Hi and CD206Low TAM populations 
had detectable cell death upon CSF1 neutralization, the CD206Hi populations were preferentially 
depleted. The CD206Hi TAM subset had significantly higher CSF1R expression levels, 
suggesting that this population may be more dependent on the CSF1 signal. Taken together, the 
heterogeneity of macrophages within the tumor tissue suggests that subsets of TAMs can be 
targeted to modulate the tumor microenvironment and enhance tumor elimination. 
CD206 is expressed in many subsets of myeloid cells other than macrophages, including 
immature dendritic cells and monocytes (Van Dyken and Locksley, 2013). Whether CD206 
expression is correlated to differential activation status in these cell types is not known. 
Interestingly, Tie2+ monocytes almost uniformly express CD206 (Pucci et al., 2009). It remains 
to be seen whether the loss of CD206Hi tumor-infiltrating monocytes upon αCSF1 treatment 
(Figure 2.9A) involves the Tie2+ monocytes and/or affects tumor vasculature. 
Although CSF1/CSF1R blockade enhances the anti-tumor activity of myeloid cells and T 
cell responses, its efficacy can be blunted by upregulation of immune checkpoint molecules, 
especially PDL1. While tumor intrinsic pathways have been reported to drive PDL1 expression 
in tumor cells (Le et al., 2013), multiple lines of evidence suggest that PDL1 expression by 
epithelial tumors is an adaptive response to interferon signaling from tumor stroma. Several 
groups have reported that IFNγ and IFNα directly lead to the upregulation of PDL1 (Chen et al., 
2012; Rowe et al., 2012; Spranger et al., 2013; Terawaki et al., 2011). Consistent with these 
studies, in vitro treatment with recombinant IFNγ markedly upregulated PDL1 expression in our 
PDAC cell lines (not shown). Given the elevated expression of interferons and interferon 
response genes in CSF1Ri-treated PDAC tumor tissue, we reason that CSF1Ri-mediated 
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interferon production might drive the upregulation of PDL1 in PDAC cells, an inherent 
limitation of this therapy. 
Even though T cell checkpoint inhibitors alone have achieved impressive clinical benefits 
in some other cancers, particularly melanoma (Hamid et al., 2013; Wolchok et al., 2013), their 
application in pancreatic cancer as single agents has had limited efficacy (Royal et al., 2010). 
This is potentially due to the immunosuppressive microenvironment of PDAC tissue, which 
could be alleviated by therapeutic strategies that reprogram dominant myeloid responses to allow 
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2.6 Figures  
	  
Figure 2.1. PDAC tumors overexpress CSF1.  
A–B) Immunohistochemical analysis of CSF1 expression in normal pancreas and PDAC tissue. 
Representative immunofluorescent images are shown. C–D) Stratification of patient PDAC 
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Figure 2.2. CSF1/CSF1R blockade reprograms the tumor immune microenvironment.  
A) Leukocyte infiltration in KI tumors from mice treated with vehicle or CSF1Ri (PLX3397) for 
8 days. The frequency of CD11b+CD3/19−Ly6G−Ly6CLoF4/80HiMHCII+ macrophages, 
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CD11b+Ly6G−Ly6CHi Mo-MDSC, and CD11b+Ly6GHiLy6C+MHCIIlow/- G-MDSC subsets is 
depicted as the mean percentage over total live cells.  
B) Cluster analysis of differential gene expression (Table S1) in vehicle- and CSF1Ri-treated 
tumors. 
C) Table of biologic processes enriched in “upregulated” or “downregulated” genes (DAVID 
analysis).  
D–E) Selected gene sets are displayed with associated biological activities.  
F) qRT-PCR analysis of orthotopic KI tumor tissue following treatment with vehicle or CSF1Ri 
for 8 days. Graph depicts mean fold change compared to vehicle.  
G) Kaplan Meier analysis of patient cohorts stratified by expression level of genes down-
regulated from the analysis in (B). 
In all panels n=4-6 mice/group and * denotes p<0.05 (Mann-Whitney U-test), unless specified. 
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Figure 2.3. CSF1/CSF1R signaling blockade reprograms TAM response. 
A) Representative flow cytometry plots with gating strategy to identify mature granulocytes, G-
MDSCs, Mo-MDSCs, and TAM subsets.  
B-D) Frequency of total, CD206Hi and CD206Low TAMs in orthotopic KI tumors treated with 
aCSF1 for 6 hours–8 days. Mean percentage of macrophages over total cells is depicted.  
C) Representative analysis of MHCII and CD206 expression in TAMs following 8-day treatment 
with vehicle or aCSF1.  
E) Analysis of dead (live/dead blue dye+) CD206Hi and CD206Low TAMs in PDAC tumors from 
(B).  
F) CSF1R expression by MFI in CD206Hi and CD206Low TAMs in vehicle-treated mice from (B).  
G) CD206 expression by MFI and CD206Hi TAM number following 8 days of aCSF1 treatment. 
H) qRTPCR analysis on CD11b+Ly6G/C-F4/80+MHCII+ TAMs sorted from KI tumors 
following 8-day treatment with vehicle or aCSF1. 
I) MHCII expression by MFI in TAMs from (H). 
All graphs depict means values or normalized fold change +/-SEM, n=4-6 mice/group and * 
denotes p<0.05 by unpaired t-test or Mann-Whitney U-test. 
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Figure 2.4. CSF1/CSF1R signaling blockade enhances TAM support for CTL responses.  
A) Analysis of T cell suppression by TAMs from vehicle- or aCSF1-treated mice. TAMs were 
isolated by FACS and assayed for their ability to suppress splenic CD8+ T cell proliferation 
following anti-CD3/CD28 stimulation. The mean number of proliferation cycles is depicted after 
70 hours. Representative data from two replicate experiments (n=3 mice/group).  
B) Flow cytometry analysis of tumor-derived mCherry fluorescence in tumor-infiltrating 
leukocytes. Representative plots from 5 mice are depicted.  
C) Frequency of CD11b+/Ly6G-/Ly6CLo/F4/80Hi/MHCII+ TAMs and CD11bLow/-/Ly6GC-/CD19-
/CD11c+/MHCII+ Lymphoid DCs in orthotopic KI tumors after 8 days of aCSF1 or CSF1Ri 
treatment. 
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D) TAMs and LyDCs were isolated by FACS from mice in (C), loaded with SIINFEKL peptide, 
co-cultured with splenic OT1 cells for 18 hours. OT1 proliferation was measured by CFSE 
dilution. Results reflect two triplicate experiments using 3 mice/group.  
All graphs depict mean values +/- SEM. * denotes p<0.05 by unpaired t-test. 
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Figure 2.5. CSF1/CSF1R blockade bolsters T cell responses. 
A–C) Mice bearing established orthotopic KI or PAN02 tumors were treated with vehicle, 
CSF1Ri, or aCSF1. Tumor burden is displayed as mean tumor weight (n=10–15 mice/group), 
normalized to five mice sacrificed at the start of treatment (“RX Start”).  
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D–E) Analysis of tumor-infiltrating CD3+CD8+CTLs, CD3+CD4+Foxp3- effector T cells, and 
CD4+Foxp3+ Treg from mice in (A–B) is depicted as mean percentage over total live cells (n=6 
mice/group). The mean effector (CTL + CD4+ effector)-to- TReg ratio is also depicted.  
F) CD69, CD44, CTLA4, and PD1 expression in CD3+CD8+CTLs from mice in (A) is depicted 
as both MFI and percentage of positive cells. Representative plots are depicted.  
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Figure 2.6. CSF1/CSF1R signaling blockade elevates PDL1 expression in tumor cells.  
A–B) qRT-PCR analysis of KI tumors following 8-day treatment with vehicle, CSF1Ri or aCSF1.  
C) PDL1 and PDL2 expression in denoted tumor-infiltrating myeloid cells from orthotopic KI 
tumors treated with vehicle or CSF1Ri. Representative FACS plots and MFI are depicted.  
	   87	  
D) Mean percentage of PDL1+ and PDL2+ TAMs and monocytes.  
E) Mean percentage of PDL1+ PDAC cells in orthotopic KI tumors from mice treated with 
vehicle, CSF1Ri, or aCSF1. PDAC cells were identified as CD45- mCherry+.  
F-G) PD1 expression in tumor-infiltrating myeloid cells following vehicle or CSF1Ri treatment. 
Representative expression plots, MFI and positive cells percentage data are depicted.  
All graphs depict means values +/-SEM, n=3-7 mice/group. * denotes p<0.05 by unpaired t-test. 	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Figure 2.7. CSF1/CSF1R signaling blockade enhances T cell checkpoint immunotherapy.  
A–D) Mice bearing orthotopic KI or KC tumors were treated with vehicle, CSF1Ri, or aCSF1, 
+/- GEM +/- aPD1, and +/-aCTLA4. The tumor burden is displayed as mean tumor weight 
(n=10–15 mice/group), normalized to five mice sacrificed at the start of treatment (“Start”).  
E) Frequency of tumor-infiltrating CD3+CD8+CTLs, CD3+CD4+Foxp3- T effectors, and Foxp3+ 
CD4+ TRegs from mice in (D) is depicted as mean percentage of total live cells (n=6 mice/group). 
Mean effector (CTL + CD4+ effector) to TReg ratio is depicted.  
F) Flow cytometric analysis of tumor-infiltrating CD11b+Ly6C/G-F4/80+MHCII+ TAMs, 
CD11b+Ly6C+Ly6G- Mo-MDSCs, and CD11b+ Ly6C+Ly6G+MHCII- G-MDSCs from mice in 
(D) is depicted as mean percentage of total cells (n=6 mice/group).  
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G) Mice bearing orthotopic KI tumors were treated with GEM, aPD1, aCTLA4, vehicle or 
aCSF1, +/- aCD4 and aCD8. The tumor burden is displayed as mean tumor weight (n=10-15 
mice/group). 
All graphs depict mean values +/- SEM and * denotes p<0.05 by unpaired t-test and/or Mann-
Whitney U-test. 	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Figure 2.8. Flow cytometric analysis of leukocyte infiltration in orthotopic PDAC tumors.  
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A) Representative FACS plots with gating strategy to identify mature granulocytes 
(CD11b+Ly6G+Ly6C-MHCII+), G-MDSCs (CD11b+Ly6G+Ly6C+), Mo-MDSCs (CD11b+Ly6G-
Ly6C+), and CD206Lo and CD206Hi TAMs (CD11b+Ly6G/C-F4/80+MHCII+).  
B) CD206 expression in TAM subsets. 
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Figure 2.9. CSF1 blockade depletes CD206+ Mo-MDSCs and upregulates MHCII 
expression in Lymphoid DCs.  
A) Frequency of CD206Hi Mo-MDSCs in orthotopic KI tumors from mice treated with aCSF1 
for 6 hours to 8 days.  
B) Frequency of Mo-MDSCs, G-MDSCs, and mature granulocytes in KI tumors from (A).  
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C) Flow cytometry analyses of MHCII, CD11c, and F4/80 expression in mCherryLow and 
mCherryHi tumor-infiltrating LyDCs from mCherry+ KI tumor-bearing mice. Representative 
plots from 6 mice are depicted.  
D) Flow cytometry analyses of MHCII, CD11c, and F4/80 expression in tumor-infiltrating 
LyDCs from orthotopic KI tumors following vehicle or CSF1Ri treatment.  
E) MHCII expression in tumor-infiltrating LyDCs from mice in (D) is quantified as MFI. 
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Figure 2.10. CSF1R signaling blockade enhances T cell checkpoint immunotherapy. 
A-B) Mice bearing orthotopic KC (A) or KI (B) tumors were treated with vehicle, PLX3397, 
GW2850, +/- GEM +/- aPD1 and/or aCTLA4. The tumor burden is displayed as mean tumor 
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3.1 Summary 
Tumor-associated macrophages (TAMs) are essential components of the cancer 
microenvironment and play critical roles in the regulation of tumor progression. Optimal 
therapeutic intervention requires in-depth understanding of the sources that sustain macrophages 
in malignant tissues. In this study, we investigated the ontogeny of TAMs in murine pancreatic 
ductal adenocarcinoma (PDAC) models. We identified both inflammatory monocytes and tissue-
resident macrophages as sources of TAMs. Unexpectedly, significant portions of pancreas-
resident macrophages originate during embryonic development and expand through in situ 
proliferation during tumor progression. While monocyte-derived TAMs play more potent roles in 
antigen presentation, embryonically derived TAMs exhibit a pro-fibrotic transcriptional profile, 
indicative of their role in producing and remodeling extracellular matrix molecules. Collectively, 
these findings uncover the heterogeneity of TAM origin and functions, and could provide 
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3.2 Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignant diseases. 
Current therapeutic interventions are extremely ineffective in PDAC treatment, partly due to 
components in the microenvironment that promote tumor growth. Two hallmarks of the PDAC 
microenvironment are the dense fibrotic stroma and extensive infiltration of myeloid cells, 
including macrophages. Tumor-associated macrophages (TAMs) are one of the most abundant 
immune cells infiltrating PDAC. TAMs promote tumor growth by releasing growth factors, 
inhibiting anti-tumor adaptive immune responses, modifying angiogenesis, and promoting 
fibrosis, among other mechanisms (Biswas and Mantovani, 2010; Noy and Pollard, 2014; Ruffell 
and Coussens, 2015). Therefore, high numbers of TAMs correlate with poor patient outcome 
(Balaz et al., 2002; Ino et al., 2013; Kurahara et al., 2011). Consequently, TAMs are considered a 
highly desirable therapeutic target (Mantovani et al., 2014; Noy and Pollard, 2014).  
Optimal therapeutic strategies targeting TAMs require an in-depth understanding of their 
ontogeny and the mechanisms governing their homeostasis. The traditional view holds that tissue 
macrophages are derived from circulating Ly6CHi monocytes. In the last few years, an increasing 
amount of evidence suggests that various types of tissue-resident macrophages are established 
during embryonic development, persist into adulthood, and self-maintain independently of the 
adult hematopoietic system (Epelman et al., 2014; Ginhoux and Guilliams, 2016; Gomez 
Perdiguero et al., 2015; Hashimoto et al., 2013; Perdiguero and Geissmann, 2016; Schulz et al., 
2012; Varol et al., 2015; Yona et al., 2013). Under homeostatic conditions, macrophages derived 
from different developmental origins co-exist in many organs. Two notable exceptions are brain 
microglia, the majority of which are generated during embryonic hematopoiesis at the yolk sac 
stage (Ginhoux et al., 2010; Hoeffel et al., 2015), and intestinal macrophages, which rely on 
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continuous replenishment by adult blood monocytes (Bain et al., 2014). Macrophages in many 
other organs, including the pancreas, have mixed origins (Calderon et al., 2015). A limited 
number of studies suggest that co-existing macrophages, derived from different developmental 
origins, have both overlapping and distinct functions within the same tissue (Epelman et al., 
2014; Gibbings et al., 2015). However, more studies are needed to address the correlation 
between the ontogeny and functionality of different macrophage subsets.  
Despite the growing body of knowledge of tissue-resident macrophages, monocytes are 
still often considered as the precursors of macrophages in tumors (Franklin and Li, 2016). Indeed, 
multiple studies in several tumor models have demonstrated the contribution of circulating 
monocytes to sustaining TAM numbers. (Franklin et al., 2014; Laoui et al., 2014; Movahedi et 
al., 2010). In addition to bone marrow, spleen was also shown to serve as an extramedullary 
hematopoietic site that supplies monocytes to replenish TAM pools (Cortez-Retamozo et al., 
2013). However, the contribution of tissue-resident macrophages to TAMs has largely been 
understudied. Tissue-resident macrophages are known to proliferate in situ under pathological 
conditions (Amano et al., 2014; Jenkins et al., 2011). In addition, in situ proliferating 
macrophages have been observed in human cancers (Campbell et al., 2010). However, it is not 
known whether proliferation of tissue-resident macrophages contributes to TAM numbers in 
malignancies.  
In this study, we document a previously unappreciated heterogeneity in the ontogeny of 
TAMs in pancreatic ductal adenocarcinoma. We identify both Ly6CHi monocytes and tissue-
resident macrophages of embryonic origin as sources of TAMs. More importantly, TAMs 
derived from different origins demonstrate distinct phenotypes and transcriptional profiles, 
suggesting divergent functionality. While monocyte-derived TAMs are more potent at sampling 
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tumor antigens and regulating adaptive immune responses, embryonically derived TAMs have 
higher expression levels of pro-fibrotic genes that encode for extracellular matrix (ECM) and 
ECM remodeling molecules. These data reveal a potential novel function of embryonically 
derived macrophages, and suggest a previously unknown interaction between TAMs and the 
fibrotic PDAC stroma, which could serve as a therapeutic target for PDAC treatment.   
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3.3 Methods and Materials 
Murine PDAC Models 
KPC mice (p48-CRE/Lox-stop-Lox(LSL)-KrasG12D/p53flox/+) used in these studies have been 
previously described (Hingorani et al., 2005) and were backcrossed to C57BL/6 background and 
screened for C57BL/6 identity using congenic markers. KPC-1 cell line was derived from PDAC 
tissues of 2.2-month-old p48-CRE+/LSL-Lox KrasG12D/p53flox/flox (KPPC); the KPC-2 cell line 
was derived from tumors of 6-month-old p48-CRE+/LSL-Lox KrasG12D/p53flox/+ (KPC) mice. 
Cells were grown on collagen-coated tissue culture flasks for <12 passages, and were tested for 
cytokeratin-19, smooth muscle actin, vimentin, and CD45 to verify their carcinoma identity and 
purity. To establish orthotopic KPC models, either 50,000 or 200,000 KPC-1 or KPC-2 cells in 
50 µL of Cultrex (Trevigen) were injected into the pancreas of 6-12-week-old C57BL/6 mice 
according to published protocol (Kim et al., 2009). For mCherry analyses or bioluminescence 
imaging (BLI), KPC-1 or KPC-2 cells were infected with mCherry or click beetle red (CBR)-
GFP vector respectively. mCherryhi or GFPhi cells were selected by FACS prior to orthotopic 
implantation.  
 
Other Mouse Models  
The following mouse strains were purchased from Jackson Laboratories: CCR2-/-, Nur77-/-, 
Rosa26- LSL-eYFP, and Cx3cr1-CreERT2 (all on the C57BL/6 background). Csf1r-Mer-iCre-
Mer mice were purchased from Jackson Laboratories, and were crossed to Rosa26-LSL-
tdTomato mice, which were a kind gift from Dr. Gregory D. Longmore; both strains are on the 
FVB background. Flt3-Cretg mice were a kind gift from Dr. Thomas Boehm and were crossed to 
Rosa26-LSL-eYFP or –tdTomato mice, all under the C57BL/6 background. Mice were 
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maintained in the Laboratory for Animal Care barrier facility at Washington University School 
of Medicine. Washington University School of Medicine Institutional Animal Studies 
Committee approved all animal studies. 
 
Labeling of Blood Ly6Chi Monocytes  
To selectively label Ly6Chi monocytes, 250 uL of liposomes containing clodronate were injected 
intraveneously (i.v.), followed by i.v. injection of 250 uL of FITC-conjugated plain microspheres 
16-18 hours later (1.0 um, 2.5% solids [wt/vol]; Polysciences, diluted 1:4 in PBS). Tissues were 
processed for flow cytometry analyses at indicated time points after bead injection. 
 
Parabiosis 
Parabiotic pairs were generated according to established protocols (Peng et al., 2013) from age- 
(3.5-month-old) and weight-matched female CD45.2+ (KPC or wild-type C57BL/6) and CD45.1+ 
(C57BL/6) mice. Mice were injected with Buprenex subcutaneously after surgery. Sulfatrim was 
continuously added in drinking water for 10 days post-surgery to minimize infections at surgical 
wounds. Mice were separated and perfused with phosphate buffered saline (PBS) containing 
0.2% heparin. Single cell suspensions from tissues were stained with antibodies for flow 
cytometry analyses 2 or 6 weeks after the establishment of parabiosis. 
 
Bone Marrow Transplantation 
Three and a half-month-old C57BL/6 mice or KPC mice were exposed to γ-irradiation dosed at 
1100 rads. Animals were subsequently injected with 2.5 x 106 bone marrow cells from CD45.1+ 
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C57BL/6 mice through i.v. injection (retro-orbital or tail vain). Leukocyte chimerism was 
analyzed 6 weeks later. 
 
Macrophage Depletion 
To deplete tissue resident macrophages, 8-16-week old C57BL/6 mice were treated with 3 doses 
of CSF1 neutralizing antibody (clone 5A1, BioXCell) (1 mg, 0.5 mg, 0.5 mg on Days -18, -14, 
and -11, Figure 3) and 3 doses of clodronate-containing liposome (200 uL/each on Days -17, -13, 
and -10). Control mice were treated with same doses/volume of IgG (clone HRPN, BioXCell) 
and liposome (or phosphate buffered saline as indicated). On Day 0, Mice were implanted 
orthotopically with 200,000 CBR+ KPC-2 cells or 50,000 CBR+ KPC-1 cells, and subjected to 
BLI on Days 3 and 7.  
Similarly, KPC and KPPC mice were treated with 2 doses of αCSF1 (0.5 mg each, Day 1 and 
Day 5) and 2 doses of clodronate-loaded liposome (100 uL each, Day 3 and Day 7) starting at 
2.5-month and 1-month of age, respectively. Tumor burden was analyzed when mice reached 4.5 
months for KPC mice or 2.0 months for KPPC mice.  
To deplete embryonically derived macrophages, C57BL/6 or Flt3-CreYFP mice were 
intraperitoneally injected with 3.0 mgs of CSF1R depleting antibody (AFS98 clone, BioXCell) 
on 13.5 dpc. Surviving mice were implanted with 50,000 CBR+ KPC-1 at 6 weeks of age. Mice 
were sacrificed 12 days after tumor establishment for flow cytometry and tumor burden analyses. 
 
Lineage Tracing of Embryonically Derived Macrophages 
Timed breeding was set up by crossing Csf1r-Mer-iCre-Mer mice with Rosa26-LSL-tdTomato 
mice (both on the FVB background). Embryonic timeline was assessed based on vaginal plug 
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observation: 12pm on the day of plug formation was estimated to be 0.5 day post coitum (dpc). 
Pregnant mice were treated with tamoxifen (Sigma-Aldrich) (75 µg/g) combined with 
progesterone (Sigma-Aldrich) (37.5 µg/g) at one of the following time points: 8.5, 9.5, 10.5, or 
13.5 dpc. To test the contribution of embryonically derived CSF1R+ cells to monocytes or 
macrophages at homeostatic conditions, tumor-free F1 mice were sacrificed for fate mapping 
analyses as they reached 6 weeks of age. To test the contribution of embryonically derived 
CSF1R+ cells to TAMs in PDAC tumors, 50,000 syngeneic Kras-INK cells were orthotopically 
implanted into F1 mice as they reached 6 weeks. Kras-INK cells were derived from p48-
Cre/Lox-Stop-Lox (LSL)-KrasG12D/Ink4a-Arflox/lox mice on the FVB background as previously 
described. Mice were sacrificed approximately 12 days after tumor implantation for the analyses 
of tdTomato signal in different leukocyte populations. 
To trace CX3CR1+ cells, Cx3cr1-CreERT2 mice were crossed with Rosa26-LSL-eFYP mice 
(both on the C57BL/6 background). Pregnant mice were treated with tamoxifen (75 µg/g) and 
progesterone (37.5 µg/g) on 13.5 dpc. F1 neonates were fostered by lactating female mice and 
then aged to 6 weeks for fate mapping analyses.  
 
Mouse Tissue Isolation and Flow Cytometry 
Mice were euthanized by intracardiac perfusion using 20 mL of PBS-heparin under isoflurane 
anesthesia. Tumor tissues and colon were manually minced and digested in 25 mL of Dulbecco’s 
Modified Eagle Medium (DMEM) (Thermo Fisher) containing 2 mg/mL of collagenase A 
(Roche) and 1X DNase I (Sigma) for 30 minutes at 37˚C with constant stirring. Normal pancreas 
was digested in the same buffer for 15 minutes at 37˚C. Digestion was quenched in 5 mL of fetal 
bovine serum (FBS) (Atlanta Biologicals) and filtered through 40 µm Nylon mesh, pelleted 
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through centrifugation (2000 rpm for 5 min at 4˚C), and resuspended in staining buffer (PBS 
containing 1% BSA). Brain and spleen were minced and triturated through 40 µm filters.  
Single cell suspensions were blocked with rat anti-mouse CD16/CD32 antibodies (eBioscience) 
(1/200) for 10 minutes, pelleted by centrifugation, and subsequently labeled with 100 uL of 
fluorophore-conjugated anti-mouse antibodies at recommended dilutions for 20 minutes on ice, 
and washed with staining buffer. For proliferation assays, mice were injected with 5-bromo-2’-
deoxyuridine (BrdU, 1 mg) i.p. 3 hours prior to sacrifice. BD Bioscience Cytofix/cytoperm kit 
was used to stain for BrdU. eBioscience transcription factor staining buffer set was used to stain 
for Ki67. Data were acquired on LSR-II (BD Biosciences), and analyzed using FlowJo software 
(Tree Star). To quantify proliferating/cycling cells in Flt3-CreYFP mice, tumors were digested as 
described above, stained with fluorophore-conjugated antibodies for 20 minutes, fixed in 4% 
formaldehyde for 10 minutes on ice, permeabilized in ice-cold 70% ethanol for 3 hours, stained 
with Ki67 antibody diluted in staining buffer for 20 minutes on ice, pelleted and resuspended in 
staining buffer, and immediately processed for data acquisition on LSR-II. To assess hypoxia, 
Flt3-CreYFP mice were intraperitoneally injected with pimonidazole hydroxychloride (60 mg/kg) 
1 hour prior to sacrifice (Hypoxyprobe). Single cell suspensions were stained with antibodies 
against pimonidazole adducts for 20 minutes at 4˚C without fixation or permeabilization prior to 
data acquisition. 
To quantitate blood monocytes, 200 uL of blood was obtained by intracardiac puncture prior to 
perfusion, incubated in red blood cell lysis buffer (BioLegend) for 15 minutes on ice, and stained 
with fluorophore-conjugated antibodies for 20 minutes on ice. Stained cells were counted using 
LSR-II.  For blood analysis that does not require numeration, blood was drawn via tail vein 
bleeding, followed by RBC lysis, antibody staining, and data acquisition.  
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Fluorescence-Activated Cell Sorting (FACS) 
Normal or tumor-bearing mice (Flt3-CreYFP, KPC, or C57BL/6 control) were perfused with 20 
mL of heparin-containing PBS. Tissues were digested in 25 mL of DMEM containing 2 mg/mL 
of collagenase A (Roche) and 1X DNase I (Sigma) for 30 minutes at 37˚C with constant stirring. 
CD45+ cells were enriched from single cell suspensions through MACS® magnetic selection 
using anti-mouse CD45 microbeads (Miltenyi). Elutes were blocked with rat anti-mouse 
CD16/CD32 antibodies (eBioscience) (1/200) for 10 minutes, pelleted by centrifugation, and 
labeled with fluorophore-conjugated anti-mouse antibodies at recommended dilutions for 20 
minutes on ice. Cells were filtered through 40 µm Nylon mesh, and immediately sorted using 
Aria-II (BD Biosciences). For microarray analyses and gene expression analyses, cells were 
sorted directly into RNA lysis buffer (Omega Biotek); RNA was isolated using the EZNA kit 
(Omega Biotek) according to instructions by the manufacturer. For ex vivo assays, cells were 
sorted into DMEM containing 20% FBS before being pelleted and resuspended for subsequent 
treatments. 
 
Human PDAC Tissues 
Human PDAC tissues were obtained from surgically resected specimens from patients diagnosed 
in the Department of Pathology at Washington University (St. Louis, MO). Patients underwent 
pancreaticoduodenectomy followed by adjuvant chemotherapy. Patients did not receive 
neoadjuvant therapy. Tissues were embedded in paraffin blocks and processed into 6 µm-thick 
sections for immunofluorescence staining.  
	   106	  
For gene expression profiling in PDAC patients, tissues were freshly obtained from 9 patients at 
pancreaticoduodenectomy, digested into single cell suspension using the protocol described 
above, stained with indicated antibodies (Table 3.4), and processed for cell isolation using Aria-
II (BD Biosciences). Cells were directly sorted into RNA lysis buffer (Omega Biotek). RNA was 
isolated using the EZNA kit (Omega Biotek) according to instructions by the manufacturer. 
cDNA was synthesized using the qScript Supermix (Quanta). cDNA targets were pre-amplified 
for 12 cycles, followed by QPCR analyses (Taqman®, Thermo Fisher). Four out of the nine 
patients have received neoadjuvant therapies, including FOLFIRINOX or 
ABRAXANE/gemcitabine prior to being scheduled for resection.  All patients were off therapy 
for 21 days prior to surgery. All tissues were collected under informed consent from patients. 
Washington University Ethics committee approved the study under IRB protocol #201108117. 
 
PDAC Patient Outcome Analysis 
We used top 110 genes whose expressions were >10-fold higher in the mouse Flt3-CreYFP-negative 
TAM subset than the Flt3-CreYFP-positive subset. Mouse gene entrez IDs were mapped to human 
ortholog based on ENSEMBLE 87 annotation using Bioconductor package “biomaRt”. Genes 
were queried in the cbioportal TCGA pancreatic RNA-seq data through the R package “cdgsr” 
on 178 primary PDAC tumors. For association analysis with survival outcomes, we considered 
the gene signature using the averaged gene expression across all mapped genes (after centering 
each by their median). The gene signature was dichotomized by associated median to divide 
patients into the two groups of over- and under-expression. The Kaplan-Meier method was used 
to estimate empirical survival probabilities and log rank test to compare survival difference 
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between patient groups. Hazard ratio from Cox proportional hazard model was reported with 
95% confidence interval.    
 
Sirius Red Staining and Immunofluorescence Staining  
Tissues were isolated from perfused mice, fixed in 10% formalin overnight, incubated in graded 
ethanol, embedded in paraffin, and cut into 6 µm-thick sections. To analyze tumor fibrosis, tissue 
sections were deparaffinized in xylene, rehydrated in graded ethanol, and processed for Picro-
Sirius Red staining according to instructions by the manufacturer (Sigma Aldrich). To visualize 
macrophages in mouse KPC and human PDAC tissues, paraffin sections were steam heated for 
antigen retrieval in citrate-based buffer (Biogenex), treated with 1% hydrogen peroxide 
(Invitrogen) for 20 minutes to quench endogenous peroxidase, incubated with blocking buffer 
(PBS containing 5% goat serum and 2.5% BSA) for 1 hour at room temperature (RT), blocked 
for biotin/avidin according to instructions by the manufacturer (Vector Labs), and stained with 
primary antibodies at recommended dilutions at 4˚C overnight (Table 3.3). Opal 4-color IHC kit 
was then used according to instructions by the manufacturer (PerkinElmer). When two 
antibodies were used for co-staining, FITC and Cy5 were used to minimize emission spectral 
overlap. To visualize YFP-positive macrophages in Flt3-CreYFP mice, orthotopic PDAC tissues 
were fixed in 4% formaldehyde at 4˚C overnight, incubated in PBS containing 30% sucrose and 
0.1% sodium azide overnight at 4˚C, and embedded in OCT compound on dry ice. Frozen 
sections (6 µm-thick) were air-dried, treated with blocking buffer at RT for 1 hour, and stained 
with CD68 (1/200) (Abcam) overnight, followed by 1 hour incubation with goat anti-rabbit-
Alexa594 (1/400) (Molecular Probes) at RT. All sections were washed in PBS containing 0.05% 
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Tween-20 between incubation steps, and mounted in DAPI-containing media (Vector Labs) for 
imaging on Nikon 80i microscope.  
 
Statistical Analyses 
Statistical analysis was performed using Unpaired Student’s t-test, Mann-Whitney U test, 
Wilcoxon matched-pairs signed rank test, or ANOVA analysis as appropriate for the data set. 
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3.4 Results  
3.4.1 Pancreatic Ductal Adenocarcinoma Tissues are Infiltrated with Macrophages 
High levels of fibrosis and extensive inflammatory cell infiltration characterize the tumor 
microenvironment of human PDAC. Among the infiltrating cells, macrophages are frequently a 
dominant component. This can be readily observed by comparing the expression of pan-
macrophage/myeloid cell markers CD68, CD163, and CD206 in paired human pancreatic tissue 
samples containing both PDAC lesions and adjacent normal tissue (Figures 3.1A-B). This 
increase in macrophage number parallels the levels of tissue fibrosis. While tumor infiltration by 
macrophages is well characterized, the sources of these macrophages have not been elucidated 
completely.  
To explore the ontogeny of TAMs in PDAC, we analyzed p48-Cre+/LSL-
KrasG12D/p53flox/+ (KPC) genetically engineered mouse models (GEMMs), which undergo 
stepwise progression through stages of pancreatic intraepithelial neoplasia (PanIN) and 
ultimately develop PDAC (Hingorani et al., 2005). The KPC model faithfully recapitulates many 
pathological features of the human disease, including progressive development of stromal 
fibrosis and extensive accumulation of macrophages (Figure 3.1C). By flow cytometry, we 
identified CD45+CD11b+CD3-CD19-Ly6G-Ly6CLow/-F4/80+MHCII+ macrophages in normal 
pancreas, autochthonous tumors in KPC mice (Figure 3.1D), and syngeneic orthotopic PDAC 
tumors established using KPC-derived cancer cell lines (KPC-1) (Figure 3.8). In all cases, we 
confirmed macrophage identity in our gating strategy based on the expression of CD68, MerTK, 
CD64 (Gautier et al., 2012), colony-stimulating factor-1 receptor (CSF1R), and CX3C 
chemokine receptor-1 (CX3CR1), but not Siglec-F (Figur2s 3.1E, 3.8C). To confirm the 
exclusion of dendritic cells (DCs) in our macrophage gating, we established orthotopic tumors in 
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Zbtb46gfp/+ reporter mice (Satpathy et al., 2012), and found minimal GFP signal in the 
macrophage population compared to DC specific gating strategies (Figures 3.1E, 3.8D). 
Furthermore, the vast majority of DCs in both normal pancreas and orthotopic PDAC (identified 
by CD45+Zbtb46-GFP+) express considerably lower levels of macrophage markers, including 
MerTK, CD64, F4/80, and CX3CR1 (Figure 3.8E), suggesting that pancreas-infiltrating 
macrophages are phenotypically distinct from DCs. Flow cytometry analyses of tissues from the 
KPC mouse model demonstrated a 24-fold increase in total number and 5-fold increase in 
density of macrophages in end-point PDAC compared to normal pancreas (Figure 3.1F). 
Similarly, macrophage numbers expand in orthotopic PDAC tissues as the tumors progress 
(Figure 3.1G). Taken together, the dramatic upregulation of the number and density of 
macrophages in KPC mouse models mimics that seen in human pancreatic cancer. However, the 
sources of these macrophages are not clearly defined.  
  
3.4.2 Subsets of Macrophages in Pancreas and PDAC Tissues Are Maintained 
Independently of Blood Monocytes 
To test the contribution of blood monocytes to macrophages in tumors, we first 
performed parabiosis by surgically joining the CD45.2-expressing KPC mice with congenic 
wild-type mice that express CD45.1. Parabiotic pairs were set up when KPC mice were 3.5 
months of age. At this age, KPC mice have developed extensive PanIN lesions, with microscopic 
evidence of progression to full PDAC. To study the contribution of blood monocytes to 
macrophages in PDAC, we analyzed chimerism after 6 weeks (at 5 months of age), when disease 
in KPC mice would have progressed to late-stage PDAC. We also evaluated chimerism in a 
cohort of mice 2 weeks after the establishment of parabiosis to study the dynamics of 
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macrophage turnover. We observed 28% chimerism of Ly6CHi monocytes in the blood of KPC 
mice within the first 2 weeks, which did not increase further after 6 weeks of parabiosis (Figures 
3.2A-3.2B). This level of chimerism was mirrored by tissue-infiltrating Ly6CHi monocytes in 
both normal pancreas and KPC tumors (Figures 3.9A-B). However, tissue macrophages in 
steady-state pancreas only achieved 2.5% chimerism after 6 weeks of parabiosis (Figure 3.2B), 
suggesting that the majority of macrophages are maintained independently of circulating 
monocytes during this time period. This level of chimerism was close to what we observed in 
brain microglia (0.5%), which are known to be locally maintained (Ginhoux et al., 2010; Hoeffel 
et al., 2015). Interestingly, the chimerism of macrophages present in KPC tumors was only 8.8%, 
compared to 27% for Ly6CHi monocytes in the same tissue. These data suggest that while 
monocytes contribute to the expansion of macrophage numbers during PDAC progression, they 
might not be the sole source of macrophages in tumor tissues. Additionally, the level of 
chimerism observed in macrophages in PDAC tissues was comparable after 2 and 6 weeks, in 
spite of significant increases in macrophage numbers during this time period (Figure 3.2B). 
These data suggest that chimerism reached equilibrium within 2 weeks of parabiosis and that the 
expansion of TAMs was maintained with equal contributions from both monocytes and other 
sources. 
It is well appreciated that macrophages in tumors exist in subsets with distinct pro-tumor 
activities. One approach to identity these TAM subsets is based on differential expression of 
major histocompatibility class (MHC) II (denoted MHCIIHi and MHCIILow here-in) (Movahedi et 
al., 2010; Zhu et al., 2014). To determine if monocytes replenish these subsets differentially, we 
analyzed the tumor tissue following parabiosis. We found that the MHCIIHi subset constituted up 
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to 80% of the donor-derived TAMs, suggesting that monocytes preferentially, but not 
exclusively, replenish this population over the 6-week time course (Figure 3.2C). 
To complement these parabiosis studies, we established bone marrow chimeras by 
lethally irradiating wild-type CD45.2+ mice and adoptively transferring bone marrow cells from 
CD45.1+ wild-type mice. Six weeks after transfer, more than 99% of the immune cells in the 
blood and the bone marrow of KPC mice were CD45.1+ donor-derived (Figure 3.2D). Strikingly, 
despite potential elimination of radio-sensitive tissue-resident macrophages and the influx of 
Ly6CHi monocytes induced by irradiation, 30% of macrophages in the pancreas were host-
derived (CD45.2+) (Figure 3.2D). In parallel, we lethally irradiated 3.5-month-old KPC mice at 
the PanIN stage, adoptively transferred bone marrow cells from CD45.1+ wild-type mice, and 
analyzed chimerism 6 weeks later in fully established PDAC. Similarly, a significant portion 
(>15%) of TAMs in KPC tumors were host-derived, which contrasts with the >99% chimerism 
detected in circulating monocytes (Figure 3.2G). These data confirmed the existence of 
pancreas-resident TAMs that were not rapidly replaced by blood monocytes. Consistent with the 
results of the parabiosis studies, host-derived (CD45.2+) macrophages were preferentially, but 
not exclusively, MHCIILow in both normal pancreas and KPC tumor tissues (Figures 3.2E-F, 
3.2H). 
To further assess the short-term contribution of blood monocytes to TAM maintenance, 
we used fluorescently labeled latex beads to selectively trace Ly6CHi blood monocytes in tumor-
bearing mice, and observed the fluorescent signals in the TAM compartments at 12, 24, 48, and 
72 hours after monocyte labeling (Figure 3.9C) (Tacke et al., 2006). While fluorescent beads 
labeled 25% of blood monocytes within 24 hours, which is the peak time for fluorescence 
detection in blood (Tacke et al., 2006), bead signal was observed in a negligible amount of 
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macrophages (<0.5%) in normal pancreas (Figure 3.2I), suggesting that the turnover of 
pancreas-resident macrophages relies minimally on monocyte influx, at least short-term. In 
orthotopic PDAC, a significantly larger percentage (12%) of TAMs were fluorescently labeled 
(Figure 3.2I), suggesting that tumors up-regulate the recruitment of circulating Ly6CHi 
monocytes to replenish a portion of TAMs. Consistent with BMT and parabiosis results, bead-
labeled monocytes almost exclusively replenished the MHCIIHi TAM subset (Figures 3.2J-K), 
and this replenishment persisted through 72 hours after bead injection (Figure 3.9D). 
 
3.4.3 Impairment of Circulating Monocytes Alone Does Not Impact PDAC Progression 
To determine the long-term contribution of blood monocytes to macrophages in the 
pancreas, we evaluated pancreas and PDAC macrophages in CCR2- and Nur77-defficient mice, 
which have impairments in circulating Ly6CHi and Ly6CLow monocytes, respectively (Hanna et 
al., 2011; Serbina et al., 2008). Despite >95% reduction in the number of circulating Ly6Chi 
monocytes (Figures 3.3A and 3.10A), the frequency of macrophages in steady-state pancreas 
was not changed in CCR2-deficient mice (Figure 3.10B). Additionally, while in PDAC tumor-
bearing CCR2-/- mice, circulating Ly6CHi monocytes was still decreased by >95%, PDAC-
infiltrating macrophages were decreased by only 50% (Figures 3.3B and 3.10C). Consistent 
with the results of the monocyte labeling experiments, CCR2 deficiency decreased MHCIIHi 
TAM frequency, while MHCIILow TAMs were not affected (Figure 3.3C). Surprisingly, while 
CCR2 deficiency did reduce macrophage numbers, this did not impact tumor growth in two 
independent PDAC models (Figures 3.3D and 3.10D). Similar to these syngeneic PDAC models, 
there were no changes in tumor burden in KPPC GEMMs treated with CCR2 inhibitors 
continuously for 45 days (Figure 3.3K). 
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To address the possibility that Ly6CLow monocytes might contribute to macrophages in 
PDAC tissues, we analyzed Nur77-/- mice. Similar to data from a previous reports (Hanna et al., 
2011), we observed a 75% decrease in circulating Ly6CLow monocyte numbers in Nur77-/- mice, 
compared to Nur77+/- littermates (Figures 3.3E and 3.10A). However, neither macrophage 
numbers nor their MHCII-subset distribution was changed in either normal pancreas or 
orthotopic PDAC tissues (Figures 3.3F-G). Additionally, Nur77 deficiency did not impact 
PDAC tumor growth in three distinct orthotopic PDAC models (Figures 3.3H and 3.10E). 
Together, these data suggest that circulating Ly6CHi monocytes are important for sustaining 
MHCIIHi macrophages, but dispensable for tumor progression. 
 
3.4.4 Tissue-Resident Macrophages Promote PDAC Progression 
To determine whether tissue-resident macrophages regulate tumor growth, we treated 
tumor-naïve mice with CSF1 neutralizing antibodies in combination with clodronate-loaded 
liposomes, followed by a 10-day chase period to allow mice to recover circulating monocyte 
numbers. Following the 10-day recovery, we found that circulating monocyte numbers in 
αCSF1/clodronate-treated animals were restored to control/untreated levels (Figure 3.3I). By 
contrast, pancreas-resident macrophages were depleted as early as 12 hours after injection and 
remained depleted by 85-95% after 10 days of recovery (Figures 3.3I and 3.10F). These data 
suggest that this regimen could allow us to test the impact of the loss of tissue-resident 
macrophages without decreasing circulating inflammatory monocyte numbers. To study how 
loss of resident macrophages affects tumor progression, we established orthotopic PDAC tumors 
10 days after treatment with αCSF1/clodronate or IgG/PBS. We found that loss of resident 
macrophages prior to tumor implantation resulted in a 50% reduction in TAMs in established 
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tumors (Figures 3.3I and 3.10F). These data suggest that loss of resident macrophages is not 
fully compensated for by monocyte-derived TAMs. In contrast to observations in CCR2-null 
mice, depletion of pancreas-resident macrophages led to a significant reduction in tumor burden, 
as measured by both bioluminescence imaging (BLI) and tumor wet-weights (Figure 3.3J). 
These studies were repeated using two distinct KPC-derived PDAC models (Figure 3.10G). To 
exclude the possibility that the impaired tumor progression was due to deficient tumor “seeding” 
upon implantation, we treated two genetic PDAC models (KPC and KPPC mice) with 
αCSF1/clodronate at the premalignant PanIN stage, and analyzed tumor burden after mice 
developed fully established PDAC. In both KPC and KPPC models, depletion of resident 
macrophages resulted in significant reduction in tumor burden (Figures 3.3K). By contrast, 
continuous treatment of KPPC-mice with CCR2 inhibitors during the same time period, in spite 
of reducing monocyte numbers, did not impact tumor burden (Figures 3.3K). More impressively, 
analysis of tumor pathology in KPPC mice showed that in addition to reducing overall tumor 
burden, depletion of resident macrophages dramatically reduced the development of high-grade 
invasive tumors, which correlated with reduced PDAC cell proliferation (Figures 3.3L-M). 
Taken together, these data suggest that pancreas-resident macrophages are more critical, 
compared to monocyte-derived TAMs, in driving PDAC tumor progression.  
 
3.4.5 Embryonically Derived Macrophages are Significant Components of Tissue-Resident 
Macrophages and Expand During Tumor Progression 
To determine whether tissue-resident macrophages are derived from the adult 
hematopoietic system, we performed lineage tracing using Flt3-Cre+/Lox-Stop-Lox (LSL)-YFP 
reporter mice (Flt3-CreYFP). Flt3 is upregulated at the multipotent progenitor stages of 
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hematopoietic stem cell (HSC) differentiation (Boyer et al., 2011). HSC-derived cells that have 
gone through the Flt3+ stage become labeled as YFP-positive, whereas macrophages derived 
from embryonic progenitors outside HSCs are YFP-negative (Schulz et al., 2012). To validate 
this model, we analyzed circulating leukocytes and found that >95.5% of leukocytes in the blood, 
including both Ly6CHi and Ly6CLow monocytes, were YFP-positive in both steady-state and 
tumor-bearing mice (Figure 3.4A). As controls, we analyzed colon macrophages and brain 
microglia. Consistent with previous reports (Bain et al., 2014; Ginhoux et al., 2010), in adult 
mice (8-10 weeks old), 93% of the macrophages in the colon were YFP-positive and 98.8% of 
brain microglia were YFP-negative (Figure 3.4B). In contrast, we observed heterogeneity of 
macrophage ontogeny in pancreatic tissues, with 32.4% of tissue macrophages labeled as YFP-
negative. To determine if this heterogeneity is retained in aged mice, we analyzed 15-month-old 
Flt3-CreYFP reporter mice and found that 30% of the macrophages in the pancreas were still 
YFP-negative (Figures 3.11A-B). These data suggest that embryonically derived pancreas-
resident macrophages persist with age.  
To determine whether these YFP-negative macrophages persist during tumor progression, 
we established orthotopic KPC tumors in Flt3-CreYFP reporter mice. Surprisingly, despite the 
known contribution from circulating monocytes to the tumor macrophage pool, 35.4% of the 
macrophages in these KPC tumors remained YFP-negative, similar to the frequency in normal 
pancreas (Figure 3.4C-D). Even more strikingly, the number of YFP-negative macrophages was 
elevated by >29-fold in tumors compared to normal pancreas (Figure 3.4E). 
Immunofluorescence analysis also identified clear subsets of both YFP-positive and YFP-
negative macrophages in normal pancreas and KPC-derived tumors (Figure 3.4F). These data 
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suggest that a significant portion of TAMs in PDAC tumors are derived independently of the 
Flt3+ progenitors, and that these TAMs expand rapidly in number during tumor progression. 
The presence of large numbers of YFP-negative macrophages suggests that many TAMs 
could be derived during embryonic hematopoiesis. Alternatively, these cells could have 
originated from adult HSCs without going through extensive Flt3+ stages. To distinguish 
between these two possibilities, we treated Flt3-CreYFP mice with one dose of a CSF1R antibody 
(αCSF1R) at 13.5 days post coitum (E13.5) (Hoeffel et al., 2015) to deplete macrophages 
derived from embryonic sources. We then quantified the abundance of YFP-negative 
macrophages in the pancreas of F1 progenies as they reached 6 weeks of age. Treatment with 
αCSF1R on embryonic day E13.5 resulted in 80% reduction in the density of YFP-negative 
macrophages in steady-state pancreas (Figure 3.4G). To further confirm the contribution of 
embryonically derived macrophages to TAMs in PDAC, we orthotopically implanted KPC tumor 
cells in adult mice following αCSF1R treatment on E13.5. Embryonic αCSF1R treatment 
resulted in a 40-60% reduction in the number of macrophages in established tumors (Figure 
3.4H). Additionally, the loss of embryonically derived macrophages led to delayed tumor 
progression in two distinct syngeneic PDAC models (Figure 3.4I). Taken together these data 
suggest that embryonically derived macrophages facilitate PDAC progression.  
To further assess the specific contribution of embryonic hematopoietic progenitors to 
PDAC TAMs, we administered one dose of tamoxifen in Csf1r-mer-iCre-mer; Rosa26-LSL-
tdTomato mice at E8.5, E9.5, E10.5, E11.5, or E13.5 to span yolk sac and fetal liver stages. 
Using this model, we observed that HSC-derived circulating monocytes were labeled at all time 
points later than E9.5 (Figures 3.12A-B). Using E8.5 or E9.5 tamoxifen pulsing, we observed 
labeling in 4% and 10% of macrophages, respectively, in normal pancreas retained the label as 
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mice reached 6 weeks of age (Figures 3.5A-B). To confirm this, we used Cx3cr1-CreERT2; 
Rosa26-LSL-eYFP reporter mice. After administration of tamoxifen on E13.5 at fetal liver stage, 
the majority of Ly6CHi monocytes are not labeled (Yona et al., 2013), but we also observed 
significant labeling in pancreas tissue macrophages (Figures 3.12C). To assess if the 
embryonically labeled macrophages would expand during tumor progression, we established 
orthotopic Kras-INK (KI)-derived PDAC tumors in Csf1r-mer-iCre-mer/ LSL-tdTomato mice. 
Consistent with results in Flt3-Cre reporter mice, tdTomato+ macrophages labeled with a 
tamoxifen pulse at E8.5 or E9.5 expanded in number by 6.8- or 13.5-fold, respectively, during 
PDAC tumor progression (Figures 3.5C). These data suggest that yolk sac-derived macrophages 
are a significant source of tissue-resident macrophages that undergo significant numerical 
expansion during tumor progression. 
In both CSF1R- and CX3CR1-driven lineage-tracing models, we observed higher levels 
of labeling in the MHCIILow macrophage subset (Figures 3.12D-E). Similarly, in the Flt3-Cre 
reporter mice, significantly larger portions of YFP-negative macrophages constitute the 
MHCIILow subset in both normal pancreas and PDAC tissues (Figures 3.11C-D). These results 
further confirm that embryonically derived macrophages are preferentially but not exclusively 
enriched in the MHCIILow macrophages. Interestingly, we found that in both HSC-derived and 
embryonically derived TAMs, the MHCIILow subset experiences higher levels of hypoxia. 
However, macrophage hypoxia level was independent of origin (Figure 3.11E-F). These data 
suggest that macrophage origin might drive intrinsic differences in macrophage phenotype and 
function that can be further molded by conditions in the tumor microenvironment.  
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3.4.6 Embryonically Derived Macrophages Expand through in situ Proliferation 
To determine if tissue-resident macrophages undergo expansion through local 
proliferation, we analyzed Ki67 expression and short-term 5-Bromo-2'-deoxyuridine (BrdU) 
incorporation in macrophages from normal pancreas and PDAC tissues. Analyses of normal 
pancreas demonstrated that <1% of macrophages incorporated BrdU following a 3-hour pulse 
and <3% were Ki67+ (Figure 3.6A-D). These data suggest that pancreas-resident macrophages 
in steady state are mostly quiescent. On the other hand, >15% of TAMs in either autochthonous 
KPC PDAC tissues or orthotopic KPC-1 tumors were Ki67+, and 3.5-4% were labeled with 
BrdU within 3 hours (Figures 3.6A-D). Of note, the 3-hour pulse resulted in no detectable BrdU 
signal in circulating monocytes (Figure 3.13A), suggesting that BrdU signals in pancreatic 
macrophages reflect in situ proliferation. Confirming these data, immunofluorescence staining 
also identified a significant portion of Ki67+F4/80+ cells in autochthonous KPC PDAC tissues 
(Figure 3.6C), but not in normal pancreas. Interestingly, the majority of these Ki67+F4/80+ cells 
localized to fibrotic tumor areas, whereas F4/80+ cells in the tumor nests were mostly Ki67 
negative (Figures 3.6C and 3.13C). Consistent with this, macrophages cultured on high-density 
collagen I gels had higher proliferation rates compared to those cultured on low-density collagen 
(Figure 3.13D), suggesting that there may be cross talks between tumor fibrosis and proliferative 
expansion of macrophages. Microarray analysis of TAMs from autochthonous KPC tumors 
demonstrated distinct changes in cell cycle regulatory genes when compared to macrophages in 
normal pancreas (Figure 3.6E). To assess if embryonically derived TAMs proliferate at higher 
rates than HSC-derived TAMs, we stained for Ki67 in tumor-bearing Flt3-CreYFP mice. 
Embryonically derived TAMs had a significantly higher frequency of Ki67 positivity than their 
HSC-derived counterparts (Figure 3.6F). This increased level of Ki67 in embryonic TAMs was 
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independent of their MHCII status (Figure 3.13B). In addition, transcriptional profiling by Q-
PCR also identified significantly reduced level of genes that negatively regulate cell cycle 
progression, such as Mafb and c-Maf, but higher levels of cell cycle promoting genes, such as 
Jun and Ets2, in the YFP-negative TAM subset (Figure 3.6G). These data suggest that 
macrophages in PDAC tissues up-regulate proliferative programs, perhaps in response to fibrosis, 
and that embryonically derived macrophages proliferate at high levels to keep pace with tumor 
progression. 
We next sought to identity what signals sustain the survival of these TAM subsets in 
PDAC tissues. We took a targeted approach and treated orthotopic PDAC-bearing Flt3-CreYFP 
mice with neutralizing antibodies against CSF1 and CSF2, both of which have been implicated 
in macrophage survival in mouse models of cancer (Hoeffel et al., 2015; Zhu et al., 2014). 
Although CSF2 signal blockade did not change the number of TAMs, inhibition of CSF1 
signaling led to a 48% reduction in the YFP-positive and a 75% reduction in the YFP-negative 
macrophages (Figure 3.6H). These data suggest that CSF1 is important for the survival of both 
TAM subsets, but embryonically derived macrophages are more sensitive. 
 
3.4.7 Embryonically Derived TAMs Have a Distinct Pro-fibrotic Phenotype. 
Having identified both embryonically derived and HSC-derived monocytes as sources of 
TAMs in PDAC, we next asked whether distinct macrophage origins correlated with phenotypic 
differences. Towards that end, we first performed flow cytometry analyses to compare the 
expression of a panel of cell surface markers in TAM subsets using the Flt3-CreYFP mice. Both 
subsets expressed similar levels of macrophage identity markers, including CD64, CD115, and 
F4/80, whereas YFP-negative TAMs expressed lower levels of CD11b (Figures 3.7A and 
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3.14A), consistent with previous reports of CD11b level in embryonically derived macrophages 
under homeostatic conditions (Schulz et al., 2012). YFP-negative TAMs also expressed 
significantly lower levels of MHCI and MHCII (Figure 3.7A). Similar differences were also 
seen between the two macrophage subsets in normal pancreas (Figure 3.14B), which suggests 
possibly inherent differences in antigen presentation activities. By contrast, co-stimulatory 
molecules (CD80, CD86), T cell-activating molecules (CD40), and immune checkpoint 
molecules (PDL1, PDL2, PD1) were expressed at comparable levels (Figure 3.7A). 
Embryonically derived TAMs also expressed significantly higher levels of CX3CR1 and lower 
levels of CD11a and CD49d (Figures 3.7A and 3.14C). Interestingly, despite the lack of 
CXCR4 expression in either macrophage subset in the normal pancreas, CXCR4 was 
significantly upregulated in TAMs, but only in the YFP-negative population (Figure 3.7A and 
3.14B). Taken together, these data suggest that TAMs derived from different origins are 
phenotypically distinct.  
To gain further insight into potential functional differences between embryonically 
derived and HSC-derived macrophages, we performed transcriptional profiling on macrophages 
sorted from Flt3-CreYFP mice (Figures 3.7B and 3.14D). Only a modest number of genes were 
expressed differentially between the YFP-positive and YFP-negative macrophages in steady-
state pancreas tissue. However, 660 genes were differentially expressed (>1.5 fold, p<0.05) 
between the two subsets in orthotopic KPC tumors, suggesting that TAMs of different origins 
may have distinct functions in PDAC tumors. Using gene set enrichment analysis, we found that 
the genes enriched in embryonic-derived macrophages showed a strong trend toward poor 
survival when mapped to data sets from human PDAC patients (Figure 3.14E). Analysis of gene 
ontogeny demonstrated that embryonically derived macrophages had a higher expression of 
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molecules involved in extracellular matrix (ECM) deposition and/or remodeling (Figure 3.7C). 
Indeed, molecules on top of the list of genes that were expressed at higher levels in 
embryonically derived TAMs were mostly involved in ECM organization (Table 3.1). This 
included genes encoding for ECM molecules (collagen isoforms, nidogen, tenascin C, and 
elastin), ECM-producing enzymes (hyaluronan synthases 2 and 3), and ECM-remodeling 
molecules (lysyl oxidase), which we validated using Q-PCR analyses in two independent 
experiments (Figures 3.7D and 3.14F). To test if the expression of pro-fibrotic genes is related 
to functional differences in ECM production, we isolated YFP-positive and YFP-negative TAMs 
from Flt3-CreYFP mice and tested their ability to produce collagen ex vivo. Correlating with their 
differential expression profiles, we found that embryonically derived TAMs could produce 
significantly more Collagen I and IV (Figure 3.7F). To correlate these ex vivo results to in vivo 
impact, we analyzed collagen density in PDAC tissue from mice treated on E13.5 with αCSF1R 
or control IgGs and compared these results to CCR2-deficient mice. We found embryonic 
macrophage depletion led to reduced collagen deposition. By contrast, CCR2-deficient mice had 
slightly elevated collagen levels compared to control mice (Figure 3.14G). These data suggest 
that macrophages of different origins have differential impacts on fibrosis. 
To rule out the possibility that the identified YFP-negative cells contained fibroblasts 
instead of macrophages, we compared cancer-associated fibroblasts (CAFs) to YFP-negative 
TAMs. We found that CAFs expressed platelet-derived growth factor receptor-a (PDGFRa), but 
not CD45, F4/80, or CD11b, whereas YFP-negative TAMs demonstrated the opposite pattern 
(Figure 3.14H). Similarly, the mRNA expression levels of macrophage/myeloid identity genes 
(Emr1, Itgam, Csf1r, Csf2r, and Cx3cr1) were comparable in both YFP-positive and YFP-
negative TAMs, as determined by Q-PCR analysis, and were 10- to 1000-fold higher in both 
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subsets of TAMs as compared to CAFs (Figure 3.14I). These data confirm that the YFP-
negative cells were not fibroblasts but were a macrophage subset with a unique pro-fibrotic 
phenotype. To evaluate how the pro-fibrotic gene signature in embryonically derived TAMs 
differed from that in CAFs, we compared selected fibrosis genes by Q-PCR. As expected, CAFs 
were the dominant producers of several isoforms of collagens (such as Col1a2 and Col3a1), 
Elastin, and Sparc (Figure 3.14J). However, mRNA for other ECM molecules, such as Col6a1, 
Nidogen, and Adamts12, were expressed at comparable levels. In contrast, embryonically derived 
TAMs were the more dominant expressers of Col4a4, Col10a1, Col17a1, Col18a1, and Has3 
(Figure 3.14J). Taken together, these data suggest that embryonically derived TAMs may be 
more involved in “fine-tuning” fibrotic responses in PDAC tumors. 
In contrast to pro-fibrotic genes, the levels of mRNA involved in class I and class II 
antigen presentations (Erap1, Psme1, and Ciita) were higher in HSC-derived TAMs (Figure 
3.7E). To test the antigen uptake capacity in TAMs subsets in vivo, we orthotopically implanted 
mCherry+ KPC-1 PDAC cells and determined the mCherry positivity in TAMs. Although both 
TAM subsets demonstrated potent capacity to uptake tumor antigen, the amount of antigen 
uptake was >2-fold higher in HSC-derived TAMs compared to their embryonic counterparts 
(Figure 3.7G). We next tested the ability of each TAM subset to present antigen (ovalbumin) to 
OT1+ CD8+ T cells and found that HSC-derived (YFP+) TAMs were far more potent at antigen 
presentation compared to their embryonically derived (YFP-) counterparts. In addition, HSC-
derived TAMs expressed significantly higher levels of Il12a, Il4, Ccl17, and Ifnb1 compared to 
their embryonic counterparts (Figure 3.7E). Taken together, these data suggest that TAMs 
derived from HSCs and embryonic sources likely play more potent roles in regulating adaptive 
immunity and/or driving immune tolerance. This is consistent with previous reports showing that 
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monocyte-derived TAMs regulate immunosuppression in PDAC models (Beatty et al., 2015; 
Mitchem et al., 2013; Sanford et al., 2013) and in early phase clinical trials (Nywening et al., 
2016).  
 
3.4.8 Subsets of TAMs in Human PDAC Tissue Resemble Murine Embryonically Derived 
TAMs 
To address whether the identification and characterization of embryonic TAMs in murine 
PDAC models is relevant for human cancer, we took advantage of the observation that CXCR4 
was almost exclusively upregulated in murine embryonic TAMs (Figure 3.7A). We first 
evaluated human PDAC tissues for CXCR4+ TAMs and found that 10-40% of TAMs expressed 
high levels of CXCR4 (Figure 3.7I). We also noted that these CXCR4+ TAMs expressed lower 
levels of HLA-DR in eight out of nine patients evaluated (Figure 3.7J). These results are 
consistent with our observation that CXCR4+ TAMs of embryonic origin expressed lower levels 
of MHCII in murine PDAC models. To determine if this subset of human PDAC TAMs shared 
the pro-fibrotic gene expression profile we identified in mice, we isolated CXCR4-positive and 
negative TAMs from PDAC tissues from three untreated surgical patients and performed Q-PCR 
analyses. Consistent with our animal model data, we found that CXCR4+ TAMs expressed 
significantly higher levels of Collagens and ECM-modulating molecules compared to their 
CXCR4-negative counterparts (Figure 3.7K). Collectively, these data suggest that CXCR4+ 
TAMs in human PDAC resemble the ECM regulatory phenotype of murine embryonically 
derived PDAC TAMs. 
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3.5 Discussion 
Ontological origins of tissue macrophages vary among different tissues under steady state. 
With the exception of brain and intestine, many other organs contain macrophages of different 
origins co-existing within the tissue context. Consistent with previous reports (Calderon et al., 
2015), our study demonstrated that pancreas-associated macrophages contain cells derived from 
both adult HSCs and embryonic hematopoietic sources. The precise nature of embryonic 
hematopoietic progenitors that gave rise to these macrophages needs to be defined; likely sources 
include yolk sac-derived erythro-myeloid progenitors (EMPs) (Gomez Perdiguero et al., 2015) 
and EMP-derived fetal monocytes (Hoeffel et al., 2015). The origin of HSC-derived 
macrophages in normal pancreas is also unclear; possible sources include fetal liver HSCs and 
bone marrow HSC-derived monocytes that may populate the pancreas perinatally. Regardless of 
developmental origin, significant portions of macrophages in the pancreatic stroma are likely 
resident in the tissue without rapid replenishment from circulating monocytes. The majority of 
pancreas-resident macrophages are quiescent under steady state, suggesting that these cells may 
self-maintain through longevity. It is also important to note that the ontogeny of tissue-resident 
macrophages is not static. Embryonically derived macrophages in multiple organs have shown 
various degrees of replacement by monocytes with different kinetics (Bain et al., 2016; Ginhoux 
and Guilliams, 2016; Molawi et al., 2014). Our study using aged mice demonstrated that 
embryonically derived macrophages could persist long-term in the pancreas, despite potential 
slow replacement by blood monocytes that we cannot rule out. It remains to be seen if and to 
what extent could embryonically derived macrophages persist in aged human patients.  
Fates of tissue-resident macrophages vary under different pathological conditions. For 
example, liver resident Kupffer cells undergo necroptosis during Listeria monocytogenes 
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infection, which recruits monocytes to replenish macrophages (Bleriot et al., 2015). On the other 
hand, tissue macrophages undergo in situ proliferation during helminth infections (Jenkins et al., 
2011). Very few studies have looked at the fate of tissue-resident macrophages during cancer 
progression. One report documented a loss of resident macrophages concomitant with the 
increase in monocyte-derived TAMs in a breast cancer model (Franklin et al., 2014). On the 
other hand, microglia were shown to be present in brain tumor models (Bowman et al., 2016; 
Hambardzumyan et al., 2016). Here, we demonstrated that in PDAC, embryonically derived 
tissue-resident macrophages not only persisted in the tissue, but also underwent significant 
proliferative expansion to keep pace with tumor progression. TAMs in the PDAC tissues adopted 
a transcriptional program to enhance proliferation, and embryonically derived tissue-resident 
macrophages further enhanced their proliferative programs compared to the monocyte-derived 
counterparts. Of note, PDAC also upregulated the proliferation of monocyte-derived 
macrophages, similar to what is seen in other cancers and tissue repair (Franklin et al., 2014; 
Wang and Kubes, 2016); though their proliferative activities were less robust than those in the 
embryonically derived macrophages. Factors that sustain and promote in situ proliferation in 
different TAM subsets, as well as the cellular sources of these factors, have yet to be identified. 
It also remains to been seen to what extent would these observations hold true in other tumors or 
if this feature is enriched in PDAC due to its uniquely fibrotic nature. One tumor type of interest 
is pancreatic neuroendocrine tumors (PNET), which originate from the islets of Langerhans. 
Under steady state, macrophages in the pancreatic islets are maintained by blood monocytes, 
whereas stromal macrophages are embryonically derived and locally maintained (Calderon et al., 
2015). It would be interestingly to see whether PNET contrasts with PDAC and relies on 
circulating monocytes to sustain TAMs in-spite of residing in the same tissue. Answers to these 
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questions could provide insights into how we can therapeutically target TAM subset-specific 
pathways in order to restrain the progression of different types of tumors even within the same 
organ.  
A highly debated question regarding macrophage ontogeny is the functional differences 
between macrophages derived from distinct origins that are located within the same tissue 
context. This question remains largely unsolved. A limited number of transcriptional studies 
suggest that macrophages of different ontogeny demonstrate mostly overlapping transcriptional 
profiles within the same tissue, at least in non-disease settings (Gibbings et al., 2015; Gundra et 
al., 2014; van de Laar et al., 2016). Upon engraftment, circulating monocytes could also 
replenish the resident macrophage pool and adopt a transcriptional profile similar to their 
embryonically derived counterparts (Scott et al., 2016). These studies led to the assumption that 
tissue environment, as opposed to ontogeny, is the main driver of macrophage functions. Indeed, 
macrophages resident in different organs or at different niches within the same organ have 
distinct transcriptional profiles, supporting the concept that tissue environment could educate 
macrophages to adopt distinct functionalities (Gautier et al., 2012; Mass et al., 2016; Movahedi 
et al., 2010; Ojalvo et al., 2009). However, our microarray data demonstrated that although gene 
expression profiles of embryonically derived and HSC-derived macrophages are fairly similar in 
the normal pancreatic tissue, their expression profiles and ex vivo functions are very distinct in 
PDAC tissues. As a harbinger of this dynamic, CXCR4 is largely not expressed in macrophages 
of either origin in the normal pancreas, but specifically upregulated in PDAC TAMs of 
embryonic origin. These data suggest that origin may epigenetically poise macrophages to 
differentially respond to inflammatory insults with distinct bioactivities, such as ECM 
modulation or antigen processing/presentation. Future experiments are needed to determine 
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which lineage commitment factors poise macrophages for differing functional responses during 
tumor progression.  
Our studies also demonstrate unique fibrosis-modulating functions in embryonically 
derived TAMs. Macrophages are well known for their ability to promote fibrosis in multiple 
physiological and pathological conditions, such as wound healing and cancer (Wynn and 
Vannella, 2016). However, such activities are thought to be indirectly executed by activating 
fibroblasts to lay down and remodel ECM. Here, our data suggest that subsets of macrophages 
may fine-tune fibrosis by directly depositing and/or remodeling the ECM. Fibrosis is a hallmark 
of PDAC, which imposes a major physical barrier that not only inhibits endogenous anti-tumor 
immune responses but also deters effective delivery of chemo- and immune-therapies (Beatty et 
al., 2011; Jiang et al., 2016). Although it has been demonstrated that tumor-derived factors 
promote macrophage expansion and fibrosis, the initiation of these two pathological features 
were considered to be independent of each other. Our data suggest these responses may be more 
integrated. Corresponding with this idea, a recent report demonstrated that TAMs directly 
construct ECM in colon cancer (Afik et al., 2016). Interestingly, such activities were carried out 
by monocyte-derived TAMs in their model. 
Strikingly, depletion of macrophage subsets had different impacts on tumor progression 
in PDAC models. Loss of monocyte-derived macrophages had limited effects on tumor 
progression, whereas depletion of tissue-resident macrophages significantly reduced tumor 
growth and aggressivity/grade. These observations form a nice comparison to several other 
tumor models, where the depletion of monocyte-derived macrophages inhibits tumor growth and 
metastasis (Afik et al., 2016; Franklin et al., 2014; Qian et al., 2011). Although we cannot rule 
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out the importance of monocyte-derived TAMs in the regulation of PDAC development, our data 
suggest that tissue-resident macrophages are important in PDAC progression.  
In summary, our study demonstrates that PDAC contains macrophages with 
heterogeneous ontological origins. In addition to Ly6CHi monocytes, tissue-resident 
macrophages derived from embryonic origin are also a major source of TAMs in murine models. 
Embryonically derived macrophages expand in PDAC tissues through in situ proliferation and 
exhibit a pro-fibrotic transcriptional profile, suggesting a potential role in fine-tuning fibrosis in 
PDAC. We provide a new paradigm of macrophage heterogeneity under the tumor setting, which 
may facilitate future investigations that ultimately improve therapeutics to target the “fibro-
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3.6 Figures and Tables 
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Figure 3.1. Pancreatic Ductal Adenocarcinomas Are Highly Infiltrated with Macrophages. 
(A) Representative images of human PDAC and adjacent normal pancreatic tissues assessed for 
macrophage density (CD68, CD206, or CD163) and fibrosis (Sirius Red). Epithelial cells were 
stained by pan-Keratin (PanK). 
(B) Quantitation of CD68+ cells in human PDAC tissue vs. normal adjacent tissue from the same 
surgical sample. 
(C) Representative images of pancreas tissue from the p48-CRE/KrasG12D/p53flox/+ (KPC) mouse 
model assessing macrophage infiltration (F4/80) and collagen density (Sirius Red).  
(D) Representative flow cytometry plots showing gating strategy to identify macrophages in 
autochthonous KPC tumors.  
(E) Measurement of listed cell surface markers analyzed by flow cytometry and pre-gated on 
macrophages as shown in (D). 
(F) Quantification of macrophages by flow cytometry in normal pancreas tissues and advanced 
KPC PDAC tissues (n=4-8/group). 
(G) Kinetics of macrophage numbers assessed by flow cytometry in syngeneic orthotopic KPC-1 
tumors. (n=4/group) 
Data are shown as mean ± SEM and * denotes p<0.05 by t-test or Mann-Whitney test. 
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Figure 3.2. Substantial Portions of Macrophages in Steady-State Pancreas and PDAC 
Maintained Independently of Blood Monocytes. 
(A) 3.5-month-old homozygous CD45.1 and CD45.2 (KPC or wild-type C57BL/6) mice were 
surgically joined to create parabiotic pairs. Tissues were analyzed after 2 or 6 weeks of 
parabiosis. Representative plots (6 weeks) of chimerism in indicated cell types are shown. 
(B) Quantification of chimerism in (A); (n=6-16/group). 
(C) MHCIIHi and MHCIILow composition of CD45.1+CD45.2(-)-derived TAMs in (B).  
(D) C57BL/6J mice were lethally irradiated and adoptively transferred with bone marrow cells 
from homozygous CD45.1 mice. Analysis of chimerism in several tissues after 6 weeks is 
depicted.  
(E) Quantification of chimerism in MHCIIHi and MHCIILow macrophage subsets in normal 
pancreas in (D).  
(F) Representative plots of (E). 
(G) Autochthonous KPC mice bearing premalignant disease (3.5-month-old) were lethally 
irradiated and adoptively transferred with bone marrow cells from CD45.1 mice. Tissues were 
analyzed for chimerism after 6 weeks, when disease had progressed to full PDAC. Relative 
CD45.1 and CD45.2 percentages analyzed by flow cytometry are depicted. 
(H) Quantification of chimerism in MHCIIHi and MHCIILow TAMs in (G). 
(I) Tumor-naïve mice and orthotopic KPC tumor-bearing mice were treated with clodronate-
loaded liposomes followed by i.v. injection of FITC-labeled beads. Tissue macrophages were 
analyzed for FITC signal by flow cytometry after 24 hours. 
(J) Representative flow cytometry plots of beads+ TAMs in orthotopic PDAC from (I). 
(K) MHCIIHi and MHCIILow composition of beads+ TAMs from (I). 
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Data are shown as mean ± SEM and * denotes p<0.05 by t-test. 	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Figure 3.3. Tissue-Resident Macrophages Promote PDAC Progression. 
(A-D) KPC cells were orthotopically implanted into CCR2+/- and CCR2-/- mice. Tumors were 
processed on Day 12 for flow cytometry analysis.  
(A) Blood was drawn from orthotopic KPC-2-bearing mice via intracardiac puncture. Monocytes 
were assessed by flow cytometry (n=3-4/group). 
(B) Frequency of macrophages orthotopic KPC-2 tissues of CCR2+/- and CCR2-/- mice. 
(C) Frequency of MHCIIHi and Low TAM subsets assessed by flow cytometry in orthotopic KPC-
2 tumors. Representative plots of TAM subsets are shown (n=3-4/group). 
(D) Wet weights of KPC-2 tumors in (B). 
(E-H) KPC-2 cells were orthotopically implanted into Nur77+/- and Nur77-/- mice. Tumors were 
processed on Day 13 for flow cytometry analysis (n=4/group normal, n=6-8/group of tumor 
bearing). 
(E) Blood was drawn from orthotopic PDAC-bearing mice via intracardiac puncture. Monocytes 
were quantified. 
(F) Quantity of macrophages in normal pancreas and orthotopic PDAC in Nur77+/- and Nur77-/- 
mice. 
(G) Representative plots of MHCIIHi and Low TAM subsets. 
(H) Wet weights of KPC-2 tumors in (F). 
(I-J) KPC-2-CBRLuc+ cells were orthotopically implanted into IgG/PBS- or αCSF1/clodronate-
treated mice. Bioluminescence imaging (BLI) was used to measure tumor progression. Tumors 
were processed on Day 12 for flow cytometry and tumor burden analyses. 
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(I) Scheme of pancreas-resident macrophage depletion followed by orthotopic PDAC of KPC-2-
CBRLuc+ cells. Blood monocytes and pancreatic macrophage numbers before and after PDAC 
implantation are shown.  
(J) Tumor burden based on BLI and wet weight measurement.  
(K) 2.5-month-old KPC or 1.0-month-old KPPC mice were treated with αCSF1/clodronate. 
Tumor burden was analyzed at 4.5 or 2.0 month of age. 
Data are shown as mean ± SEM and * denotes p<0.05 by t-test or Mann-Whitney test. 
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Figure 3.4. Embryonically Derived Macrophages are Significant Components of Tissue-
Resident TAMs and Expand During PDAC Progression. 
(A-C) KPC-1 cells were orthotopically implanted into Flt3-CreYFP mice. Indicated tissues were 
analyzed by flow cytometry for YFP expression. Representative flow cytometry plots of YFP 
signal in leukocytes from blood (A), macrophages from colon and brain (B), and macrophages in 
normal pancreas and end stage PDAC tissues (C) are depicted. 
(D) Quantifications of percentage of YFP-negativity in leukocytes from (A-C; n=7-22/group). 
(E) Kinetics of YFP-negative macrophages quantity and density in orthotopic KPC-1 tumors. 
(F) Representative immunofluorescence images of CD68 and YFP from (C). Inlets identify YFP-
positive and YFP-negative macrophages. 
(G) Flt3-CreYFP reporter mice were treated with αCSF1R on E13.5. Pancreas was isolated at 6 
weeks of age. Density of YFP-negative macrophages was quantified (n=3-5/group). 
(H) C57BL/6 mice were treated with αCSF1R or vehicle on E13.5. Orthotopic PDAC was 
established at 6 weeks of age. TAMs were quantified after 12 days (n=5-6/group). 
(I) Tumor burden from (H) was analyzed (n=6-9/group). 
Data are shown as mean ± SEM and * denotes p<0.05 by t-test. 
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Figure 3.5. Yolk Sac-Derived Macrophages Expand during PDAC Progression.  
(A) Representative flow cytometry plot of tdTomato signals in the normal pancreas and 
orthotopic KI tumors of adult mice upon E8.5 or E9.5 tamoxifen pulse. 
(B) Percentage of indicated leukocytes that were labeled upon E8.5 or E9.5 tamoxifen pulse 
(n=3-7/group). 
(C) Absolute numbers of tdTomato+ macrophages in the normal pancreas and orthotopic KI 
tumors (n=3-4/group). 
Data are shown as mean ± SEM and * denotes p<0.05 by t-test. 
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Figure 3.6. Embryonically Derived Macrophages in PDAC Expand through in situ 
Proliferation. 
(A) Analysis of autochthonous KPC PDAC and normal pancreas tissues for BrdU+ macrophages. 
Animals were injected with BrdU 3 hours prior to sacrifice. Representative plots are shown.  
(B) Quantification of BrdU incorporation in (A).  
(C) Representative immunofluorescence images of Ki67 and F4/80 staining in autochthonous 
KPC tumors. 
(D) Quantification of flow cytometry data for Ki67 and BrdU positivity in macrophages in 
normal pancreas and orthotopic KPC-1 tumors (n=4-5/group). 
(E) Heat map of cell cycle regulation genes assessed by array on RNA in macrophages isolated 
from normal pancreas and autochthonous KPC PDAC tissues (n=6/group). 
(F) Orthotopic KPC-1 tumors were established in Flt3-CreYFP reporter mice. Proliferation of 
TAM subsets was analyzed by flow cytometry for Ki67. 
(G) TAM subsets were sorted from orthotopic KPC-1 tumors in Flt3-CreYFP mice. Q-PCR 
analyses were performed to quantify transcripts of proliferation regulation genes. 
(H) Orthotopic KPC-1-bearing Flt3-CreYFP reporter mice were treated with three doses of aCSF1 
or αCSF2 on Days 7, 11, and 14. TAM subsets were quantified on Day 15. 
Data are shown as mean ± SEM and * denotes p<0.05 by t-test. 
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Figure 3.7. Embryonically Derived TAMs Have Distinct Phenotypes and Functions that are 
Recapitulated by Subsets of TAMs in Human PDAC. 
(A) Flow cytometry analysis of orthotopic KPC-1 PDAC tissues in Flt3-CreYFP mice stained with 
indicated antibodies and gated on TAMs (gray, isotype control; blue, YFP-negative TAMs; red 
YFP-positive TAMs). 
(B) YFP-positive and YFP-negative macrophages were sorted from normal pancreas or late-
stage orthotopic KPC-1 tumors of Flt3-CreYFP mice. RNA was extracted for microarray analyses. 
Hierarchical clustering of genes that were differentially expressed between macrophage subsets 
either in normal pancreas or PDAC is shown. 
(C) Gene ontogeny analyses of molecules expressed at higher levels in YFP-negative TAMs. 
(D-E) Q-PCR analyses of gene expression for molecules involved in ECM modification (D) or 
immune modulation (E). Analysis was performed on RNA from sorted YFP+ and (-) TAMs from 
Flt3-CreYFP mice bearing KCP-1 tumors (n=5/group). Genes were selected from the top 
candidates in (B). 
(F) Analysis of collagen production ex vivo by YFP+ and (-) TAMs sorted from orthotopic KPC-
1 PDAC tissues in Flt3-CreYFP mice. Collagen laydown was assessed after 36 hours by 
immunofluorescence intensity. Experiments are representative of three independent repeats.  
(G) Orthotopic tumors were established in Flt3-CreYFP reporter mice using KPC-1-mCherry+ 
tumor cells. TAMs were analyzed for mCherry positivity. Representative flow plots and mean 
fluorescence intensity (MFI) are depicted (n=4/group). 
(H) Analysis of antigen presentation to CD8+ T cells by YFP+ and (-) TAMs sorted from Flt3-
CreYFP mice bearing KPC-1 tumors. Antigen presentation was assessed by the ability of TAMs to 
activate OT1 cells after SIINFEKL loading and measured by CFSE-dilution and/or 
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CD44+/CD69+/CD62L- expression on T cells. Three independent sorting experiments are 
depicted as paired analyses. 
(I) Flow cytometry analysis of human PDAC tissues from surgical resections is depicted. The 
percentage of CXCR4+ TAMs of total is shown for nine patients. 
(J) Analysis of HLA-DR expression in CXCR4-positive and negative TAMs using data from (I). 
A representative flow plot and MFI analysis in paired samples are depicted. 
(K) Q-PCR analysis of mRNA from CXCR4-positive and negative TAMs sorted from human 
PDAC tissues. Pro-fibrotic genes assessed were identified in (B), and analysis of paired isolates 
from three patients is depicted. All graphs depict mean values +/- SEM and * denotes p<0.05 by 
t-test, Mann-Whitney test, or Wilcoxon matched pairs rank test as appropriate for the data set. 
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Figure 3.8, related to Figure 3.1. Macrophage Gating Strategy in Normal Pancreas and 
Orthotopic Tumors. 
(A) Representative flow cytometry plots showing gating strategy to identify macrophages in 
normal pancreas.  
(B) Representative flow cytometry plots showing gating strategy to identify macrophages in 
orthotopic tumors established using KPC-1 cells.  
(C) Measurement of listed surface markers analyzed by flow cytometry and pre-gated on 
macrophages in orthotopic KPC-1 tumors as shown in (B). To confirm CX3CR1 antibody 
staining, orthotopic KPC-1 tumors were established in CX3CR1gfp/gfp mice; Representative flow 
cytometry plot of GFP signals in TAMs is shown. (representative of n=15).  
(D) Representative flow cytometry plots of Zbtb46-GFP fluorescence in TAMs of orthotopic 
KPC-1 tumors, brain microglia (CD45Low/CD11bHi/F4/80+), and splenic dendritic cells (DCs) 
(CD45+/CD11c+/MHCII+/B220-/CD8+ or CD11b+). Mean fluorescence intensity (MFI) for each 
cell population is calculated by deducting baseline MFI of isotype staining control from the MFI 
of stained samples. (n=4-5/group, mean ± SEM). 
(E) Measurement of listed surface markers in pancreatic dendritic cells (DCs) and macrophages 
by flow cytometry.  
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Figure 3.9, related to Figure 3.2. Substantial Portions of Macrophages in Normal Pancreas 
and PDAC Self-Maintain Independently of Blood Monocytes. 
(A-B) 3.5-month-old homozygous CD45.1 and CD45.2 (KPC or wild-type C57BL/6) mice were 
surgically joined to create parabiotic pairs. Chimerism of indicated leukocytes were analyzed 2 
weeks (A) or 6 weeks (B) after the establishment of parabiosis. (n=6-16/group, mean ± SEM). 
(C) KPC-1 orthotopic tumor-bearing mice were treated with clodronate i.v. to deplete circulating 
Ly6CLow monocytes, followed by retro-orbital injection of FITC-labeled latex beads. 
Representative flow cytometry plots showing FITC signals in blood Ly6CHi monocytes 24 hours 
after bead injection.   
(D) Representative flow cytometry plots of beads+ TAMs in orthotopic KPC-1 tumors at 
indicated time points (n=3/time point).  
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Figure 3.10, related to Figure 3.3. Deficiencies in Tissue Resident Macrophages but Not in 
Blood Monocytes Impact PDAC Tumor Burden. 
(A) Representative quantification of blood monocyte frequency in tumor-bearing B6, CCR2-/- 
and Nur77-/- mice. (n=3-5/group). 
(B) Representative quantification of pancreatic macrophage frequency in tumor-free CCR2+/- and 
CCR2-/- mice. (n=3/group). 
(C) Orthotopic tumors were established in B6, CCR2+/- or CCR2-/- mice with 200,000 or 50,000 
KPC-1 or KPC-2 cells. Frequencies or quantities of TAMs from 4 independent experiments were 
analyzed at indicated time points after tumor implantation. Each bar graph represents an 
independent experiment. 
(D) Tumor burden analysis from (C). 
(E) Orthotopic tumors were established in B6, Nur77+/-, or Nur77-/- mice (numbers and cell types 
indicated). Tumor weights were measured at indicated time points. Each bar graph represents an 
independent experiment. 
(F) 8-week old C57BL/6 (left and middle) or Flt3-CreYFP (right) mice were treated with αCSF1 
combined with clodronate as described in Experimental Approach. Orthotopic tumors were 
subsequently established using KPC-2 or KPC-1 cells. Quantities of macrophages prior to or 
after tumor establishment were assessed by flow cytometry. (n=3-4/data point) 
(G) Tumor burden from (F) were analyzed by bioluminescence imaging (BLI) or wet tumor 
weight. (n=4-5/data point/group) 
Data are shown as mean ± SEM and ∗ denotes p<0.05 by t-test. 
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Figure 3.11, related to Figure 3.4. Embryonically Derived Macrophages are Present in the 
Pancreas and PDAC of Adult Mice and are Enriched in the MHCIILow Subset. 
(A) Representative flow cytometry plots of YFP signals in pancreatic macrophages of 15-month-
old tumor-free Flt3-CreYFP mice. 
(B) Percentage of YFP-negativity in indicated leukocytes from 15-month-old tumor-free Flt3-
CreYFP mice. (n=3). 
(C) Representative flow cytometry plots showing YFP and MHCII signals in macrophages from 
normal pancreas of orthotopic KPC-1 tumors. 
(D) Percentage of YFP-negativity in MHCIIHi and MHCIILow macrophage subsets in normal 
pancreas and orthotopic KPC-1 tumors. 
(E) Representative flow cytometry plots of pimonidazole (PIMO) signals in indicated TAM 
subsets. 
(F) MFI of PIMO signals in indicated TAM subsets from (E). 
Data are shown as mean ± SEM and ∗ denotes p<0.05 by t-test. 
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Figure 3.12, related to Figure 3.5. Yolk Sac and Fetal Liver Derived Pancreatic 
Macrophages are Present in the Pancreas and PDAC of Adult Mice and are Enriched in 
the MHCIILow Subset. 
(A) Csf1r-Mer-iCre-Mer; Rosa26-LSL-tdTomato mice were treated with tamoxifen at indicated 
time points. Labeling efficiency in indicated leukocyte populations was analyzed by flow 
cytometry. (n=3-7/group) 
(B) Kinetics of labeling efficiency in brain microglia, pancreas macrophages, and PDAC TAMs 
from (A). 
(C) Cx3cr1-CreERT2; Rosa26-LSL-eYFP mice were treated with tamoxifen at E13.5. Labeling 
efficiency in indicated leukocyte populations was analyzed by flow cytometry. Representative 
flow cytometry plots of YFP signals in pancreatic macrophages are shown. 
(D) Labeling efficiency of CSF1R+ cells in pancreatic macrophage subsets from (A-B). 
(E) Labeling efficiency of CX3CR1+ cells in pancreatic macrophage subsets from (C). 
Data are shown as mean ± SEM and ∗ denotes p<0.05 by t-test. 
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Figure 3.13, related to Figure 3.6. In Situ Proliferating Macrophages Localize in Proximity 
to Fibrotic Tumor Areas. 
(A) Representative flow cytometry plot showing 3-hour BrdU incorporation in blood Ly6CHi 
monocytes.  
(B) Percentage of Ki67 positivity in indicated TAM subsets of KPC-1 tumor-bearing Flt3-CreYFP 
mice. 
(C) Serial sections from autochthonous KPC tumors were stained for macrophages (F4/80) and 
proliferation marker Ki67. Inlets demonstrate double positive cells. Fibrosis was assessed in the 
adjacent section by Sirius Red staining.  
(D) Bone marrow-derived macrophages were cultured on collagen I at different densities. 
Percent of Ki67 positivity were quantified by immunofluorescence staining. 
Data are shown as mean ± SEM and ∗ denotes p<0.05 by t-test. 
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Figure 3.14, related to Figure 3.7. Embryonically Derived TAMs Have Distinct Surface 
Marker Expression and Unique Pro-fibrotic Transcriptional Profile. 
(A) MFI of indicated markers in TAMs from orthotopic KPC-1 tumors in Flt3-CreYFP mice. 
Value is calculated by deducting baseline MFI of isotype staining control from the MFI of 
stained samples. 
(B) MFI of CXCR4 and MHCII in normal pancreatic macrophages. Representative histograms 
are shown. 
(C) MFI of CD11a and CD49d in TAMs from orthotopic KPC-1 tumors in Flt3-CreYFP mice. 
Representative histograms are shown. 
(D) Representative flow cytometry plots showing gating strategies used to sort YFP-positive and 
-negative TAMs from Flt3-CreYFP mice. 
(E) Kaplan-Meier analysis of patient cohorts stratified by expression level of genes that are 
higher in Flt3-CreYFP-negative TAMs based on analysis in Figure 3.7B.  
(F) Q-PCR analyses of indicated genes in Flt3-CreYFP-positive (red) and Flt3-CreYFP-negative (blue) 
TAMs in a second repeat of sorting. (n=5/group for normal pancreas macrophages, n=6/group 
for TAMs). 
(G) Quantification of PDAC collagen density by image analysis of Trichrome or Sirus Red 
staining on orthotopic KPC-2 tumors implanted in mice treated with anti-CD115 at E13.5 or 
CCR2-/- mice or control mice.  
(H) Expression of listed surface markers in cancer-associated fibroblasts (CAFs) (orange) and 
TAMs (pink). 
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(I) Q-PCR analyses of indicated genes coding for macrophage surface identity markers in 
cancer-associated fibroblasts (CAFs) (orange), Flt3-CreYFP-positive (red) and Flt3-CreYFP-negative 
(blue) TAMs. (n=6/group for TAMs) 
(J) Q-PCR analyses of indicated genes coding for ECM production and modification molecules 
in cancer-associated fibroblasts (CAFs) (orange) and Flt3-CreYFP-negative TAMs (blue). (n=6/group 
for TAMs) 
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Table 3.1, Top 40 Genes Higher in the Flt3-CreYFP-Negative TAM subset on Microarray 
 
Entrez Gene ID Gene Symbol Fold Change (YFP- 
Negative vs. -Positive) 
Adjusted p-Value 
16949 Loxl1 63.289225 0.000875412 
20319 Sfrp2 49.434489 0.002976931 
14125 Fcer1a 47.168637 0.001479908 
13078 Cyp1b1 46.682438 0.000577909 
12833 Col6a1 44.095025 0.005380821 
14107 Fat1 43.982448 0.00067664 
17022 Lum 43.106335 0.002411298 
20716 Serpina3n 42.226946 2.36575E-06 
107449 Unc5b 37.411451 6.02918E-05 
21923 Tnc 36.737766 1.75967E-05 
12834 Col6a2 33.948455 0.0107914 
13179 Dcn 32.864451 0.000918713 
109624 Cald1 32.081952 0.009871551 
20692 Sparc 30.158108 0.002911626 
12945 Dmbt1 29.555895 0.002827771 
71228 Dlg5 28.841214 0.000450364 
218952 Fermt2 28.552239 0.000900703 
12873 Cpa3 28.488505 0.009611972 
50781 Dkk3 28.452825 0.000765057 
16948 Lox 28.392067 2.20501E-05 
18073 Nid1 26.763409 0.006042784 
13602 Sparcl1 26.16561 0.02195566 
18028 Nfib 24.737366 0.0450516 
242608 Podn 23.756922 0.001129132 
16948 Lox 23.563272 0.000163479 
170643 Kirrel 23.48621 0.004143432 
19662 Rbp4 23.361095 0.000281845 
22601 Yap1 22.207021 0.001841186 
67701 Wfdc2 22.1382 0.001520571 
12111 Bgn 22.120345 0.004549826 
69675 Pxdn 22.116972 0.003057716 
12831 Col5a1 22.061485 0.004469495 
17534 Mrc2 21.234791 0.001029897 
18596 Pdgfrb 21.193765 0.003426061 
17153 Mal 21.021883 0.000893123 
15228 Foxg1 21.009472 0.000115044 
239337 Adamts12 20.932199 0.008746559 
12842 Col1a1 20.290887 0.000281845 
17112 Tm4sf1 19.497997 0.00545794 
66773 Gm17019 19.069459 0.000785569 
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Table 3.2, Mouse Antibodies for Flow Cytometry and FACS 
 
 Antigen Clone Fluorophore Source 
B220 RA3-6B2 APC BioLegend 
BrdU 3D4 FITC BD Bioscience 
CD3 145-2C11 APC, PerCP-Cy5.5 eBioscience 
CD11a M17/4 PE BioLegend 
CD11b M1/70 Alexa700, PE-Cy7 eBioscience 
CD16/CD32 93 Unconjugated eBioscience 
CD19 eBio1D3 APC eBioscience 
CD40 1C10 PE-Cy5 eBioscience 
CD45 30-F11 PE-Cy7, APC-Cy7 eBioscience 
CD45.1 A20 APC eBioscience 
CD45.2 104 FITC eBioscience 
CD49d R1-2 PE BioLegend 
CD64 X54-5/7.1 PE eBioscience 
CD68 FA-11 FITC eBioscience 
CD80 16-10A1 PE-Cy5 eBioscience 
CD86 GL1 PE-Cy5 eBioscience 
CD115 AFS98 PE eBioscience 
BV605 BioLegend 
CD124 mIL4R-M1 PE BD Biosciences 
CD206 MR5D3 FITC AbD Serotec 
C068C2 PE-Cy7 BioLegend 
CX3CR1 SA011F11 PE BioLegend 
CXCR4 2B11 PerCP-eFluor710 eBioscience 
F4/80 BM8 PE-Cy5, PE eBioscience 
Keratin C11 Alexa488 Cell Signaling 
Ki67 SolA15 FITC eBioscience 
16A8 BV605 BioLegend 
Ly6C HK1.4 PerCP-Cy5.5, Alexa488 eBioscience 
Ly6G 1A8 PE eBioscience 
APC BioLegend 
MerTK 108928 PE R&D 
DS5MMER PE-Cy7 eBioscience 
MHCI 34-1-2S PE eBioscience 
MHCII M5/114.15.2 eFluor450, APC-Cy7 eBioscience 
PD1 J43 PE eBioscience 
PDGFRα APA5 PE eBioscience 
PDL1 MIH5 PE eBioscience 
PDL2 122 PE eBioscience 
SiglecF ES22-10D8 APC, PE-Vio770 Miltenyi 
E50-2440 PE BD Biosciences 
Tie2 TEK4 PE BioLegend 
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Table 3.3, Antibodies for Immunofluorescence Staining 
 
Antigen Clone Species Source 
CD68 KP-1 Mouse anti-human NeoMarkers 
Polyclonal Ab125212 Rabbit anti-mouse Abcam 
CD163 EPR19518 Rabbit anti-human Abcam 
CD206 Polyclonal Ab64693 Rabbit anti-human Abcam 
Collagen I 3G3 Rabbit anti-mouse Abcam 
Collagen IV Polyclonal Ab6586 Mouse anti-mouse Abcam 
CXCR4 D4Z7W Rabbit anti-human/mouse Cell Signaling 
F4/80 BM8 Rat anti-mouse eBioscience 
Ki67 MIB-1 Mouse anti-human DaKo 
Polyclonal Ab15580 Rabbit anti-mouse Abcam 
Pan-Keratin C11 Anti-Human/Mouse Cell Signaling 
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Table 3.4. Human Antibodies for Flow Cytometry and FACS 
  
Antigen Clone Fluorophores  Source 
CD3 HIT3a PE BD Biosciences 
CD11b ICRF44 Alexa488 BioLegend 
CD14 61D3 Qdot605 eBioscience 
CD16 3G8 PE BD Biosciences 
CD19 HIB19 PE BD Biosciences 
CD45 2D1 APC-Cy7 BD Biosciences 
CD115 12-3A3-1B10 PE-Cy7 eBioscience 
CXCR4 12G5 Alexa488 R&D Systems 
PerCP-Cy5.5 eBioscience 
HLA-DR L243 eFluor450 eBioscience 
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Chapter 4: Future Directions 
 
4.1 Reprogramming myeloid responses to improve cancer immunotherapies 
Therapeutics that activates anti-tumor immune responses has demonstrated significant 
potential for the treatment of solid tumors. One of the most promising strategies targets immune 
checkpoint molecules, such as programmed death 1 (PD1) or cytotoxic T lymphocyte-associated 
antigen 4 (CTLA4) (Simpson et al., 2013). These immune checkpoint molecules counteract pro-
inflammatory signals and block anti-tumor T cell activities. The potential of this type of 
strategies was demonstrated by the efficacy of CTLA4 antagonistic antibody, ipilimumab, in the 
treatment of subsets of metastatic melanoma (Hodi et al., 2010), as well as recent FDA approval 
of PD1 for the same indication. Another category of immunotherapies involves tumor 
vaccination through adoptive transfer of tumor antigen-specific T cells or dendritic cells 
(Rosenberg et al., 2008). An example is Sipuleucel-T, an autologous dendritic cell-based 
vaccination designed to activate T cells targeting a prostate cancer antigen, which significantly 
improved patient overall survival in a phase III trial (Kantoff et al., 2010). Despite clear efficacy 
in subsets of human cancer, these approaches are not effective in all patients or all cancer types. 
For example, although ipilimumab achieved impressive response rates in melanoma patients, it 
failed as a monotherapy to improve clinical outcome of patients with pancreatic cancer (Royal et 
al., 2010). 
One possible explanation for the lack of responses in many patients to immunotherapy is 
the presence of a suppressive immune microenvironment. While tumor antigen-specific T cells 
may be present in many cancers, the immune infiltrate is often dominated by various subsets of 
myeloid cells. Tumor-infiltrating suppressive myeloid cells include macrophages, immature 
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dendritic cells, and monocytic or granulocytic myeloid-derived suppressor cells (MDSCs). These 
suppressive cells can silence adaptive immune responses by blocking the recruitment of 
cytotoxic T lymphocytes (CTLs) to the tumor tissue, metabolically inhibiting CTL functions, 
chemically modifying T cell receptors to hinder the recognition of tumor antigens, and/or 
amplifying immune suppression via the expansion of regulatory T cells (Gabrilovich and Nagaraj, 
2009; Qian and Pollard, 2010). Altogether, these myeloid cell activities can allow tumor cells to 
evade endogenous and treatment-elicited immune surveillance. Therefore, these subsets of 
suppressive myeloid cells could impose significant limitations on efficient immunotherapies 
(Figure 4.1). Correspondingly, strategies to manipulate suppressive myeloid cells may also 
provide opportunities to improve the efficacy of immunotherapy. Several recent studies 
demonstrated that combining therapeutics that alleviates immune suppression by targeting 
myeloid cell activities could improve the outcome of immunotherapy in mouse models. 
Work from our own group assessed if targeting tumor-associated macrophages (TAMs) 
could mitigate immune suppression and improve immunotherapy in pancreatic ductal 
adenocarcinoma (PDAC) models (Zhu et al., 2014). We targeted TAMs through the inhibition of 
macrophage colony-stimulating factor receptor (CSF1R) signaling, which plays an essential role 
in macrophage differentiation, trafficking, and survival. Blockade of CSF1R signaling not only 
reduced the total number of suppressive macrophages in the tumor tissue, but also reprogrammed 
the remaining TAMs to support anti-tumor T cell responses, as shown by elevated interferon 
expression, reduced immunosuppressive activities, and improved antigen presentation capacity 
in the remaining TAMs. One unwanted consequence of CSF1R signal blockade is the 
upregulation of programmed death ligand 1 (PDL1) in tumor cells and CTLA4 in T cells, which 
potentially poses a significant limitation on the efficacy of CSF1R blockade. However, this may 
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also provide an opportunity to convert tumors that are unresponsive to PD1/CTLA4 antagonists 
to be more sensitive to checkpoint-based immunotherapeutics. Based on this rationale, we 
designed a combination therapy by coupling CSF1/CSF1R signal blockade with immune 
checkpoint antagonists in murine PDAC models. While checkpoint inhibitors alone achieved 
limited efficacy in restraining tumor growth, the addition of CSF1R blockade markedly 
improved the efficacy of PD1 and CTLA4 antagonists and led to regression of well-established 
tumors (Zhu et al., 2014). These data demonstrated that CSF1R signal blockade could render 
tumors more responsive to checkpoint antagonist-based therapies. Similarly, work by Mok et al. 
showed that targeting TAMs through CSF1R blockade could also enhance the efficacy of 
adoptive cell transfer (ACT)-based immunotherapy to reduce tumor burden in a mouse 
melanoma model (Mok et al., 2014). Interestingly, these tumor restraining effects correlated with 
increased expansion of adoptively transferred T cells both in the tumor and in peripheral 
lymphoid tissues, suggesting that reprograming myeloid responses could lead to increased anti-
tumor T cell function systemically. Taken together, these studies indicate that mitigation of 
immune suppression through depletion or reprogramming of TAMs could enhance the clinical 
outcomes of checkpoint-based therapeutics and adoptive cell transfer-based immunotherapies.  
It is important to note that innate immune cells other than macrophages are also 
promising targets. Examples include neutrophils, which are similarly abundant in many types of 
cancers. In a syngeneic murine rhabdomyosarcoma model, Highfill et al. demonstrated that an 
immunosuppressive microenvironment driven by granulocytic MDSC populations suppresses the 
efficacy of anti-PD1 treatment (Highfill et al., 2014). In human sarcoma patients and mouse 
models, tumor cells often overexpress a family of C-X-C motif chemokines, including CXCL1, 2, 
and 8. Their predominant receptor, CXCR2, is expressed on granulocytes and promotes 
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granulocytic MDSC trafficking into tumor sites. Inhibition of CXCR2 signaling blocked the 
recruitment of granulocytic MDSCs to the tumor site and significantly enhanced the efficacy of 
PD1 blockade. These data suggest that responses to immune checkpoint blockade are limited by 
the suppressive microenvironment driven by granulocytes, and that alleviation of this 
suppression could improve the efficacy of checkpoint-based therapies. 
In conclusion, the suppressive tumor microenvironment driven by myeloid cells may 
pose a major limitation on the efficiency of immunotherapy. Therefore, combining 
immunotherapy with strategies that reprogram the suppressive tumor microenvironment holds 
significant promises in cancer treatment (Figure 4.1). Development of such strategies will 
require careful evaluation, as tumor cells, immune responses, and chosen therapeutic strategies 
all interact in a complex and dynamic manner. Future work is needed to determine which 
myeloid populations mediate suppression in specific tumor types, and what immunotherapeutic 
strategies are optimal for combination. 
 
4.2 Regulation of tissue resident macrophages 
Having identified the contribution of pancreas resident macrophages to TAM populations 
in PDAC, the logical next question is how we can target these cells to improve cancer treatment. 
Solution to this question relies on better understanding of the basic biological activities of tissue 
resident macrophages.  
Tissue resident macrophages face two major challenges throughout the life of an 
organism. First, they need to self-maintain long-term both during homeostatic conditions and 
during aging. Second, they need to be able to expand to meet the proliferative demands upon 
pathological challenges, exemplified by the case of tumor development. To persist with aging, 
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tissue resident macrophages could be replenished through self-renewal. However, based on 
propidium iodine staining and BrdU incorporation assays, we saw very minimal level of 
apoptosis and proliferation in pancreas resident macrophages under homeostatic conditions. 
While low level of “tonic” proliferation could sustain long-term self-renewal, this could also 
suggest a second possibility that tissue resident macrophages persist through longevity. Further 
experiments are needed to distinguish between these two possibilities. One approach would be to 
perform a pulse chase experiment, such as BrdU or doxycycline-inducible H2B-GFP pulse. 
During the extended pulse period in young adult mice, tissue resident cells will be labeled as 
BrdU-or GFP-positive. The dilution or retention of the BrdU/GFP signals would tell us whether 
proliferation or longevity is responsible for the maintenance of tissue resident macrophages 
during aging.    
On the other hand, embryonically derived macrophages dramatically enhance their 
proliferative activities during tumor challenge. Concomitantly, molecules involved in both 
extrinsic and intrinsic apoptosis pathways are upregulated, leading to elevated level of apoptosis. 
This suggests that as embryonically derived macrophages expand through in situ proliferation, 
these cells achieve high turnover rates at the expense of the longevity machinery. It is important 
to note that we only observed proliferation in a small fraction of tumor-associated macrophages. 
This leads us to ask: during tumor progression, is the proliferative activity restricted to a small 
subset of macrophages with progenitor-like properties, or is the macrophage pool simply a 
uniform collection of terminally differentiated cells that undergo proliferation in a stochastic 
manner? The current paradigm supports the latter, despite the lack of sufficient number of 
studies to support these claims. Hashimoto et al. attempted to address this question using a 
combination of a diphtheria toxin (DT)-mediated macrophage double depletion model with BrdU 
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pulse-chase experiment. They treated CD169-DTR (diphtheria toxin receptor) with DT to deplete 
lung resident macrophages, and treated mice with daily doses of BrdU for 11 days, at the end of 
which the lung macrophage numbers recovered to pre-treatment level. Following a BrdU-free 
chase period, they treated mice again with one dose of DT, and analyzed cell cycle status 2 days 
later based on Ki67 staining. The prediction was that if there were progenitor-like cells within 
the macrophage population, the Ki67 positive cells, which indicate cell repopulation during the 
second recovery, would be restricted to the BrdU-labeled subset, i.e. cells that have proliferated 
during the first recovery. On contrary, if macrophages stochastically proliferate to repopulate, a 
fraction of Ki67-positive cells could be observed in both the BrdU-labeled and BrdU-negative 
cells. Indeed, the latter is what they observed, suggesting that lung macrophages proliferate in a 
stochastic model to repopulate, at least in this model (Hashimoto et al., 2013). Similarly, in a 
CX3CR1-CreER-based pulse-chase experiment, Bruttger et al. demonstrated that upon depletion 
using the DTR system, microglia repopulate possibly in a stochastic manner from a pre-existing 
population labeled by tamoxifen (Bruttger et al., 2015). On the contrary, in a different depletion 
experiment using CSF1R blockade, Elmore et al. showed that CX3CR1+ microglia repopulate 
through in situ proliferation of a CX3CR1- progenitor population (Elmore et al., 2014). Further 
characterization showed the expression of Nestin and IB4 in these population, which are markers 
not associated with microglia. Despite being positive for IBA1, which indicates microglia 
identity, these progenitor-like cells also express c-Kit and CD34, which are expressed in 
hematopoietic stem and progenitor cells. This study showed the possible existence of a 
progenitor subset that is capable of sustaining tissue macrophages, at least during the recovery of 
these cells.  
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In murine pancreatic ductal adenocarcinoma models, not all macrophages seem to expand 
during tumor progression. In the CSF1R-mer-iCre-mer; Rosa26-LSL-tdTomato lineage tracing 
model, yolk sac-derived macrophages can be labeled upon tamoxifen induction on E8.5 or E9.5. 
Labeled cells persist in adult mice and further expand numerically in established tumors 
(Figures 3.5 and 3.12). However, in the CX3CR1-CreER; Rosa26-LSL-eYFP model, E13.5 
tamoxifen treatment led to the labeling of a significant percentage of macrophages in normal 
pancreas of adult mice. However, the labeled population was dramatically decreased. Similarly, 
if we treat mice of this genotype in adulthood with 30 days of tamoxifen labeling followed by 
tumor implantation, the number of tamoxifen labeled macrophages was decreased in established 
tumors. This suggests the possibility that a population of CX3CR1Low/Neg macrophages residing 
the pancreas actively proliferated during tumor progression and replaced the CX3CR1Hi subset. 
Further experiments are needed to address the possibility that a macrophage progenitor subset is 
responsible for the expansion of tissue resident macrophages during PDAC progression. 
In order to target tissue resident macrophages, we need to understand what signals 
regulate their proliferation, and what stromal components produce these signals. These signals 
require tight regulation for several reasons. First, these signals need to be inhibited at steady state, 
so that the cells do not prematurely exhaust their proliferative potential that precludes their 
persistence with aging. Second, these signals need to be recognized to activate division cycles 
before the proliferative demands are overwhelmed.  Preliminary data demonstrate that loss of 
microbiota induces the expansion of macrophage numbers in normal pancreas (not shown), 
suggesting that signaling pathways downstream of certain pattern recognition receptors could 
mediate the quiescence of tissue resident macrophages. Alternatively, microbiota could educate 
some other circulating leukocytes, which then suppress the proliferative activities of pancreas 
	   173	  
resident macrophages. It would be interesting to see if microbiota is altered in PDAC-bearing 
mice to change the in situ proliferation of embryonically derived TAMs.  
Microarray analyses of embryonically derived and hematopoietic stem cell-derived 
macrophages in normal pancreas and PDAC also demonstrated potential signaling pathways that 
mediate macrophage proliferation. A number of receptors are upregulated in the embryonically 
derived macrophages, including I-7 receptor, Frizzled B, cKit, CD44, CXCR4, CXCR7, CCR2, 
Endothelin receptor A, Ephrin A2, TGF beta receptor 1, nuclear hormone receptors (NR4A1, 
NR4A3, Retinoic acid receptor alpha 2), and GPR132. Comparison between embryonically 
derived and HSC-derived TAMs demonstrated that embryonically derived TAMs have higher 
level of TGF beta-receptor 3, FGF receptor like-1, Frizzled 1, and N-cadherin genes. 
Interestingly, among the genes in the embryonic macrophages that are upregulated by the tumor, 
three genes remained higher than their monocyte-derived TAM counterparts: PDGF receptor 
beta, Frizzled 4, and secreted Frizzled-related protein 2 (Sfrp2). Both Frizzled 4 and Sfrp2 are 
involved in Wnt signaling pathways. The identification of interesting targets suggests that we 
could explore the potential relevance of PDGF and Wnt signaling pathways in the regulation of 
TAM proliferation. 
Lastly, it is important to note that the pathways that mediate TAM proliferation and 
functionality may be uncoupled. CXCR4 is a unique marker of embryonically derived 
macrophages, and its specificity is only manifested in PDAC but not normal pancreas. Treatment 
of orthotopic PDAC-bearing mice did not alter TAM numbers or proliferation (data not shown). 
However, it would be interesting to see if CXCR4 signaling is involved in shaping the functions 
of the embryonically derived TAM subset. 
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4.3 Targeting the cancer cell-macrophage-fibrosis triad 
As we develop therapeutic strategies to target the cancer microenvironment, it is 
important to note that not all tumor types are created equal. Each tumor has its unique stromal 
structure that needs to be considered.  
Two hallmarks of pancreatic ductal adenocarcinoma are the extensive myeloid infiltration 
and dense desmoplastic reactions characterized by high level of fibrosis. High levels of 
macrophage infiltration predict worse survival duration for PDAC patients (DeNardo et al., 
2011; Ino et al., 2013), making them a good therapeutic target. Indeed, depletion of TAMs in 
murine models of PDAC decreased tumor infiltrating cells, relieved immunosuppression, and 
improved responses to both chemotherapies and checkpoint-based immune therapies (Mitchem 
et al., 2013; Zhu et al., 2014). On the other hand, fibrosis is considered to be another major 
barrier of PDAC treatment. While fibrosis was originally considered to provide a mechanical 
encapsulation that contains the primary tumor and prevents its spread, high level of fibrosis was 
later found to negatively correlate with patient outcome. Excessive amount of fibrosis increases 
interstitial fluid pressures, induces collapses of vasculature, and presents major physical barriers 
to perfusion and diffusion of small molecule-based therapeutics (Provenzano et al., 2012). 
Therefore, alleviation of fibrotic elements in the stroma, by targeting hyaluronan acid for 
example, enhances the delivery of chemotherapies and improves overall survival in preclinical 
mouse models. Alternatively, targeting tumor cell-intrinsic pathways, such as the focal adhesion 
kinase pathway, to reduce fibrosis also improves chemotherapy and checkpoint-based and 
adoptive cell transfer-based immunotherapies (Jiang et al., 2016). It is important to note that 
while fibroblast cells are the major source of fibrosis, simply stripping fibroblasts may not 
generate favorable outcome (Ozdemir et al., 2014). This could be due to the heterogeneity in the 
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quality of fibrosis: certain configurations of extracellular matrix structure could be necessary for 
anti-tumor activities. Therefore, it may be more favorable to reprogram tumor cells or fibroblasts 
to alleviate fibrosis, or alter the qualities of the ECM components. It would be interesting to see 
if macrophages could serve as a target during these processes. Our study demonstrated that 
myeloid cells, in particular tissue resident macrophages of embryonic origin, are involved in the 
modulation of fibrosis. Fibrosis, in turn, could serve as a positive feedback loop to enhance the in 
situ proliferation of tissue resident macrophages. Therefore, it is possible to foresee a 
combination treatment option that combines the reprogramming of macrophages with the 
alleviation of desmoplasia.  
 
4.4 Targeting the hematopoietic system to optimize tumor immunity 
As we expand our knowledge of the tumor immune microenvironment, it is important to 
remind ourselves that the local immune microenvironment likely results from a systemic level of 
immune responses. Immune cells are not generated in isolation, but are provided by the 
hematopoietic system at different stages in various lymphoid organs, such as bone marrow, 
spleen, and embryonic organs including yolk sac and fetal liver. This is not only true in mouse 
models but also observed in human patients: patients not only show enhanced level of immune 
infiltration in the tumor tissue, but also have elevated level of circulating immune cells and 
increased production in the bone marrow. Change in the qualities of systemic immune cell 
production is also seen in the hematopoietic system, as shown by the expansion of myeloid 
progenitors at the expense of lymphoid production (Casbon et al., 2015), which leads to 
increased myeloid-mediated immunosuppression coupled with impaired adaptive T cell 
cytotoxicity. Therefore, it is important to study how the hematopoietic differentiation pathways 
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are skewed in tumors, and how we can target these processes to combat cancer. Interestingly, 
bias towards myeloid expansion at the cost of lymphopoiesis is also seen during aging, 
suggesting the possibility that this skewed hematopoiesis during aging could contribute to cancer 
initiation by promoting chronic inflammation (Akunuru and Geiger, 2016; Geiger et al., 2013). 
In addition, knowledge of how tumors communicate with distant sites such as the bone marrow 
to modulate the immune system on an organismal level is still lacking. Such studies could 
provide insights into whether we can engineer an immune system from the source, i.e. 
hematopoietic stem and progenitor cells, and provide novel options that can further improve 
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Figure 4.1. Reprogramming of the myeloid responses to enhance anti-tumor immunity. 
Tumor tissues contain extensive infiltration of suppressive myeloid cells, such as tumor-
associated macrophages (TAMs), immature dendritic cells (DCs), and granulocytic myeloid-
derived suppressor cells (G-MDSCs), which inhibit anti-tumor activities of cytotoxic T 
lymphocytes (CTLs). Strategies to alleviate immune suppression mediated by these myeloid cells, 
such as using CSF1R inhibition or CXCR1/2 signal blockade, could reprogram these myeloid 
cells to activate the adaptive immune system and enhance the efficacy of immunotherapeutics to 
eliminate tumor cells.  
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